CA2436846C - Thioether substituted imidazoquinolines - Google Patents
Thioether substituted imidazoquinolines Download PDFInfo
- Publication number
- CA2436846C CA2436846C CA2436846A CA2436846A CA2436846C CA 2436846 C CA2436846 C CA 2436846C CA 2436846 A CA2436846 A CA 2436846A CA 2436846 A CA2436846 A CA 2436846A CA 2436846 C CA2436846 C CA 2436846C
- Authority
- CA
- Canada
- Prior art keywords
- imidazo
- butyl
- quinolin
- amine
- alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/08—Antibacterial agents for leprosy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/08—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis for Pneumocystis carinii
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Abstract
Imidazoquinoline and tetrahydroimidazoquinoline compounds that contain thioether functionality at the 1-position are useful as immune response modifiers. The compounds and compositions of the invention can induce the biosynthesis of various cytokines and are useful in the treatment of a variety of conditions including viral diseases and neoplastic diseases.
Description
Thioether Substituted Imidazoquinolines Field of the Invention This invention relates to imidazoquinoline compounds that have thioether functionality at the 1-position, and to pharmaceutical compositions containing such compounds. A further aspect of this invention relates to the use of these compounds as immunomodulators, for inducing cytokine biosynthesis in animals, and in the treatment of diseases, including viral and neoplastic diseases.
Background of the Invention The first reliable report on the 1H-inidazo[4,5-c]quinoline ring system, Backman et at., J. Org. Chem. 15, 1278-1284 (1950) describes the synthesis of 1-(6-methoxy-8-quinolinyl)-2-methyl-lH-imidazo[4,5-c]quinoline for possible use as an antimalarial agent. Subsequently, syntheses of various substituted 1H-imidazo[4,5-c]
quinolines were reported. For example, Jain et al., J. Med. Chem. 11, pp. 87-92 (1968), synthesized the compound 1-[2-(4-piperidyl)ethyl]-1H-imidazo[4,5-c]quinoline as a possible anticonvulsant and cardiovascular agent. Also, Baranov et al., Chem. Abs. 85, (1976), have reported several 2-oxoimidazo[4,5-c]quinolines, and Berenyi et al., J.
Heterocyclic Chem. 18, 1537-1540 (1981), have reported certain 2-oxoimidazo[4,5-c]quinolines.
Certain 1H-imidazo[4,5-c]quinolin-4-amines and 1- and 2-substituted derivatives thereof were later found to be useful as antiviral agents, bronchodilators and immunomodulators. These are described in, inter alia, U.S. Patent Nos.
4,689,338;
4,698,348; 4,929,624; 5,037,986; 5,268,376; 5,346,905; and 5,389,640.
There continues to be interest in the imidazoquinoline ring system.
Certain 1H-imidazo[4,5-c] naphthyridine-4-amines, 1H-imidazo [4,5-c] pyridin-4-amines, and 1H-imidazo[4,5-c] quinolin-4-amines having an ether containing substituent at the 1 position are known. These are described in U.S. Patent Nos.
5,268,376;
5,389,640; 5,494,916; and WO 99/29693.
Background of the Invention The first reliable report on the 1H-inidazo[4,5-c]quinoline ring system, Backman et at., J. Org. Chem. 15, 1278-1284 (1950) describes the synthesis of 1-(6-methoxy-8-quinolinyl)-2-methyl-lH-imidazo[4,5-c]quinoline for possible use as an antimalarial agent. Subsequently, syntheses of various substituted 1H-imidazo[4,5-c]
quinolines were reported. For example, Jain et al., J. Med. Chem. 11, pp. 87-92 (1968), synthesized the compound 1-[2-(4-piperidyl)ethyl]-1H-imidazo[4,5-c]quinoline as a possible anticonvulsant and cardiovascular agent. Also, Baranov et al., Chem. Abs. 85, (1976), have reported several 2-oxoimidazo[4,5-c]quinolines, and Berenyi et al., J.
Heterocyclic Chem. 18, 1537-1540 (1981), have reported certain 2-oxoimidazo[4,5-c]quinolines.
Certain 1H-imidazo[4,5-c]quinolin-4-amines and 1- and 2-substituted derivatives thereof were later found to be useful as antiviral agents, bronchodilators and immunomodulators. These are described in, inter alia, U.S. Patent Nos.
4,689,338;
4,698,348; 4,929,624; 5,037,986; 5,268,376; 5,346,905; and 5,389,640.
There continues to be interest in the imidazoquinoline ring system.
Certain 1H-imidazo[4,5-c] naphthyridine-4-amines, 1H-imidazo [4,5-c] pyridin-4-amines, and 1H-imidazo[4,5-c] quinolin-4-amines having an ether containing substituent at the 1 position are known. These are described in U.S. Patent Nos.
5,268,376;
5,389,640; 5,494,916; and WO 99/29693.
Despite these attempts to identify compounds that are useful as immune response modifiers, there is a continuing need for compounds that have the ability to modulate the immune response, by induction of cytokine biosynthesis or other mechanisms.
Summary of the Invention We have found a new class of compounds that are useful in inducing cytokine biosynthesis in animals. Accordingly, this invention provides imidazoquinoline-4-amine and tetrahydroimidazoquinoline-4-amine compounds that have a thioether containing substituent at the 1-position. The compounds are defined by Formulas (I) and (II), which are defined in more detail infra. These compounds share the general structural formula:
N
~-R2 N X- Z- Rl Rn P
wherein X, Z, R1, R2, and R are as defined herein for each class of compounds having formulas (I) and (II).
The compounds of formulas (I) and (II) are useful as immune response modifiers due to their ability to induce cytokine biosynthesis and otherwise modulate the immune response when administered to animals. This makes the compounds useful in the treatment of a variety of conditions such as viral diseases and tumors that are responsive to such changes in the immune response.
The invention further provides pharmaceutical compositions containing the immune response modifying compounds, and methods of inducing cytokine biosynthesis in an animal, treating a viral infection in an animal, and/or treating a neoplastic disease in an animal by administering a compound of Formula (I) or (II) to the animal.
In addition, the invention provides methods of synthesizing the compounds of the invention.
As mentioned earlier, we have found certain compounds that induce cytoline biosynthesis and modify the immune response in animals. Such compounds are represented by Formulas (T) and (II) as shown below.
Imidazoquinoline compounds of the invention, which have thioether functionality at the 1-position are represented by Formula (I):
N N
`}-R2 N
X- Z-- RI
(I) wherein: X is -CHR3-, -CHR3-alkyl-, or -CHR3-alkenyl-;
Z is -S-, -SO-, or -SO2-;
R, is: -alkyl;
-aryl;
-heteroaryl;
-heterocyclyl;
-alkenyl;
-R4-aryl;
-R4-heteroaryl; or -R4-heterocyclyl;
R2 is: -hydrogen;
-alkyl;
-alkenyl;
-aryl;
Summary of the Invention We have found a new class of compounds that are useful in inducing cytokine biosynthesis in animals. Accordingly, this invention provides imidazoquinoline-4-amine and tetrahydroimidazoquinoline-4-amine compounds that have a thioether containing substituent at the 1-position. The compounds are defined by Formulas (I) and (II), which are defined in more detail infra. These compounds share the general structural formula:
N
~-R2 N X- Z- Rl Rn P
wherein X, Z, R1, R2, and R are as defined herein for each class of compounds having formulas (I) and (II).
The compounds of formulas (I) and (II) are useful as immune response modifiers due to their ability to induce cytokine biosynthesis and otherwise modulate the immune response when administered to animals. This makes the compounds useful in the treatment of a variety of conditions such as viral diseases and tumors that are responsive to such changes in the immune response.
The invention further provides pharmaceutical compositions containing the immune response modifying compounds, and methods of inducing cytokine biosynthesis in an animal, treating a viral infection in an animal, and/or treating a neoplastic disease in an animal by administering a compound of Formula (I) or (II) to the animal.
In addition, the invention provides methods of synthesizing the compounds of the invention.
As mentioned earlier, we have found certain compounds that induce cytoline biosynthesis and modify the immune response in animals. Such compounds are represented by Formulas (T) and (II) as shown below.
Imidazoquinoline compounds of the invention, which have thioether functionality at the 1-position are represented by Formula (I):
N N
`}-R2 N
X- Z-- RI
(I) wherein: X is -CHR3-, -CHR3-alkyl-, or -CHR3-alkenyl-;
Z is -S-, -SO-, or -SO2-;
R, is: -alkyl;
-aryl;
-heteroaryl;
-heterocyclyl;
-alkenyl;
-R4-aryl;
-R4-heteroaryl; or -R4-heterocyclyl;
R2 is: -hydrogen;
-alkyl;
-alkenyl;
-aryl;
-heteroaryl;
-heterocyclyl;
-alkyl-Y-alkyl;
- alkyl-Y- alkenyl;
-alkyl-Y-aryl; or - alkyl or alkenyl substituted by one or more substituents being:
-OH;
-halogen;
-N(R3)2;
-CO-N(R3)2;
-CO-C1_10 alkyl;
-CO-0-C1-1o alkyl;
-N3;
-aryl;
-heteroaryl;
-heterocyclyl;
-CO-aryl; or -CO-heteroaryl;
each R3 is independently H or C1-10 alkyl;
each R4 is independently alkyl or alkenyl;
each Y is independently -0- or -S(O)0_2_;
n is 0 to 4; and each R present is independently C1_10 alkyl, C1_10 alkoxy, hydroxy, halogen or trifluoromethyl;
or a pharmaceutically acceptable salt thereof.
The invention is also directed to a compound being:
-heterocyclyl;
-alkyl-Y-alkyl;
- alkyl-Y- alkenyl;
-alkyl-Y-aryl; or - alkyl or alkenyl substituted by one or more substituents being:
-OH;
-halogen;
-N(R3)2;
-CO-N(R3)2;
-CO-C1_10 alkyl;
-CO-0-C1-1o alkyl;
-N3;
-aryl;
-heteroaryl;
-heterocyclyl;
-CO-aryl; or -CO-heteroaryl;
each R3 is independently H or C1-10 alkyl;
each R4 is independently alkyl or alkenyl;
each Y is independently -0- or -S(O)0_2_;
n is 0 to 4; and each R present is independently C1_10 alkyl, C1_10 alkoxy, hydroxy, halogen or trifluoromethyl;
or a pharmaceutically acceptable salt thereof.
The invention is also directed to a compound being:
2-butyl-1-[4-(phenylthio)butyl]-1H-imidazo[4,5-c]quinolin-4-amine;
2-butyl-1-[2-(phenylthio)ethyl]-6,7,8,9-tetrahydro-lH-imidazo[4,5-c]quinolin-4-amine;
2-butyl-1-[4-(phenylsulfonyl)butyl] -1 H-imidazo [4, 5 -c] quinolin-4-amine;
2-butyl-1-[4-(methylthio)butyl]-1H-imidazo[4,5-c]quinolin-4-amine;
2-butyl-l-[4-(methylsulfonyl)butyl]-1H-imidazo[4,5-c]quinolin-4-amine;
1-[2-(phenylthio)ethyl]-1H-imidazo[4,5-c]quinolin-4-amine;
1 - [4-(phenylsulfonyl)butyl] - I H-imidazo [4, 5 -c] quinolin-4-amine;
1 - [4-(methylsulfonyl)butyl] -1 H-imidazo [4, 5 -c] quino lin-4-amine;
1 -[4-(phenylthio)butyl]-I H-imidazo [4,5-c]quinolin-4-amine;
1 -[4-(methylthio)butyl]-1 H-imidazo [4, 5 -c]quinolin-4-amine;
2-butyl-1-[5-(methylsulfonyl)pentyl]-1H-imidazo[4,5-c]quinolin-4-amine;
2-methyl-1 -[5-(methylsulfonyl)pentyl]-1H-imidazo[4,5-c]quinolin-4-amine;
2-ethyl- l - [5-(methylsulfonyl)pentyl]-1H-imidazo [4,5-c]quinolin-4-amine;
1-[5-(methylsulfonyl)pentyl]-1H-imidazo[4,5-c]quinolin-4-amine;
2-hexyl-l-[5-(methylsulfonyl)pentyl]-1H-imidazo[4,5-c]quinolin-4-amine;
2-(2-methoxyethyl)-1-[5-(methylsulfonyl)pentyl]-1H-imidazo[4,5-c]quinolin-4-amine;
2-butyl-1-[5-(methylthio)pentyl]-1H-imidazo[4,5-c]quinolin-4-amine;
2-butyl-1-[5-(methylsulfnyl)pentyl]-1H-imidazo[4,5-c]quinolin-4-amine;
2-butyl-1-[3-(methylsulfonyl)propyl]-1 H-imidazo[4,5-c]quinolin-4-amine; or 2-butyl-l-[3-(phenylsulfonyl)propyl]-1H-imidazo[4,5-c]quinolin-4-amine;
or a pharmaceutically acceptable salt thereof.
The invention also includes tetrahydroiinidazoquinoline compounds that bear a thioether containing substituent at the 1-position. Such tetrahydroimidazoquinoline compounds are represented by Formula (II):
2-butyl-1-[2-(phenylthio)ethyl]-6,7,8,9-tetrahydro-lH-imidazo[4,5-c]quinolin-4-amine;
2-butyl-1-[4-(phenylsulfonyl)butyl] -1 H-imidazo [4, 5 -c] quinolin-4-amine;
2-butyl-1-[4-(methylthio)butyl]-1H-imidazo[4,5-c]quinolin-4-amine;
2-butyl-l-[4-(methylsulfonyl)butyl]-1H-imidazo[4,5-c]quinolin-4-amine;
1-[2-(phenylthio)ethyl]-1H-imidazo[4,5-c]quinolin-4-amine;
1 - [4-(phenylsulfonyl)butyl] - I H-imidazo [4, 5 -c] quinolin-4-amine;
1 - [4-(methylsulfonyl)butyl] -1 H-imidazo [4, 5 -c] quino lin-4-amine;
1 -[4-(phenylthio)butyl]-I H-imidazo [4,5-c]quinolin-4-amine;
1 -[4-(methylthio)butyl]-1 H-imidazo [4, 5 -c]quinolin-4-amine;
2-butyl-1-[5-(methylsulfonyl)pentyl]-1H-imidazo[4,5-c]quinolin-4-amine;
2-methyl-1 -[5-(methylsulfonyl)pentyl]-1H-imidazo[4,5-c]quinolin-4-amine;
2-ethyl- l - [5-(methylsulfonyl)pentyl]-1H-imidazo [4,5-c]quinolin-4-amine;
1-[5-(methylsulfonyl)pentyl]-1H-imidazo[4,5-c]quinolin-4-amine;
2-hexyl-l-[5-(methylsulfonyl)pentyl]-1H-imidazo[4,5-c]quinolin-4-amine;
2-(2-methoxyethyl)-1-[5-(methylsulfonyl)pentyl]-1H-imidazo[4,5-c]quinolin-4-amine;
2-butyl-1-[5-(methylthio)pentyl]-1H-imidazo[4,5-c]quinolin-4-amine;
2-butyl-1-[5-(methylsulfnyl)pentyl]-1H-imidazo[4,5-c]quinolin-4-amine;
2-butyl-1-[3-(methylsulfonyl)propyl]-1 H-imidazo[4,5-c]quinolin-4-amine; or 2-butyl-l-[3-(phenylsulfonyl)propyl]-1H-imidazo[4,5-c]quinolin-4-amine;
or a pharmaceutically acceptable salt thereof.
The invention also includes tetrahydroiinidazoquinoline compounds that bear a thioether containing substituent at the 1-position. Such tetrahydroimidazoquinoline compounds are represented by Formula (II):
N N
R
N
I
(II) wherein: X is -CHR3-, -CHR3-alkyl-, or -CHR3-alkenyl-;
Z is -S-, -SO-, or -SO2-;
R1 is: -alkyl;
-aryl;
-heteroaryl;
-heterocyclyl;
-alkenyl;
-R4-aryl;
-R4- heteroaryl; or -R4-heterocyclyl;
R2 is: -hydrogen;
-alkyl;
-alkenyl;
-aryl;
-heteroaryl;
-heterocyclyl;
-alkyl-Y-alkyl;
-alkyl-Y-alkenyl;
-alkyl-Y-aryl; or - alkyl or alkenyl substituted by one or more substituents being:
-OH;
-halogen;
-N(R3)2;
-CO-N(R3)2;
-CO-Cl_1o alkyl;
-CO-O-Ci_io alkyl;
-N3;
-aryl;
-heteroaryl;
-heterocyclyl;
-CO-aryl; or -CO-heteroaryl;
each R3 is independently H or Ci_io alkyl;
each R4 is independently alkyl or alkenyl;
each Y is independently -0- or -S(O)0_2_;
n is 0 to 4; and each R present is independently CI-10 alkyl, Ci_1o alkoxy, hydroxy, halogen or trifluoromethyl;
or a pharmaceutically acceptable salt thereof.
The invention is further directed to a pharmaceutical composition comprising a compound or a pharmaceutically acceptable salt thereof as defined above, and a pharmaceutically acceptable carrier.
The invention is yet directed to the use of a compound as defined above for:
- inducing cytokine biosynthesis in an animal, preferably the cytokine being IFN-a.;
- for treating a viral disease in an animal; or - for treating neoplastic disease in an animal.
6a The invention is yet directed to the use of a compound as defined above for the manufacture of a medicament for:
- inducing cytokine biosynthesis in an animal, preferably the cytokine being IFN-a;
- treating a viral disease in an animal; or - treating a neoplastic disease in an animal.
DETAILED DESCRIPTION OF THE INVENTION
Preparation of the Compounds Compounds of the invention can be prepared according to Reaction Scheme I
where R, R1, R2, X and n are as defined above.
In step (1) of Reaction Scheme I a 4-chloro-3-nitroquinoline of Formula X is reacted with an amine of formula HO-X-NH2 to provide a 3-nitroquinolin-4-amine of Formula XI. The reaction can be carried out by adding the amine to a solution of a compound of Formula X in a suitable solvent such as chloroform or dichloromethane in the presence of triethylamine and optionally heating. Many quinolines of Formula X are known compounds (see for example, U.S. Patent 4,689,338 and references cited therein).
6b Many amines of formula HO-X-NH2 are commercially available; others can be readily prepared using known synthetic routes.
In step (2) of Reaction Scheme I a 3-nitroquinolin-4-amine of Formula XI is chlorinated to provide a 3-nitroquinolin-4-amine of Formula XII. Conventional chlorinating agents can be used. Preferably the reaction is carried out by combining a compound of Formula XI with thionyl chloride in a suitable solvent such as dichloromethane and heating. Alternatively the reaction may be run neat.
In step (3) of Reaction Scheme I a 3-nitroquinolin-4-amine of Formula XII is reduced to provide a quinoline-3,4-diamine of Formula XIII. Preferably, the reduction is carried out using a conventional heterogeneous hydrogenation catalyst such as platinum on carbon. The reaction can conveniently be carried out on a Parr apparatus in a suitable solvent such as toluene.
In step (4) of Reaction Scheme I a quinoline-3,4-diamine of Formula XIII is reacted with a carboxylic acid or an equivalent thereof to provide a 1H-imidazo[4,5-c]quinoline of Formula XIV. Suitable equivalents to a carboxylic acid include orthoesters, and 1, 1 -dialkoxyalkyl alkanoates. The carboxylic acid or equivalent is selected such that it will provide the desired R2 substituent in a compound of Formula XIV. For example, triethyl orthoformate will provide a compound where R2 is hydrogen and trimethyl orthovalerate will provide a compound where R2 is butyl. The reaction can be run in the absence of solvent or in an inert solvent such as toluene. The reaction is run with sufficient heating to drive off any alcohol or water formed as a byproduct of the reaction.
Optionally a catalyst such as pyridine hydrochloride can be included.
Alternatively, step (4) can be carried out by (i) reacting the diamine of Formula XIII with an acyl halide of Formula R2C(O)Cl or R2C(O)Br and then (ii) cyclizing. In part (i) the acyl halide is added to a solution of the diamine in a suitable solvent such as pyridine. The reaction can be carried out at ambient temperature. In part (ii) the product of part (i) is heated in pyridine in the presence of pyridine hydrochloride.
In step (5) of Reaction Scheme I a 1H-imidazo[4,5-c]quinoline of Formula XIV
is oxidized to provide a IH-imidazo[4,5-c]quinoline-5N-oxide of Formula XV using a conventional oxidizing agent capable of forming N-oxides. Preferably a solution of a compound of Formula XIV in a suitable solvent such as chloroform or dichloromethane is treated with 3-chloroperoxybenzoic acid at ambient temperature.
R
N
I
(II) wherein: X is -CHR3-, -CHR3-alkyl-, or -CHR3-alkenyl-;
Z is -S-, -SO-, or -SO2-;
R1 is: -alkyl;
-aryl;
-heteroaryl;
-heterocyclyl;
-alkenyl;
-R4-aryl;
-R4- heteroaryl; or -R4-heterocyclyl;
R2 is: -hydrogen;
-alkyl;
-alkenyl;
-aryl;
-heteroaryl;
-heterocyclyl;
-alkyl-Y-alkyl;
-alkyl-Y-alkenyl;
-alkyl-Y-aryl; or - alkyl or alkenyl substituted by one or more substituents being:
-OH;
-halogen;
-N(R3)2;
-CO-N(R3)2;
-CO-Cl_1o alkyl;
-CO-O-Ci_io alkyl;
-N3;
-aryl;
-heteroaryl;
-heterocyclyl;
-CO-aryl; or -CO-heteroaryl;
each R3 is independently H or Ci_io alkyl;
each R4 is independently alkyl or alkenyl;
each Y is independently -0- or -S(O)0_2_;
n is 0 to 4; and each R present is independently CI-10 alkyl, Ci_1o alkoxy, hydroxy, halogen or trifluoromethyl;
or a pharmaceutically acceptable salt thereof.
The invention is further directed to a pharmaceutical composition comprising a compound or a pharmaceutically acceptable salt thereof as defined above, and a pharmaceutically acceptable carrier.
The invention is yet directed to the use of a compound as defined above for:
- inducing cytokine biosynthesis in an animal, preferably the cytokine being IFN-a.;
- for treating a viral disease in an animal; or - for treating neoplastic disease in an animal.
6a The invention is yet directed to the use of a compound as defined above for the manufacture of a medicament for:
- inducing cytokine biosynthesis in an animal, preferably the cytokine being IFN-a;
- treating a viral disease in an animal; or - treating a neoplastic disease in an animal.
DETAILED DESCRIPTION OF THE INVENTION
Preparation of the Compounds Compounds of the invention can be prepared according to Reaction Scheme I
where R, R1, R2, X and n are as defined above.
In step (1) of Reaction Scheme I a 4-chloro-3-nitroquinoline of Formula X is reacted with an amine of formula HO-X-NH2 to provide a 3-nitroquinolin-4-amine of Formula XI. The reaction can be carried out by adding the amine to a solution of a compound of Formula X in a suitable solvent such as chloroform or dichloromethane in the presence of triethylamine and optionally heating. Many quinolines of Formula X are known compounds (see for example, U.S. Patent 4,689,338 and references cited therein).
6b Many amines of formula HO-X-NH2 are commercially available; others can be readily prepared using known synthetic routes.
In step (2) of Reaction Scheme I a 3-nitroquinolin-4-amine of Formula XI is chlorinated to provide a 3-nitroquinolin-4-amine of Formula XII. Conventional chlorinating agents can be used. Preferably the reaction is carried out by combining a compound of Formula XI with thionyl chloride in a suitable solvent such as dichloromethane and heating. Alternatively the reaction may be run neat.
In step (3) of Reaction Scheme I a 3-nitroquinolin-4-amine of Formula XII is reduced to provide a quinoline-3,4-diamine of Formula XIII. Preferably, the reduction is carried out using a conventional heterogeneous hydrogenation catalyst such as platinum on carbon. The reaction can conveniently be carried out on a Parr apparatus in a suitable solvent such as toluene.
In step (4) of Reaction Scheme I a quinoline-3,4-diamine of Formula XIII is reacted with a carboxylic acid or an equivalent thereof to provide a 1H-imidazo[4,5-c]quinoline of Formula XIV. Suitable equivalents to a carboxylic acid include orthoesters, and 1, 1 -dialkoxyalkyl alkanoates. The carboxylic acid or equivalent is selected such that it will provide the desired R2 substituent in a compound of Formula XIV. For example, triethyl orthoformate will provide a compound where R2 is hydrogen and trimethyl orthovalerate will provide a compound where R2 is butyl. The reaction can be run in the absence of solvent or in an inert solvent such as toluene. The reaction is run with sufficient heating to drive off any alcohol or water formed as a byproduct of the reaction.
Optionally a catalyst such as pyridine hydrochloride can be included.
Alternatively, step (4) can be carried out by (i) reacting the diamine of Formula XIII with an acyl halide of Formula R2C(O)Cl or R2C(O)Br and then (ii) cyclizing. In part (i) the acyl halide is added to a solution of the diamine in a suitable solvent such as pyridine. The reaction can be carried out at ambient temperature. In part (ii) the product of part (i) is heated in pyridine in the presence of pyridine hydrochloride.
In step (5) of Reaction Scheme I a 1H-imidazo[4,5-c]quinoline of Formula XIV
is oxidized to provide a IH-imidazo[4,5-c]quinoline-5N-oxide of Formula XV using a conventional oxidizing agent capable of forming N-oxides. Preferably a solution of a compound of Formula XIV in a suitable solvent such as chloroform or dichloromethane is treated with 3-chloroperoxybenzoic acid at ambient temperature.
In step (6) of Reaction Scheme I a lH-imidazo[4,5-c]quinoline-5N-oxide of Formula XV is aminated to provide a 1H-imidazo[4,5-c]quinolin-4-amine of Formula XVI. Step (6) involves (i) reacting a compound of Formula XV with an acylating agent and then (ii) reacting the product with an aminating agent. Part (i) of step (6) involves reacting an N-oxide of Formula XV with an acylating agent. Suitable acylating agents include alkyl- or arylsulfonyl chlorides (e.g., benezenesulfonyl chloride, methanesulfonyl chloride, p-toluenesulfonyl chloride). Arylsulfonyl chlorides are preferred.
Para-toluenesulfonyl chloride is most preferred. Part (ii) of step (6) involves reacting the product of part (i) with an excess of an aminating agent. Suitable aminating agents include ammonia (e.g., in the form of ammonium hydroxide) and ammonium salts (e.g., ammonium carbonate, ammonium bicarbonate, ammonium phosphate). Ammonium hydroxide is preferred. The reaction is preferably carried out by dissolving the N-oxide of Formula XV in an inert solvent such as dichloromethane or chloroform, adding the aminating agent to the solution, and then slowly adding the acylating agent.
In step (7) of Reaction Scheme I a 1H-imidazo[4,5-c]quinolin-4-amine of Formula XVI is reacted with a compound of Formula Rl-SNa to provide a 1H-imidazo[4,5-c]quinolin-4-amine of Formula XVII which is a subgenus of Formula I. The reaction can be carried out by combining a compound of Formula XVI with a compound of formula Rl SNa in a suitable solvent such as N,N-dimethylformamide or dimethyl sulfoxide and heating (60-80 C). The product or a pharmaceutically acceptable salt thereof can be isolated using conventional methods.
In step (8) of Reaction Scheme I a 1H-imidazo[4,5-c]quinolin-4-amine of Formula XVII is oxidized using a conventional oxidizing agent to provide a 1H-imidazo[4,5-c]quinolin-4-amine of Formula XVIII which is a subgenus of Formula I.
Preferably a solution of a compound of Formula XVII in a suitable solvent such as chloroform or dichloromethane is treated with 3-chloroperoxybenzoic acid at ambient temperature. The degree of oxidation is controlled by adjusting the amount of 3-chloroperoxybenzoic acid used in the reaction; i.e., using approximately one equivalent will provide the sulfoxide whereas using two equivalents will provide the sulfone. The product or a pharmaceutically acceptable salt thereof can be isolated using conventional methods.
Para-toluenesulfonyl chloride is most preferred. Part (ii) of step (6) involves reacting the product of part (i) with an excess of an aminating agent. Suitable aminating agents include ammonia (e.g., in the form of ammonium hydroxide) and ammonium salts (e.g., ammonium carbonate, ammonium bicarbonate, ammonium phosphate). Ammonium hydroxide is preferred. The reaction is preferably carried out by dissolving the N-oxide of Formula XV in an inert solvent such as dichloromethane or chloroform, adding the aminating agent to the solution, and then slowly adding the acylating agent.
In step (7) of Reaction Scheme I a 1H-imidazo[4,5-c]quinolin-4-amine of Formula XVI is reacted with a compound of Formula Rl-SNa to provide a 1H-imidazo[4,5-c]quinolin-4-amine of Formula XVII which is a subgenus of Formula I. The reaction can be carried out by combining a compound of Formula XVI with a compound of formula Rl SNa in a suitable solvent such as N,N-dimethylformamide or dimethyl sulfoxide and heating (60-80 C). The product or a pharmaceutically acceptable salt thereof can be isolated using conventional methods.
In step (8) of Reaction Scheme I a 1H-imidazo[4,5-c]quinolin-4-amine of Formula XVII is oxidized using a conventional oxidizing agent to provide a 1H-imidazo[4,5-c]quinolin-4-amine of Formula XVIII which is a subgenus of Formula I.
Preferably a solution of a compound of Formula XVII in a suitable solvent such as chloroform or dichloromethane is treated with 3-chloroperoxybenzoic acid at ambient temperature. The degree of oxidation is controlled by adjusting the amount of 3-chloroperoxybenzoic acid used in the reaction; i.e., using approximately one equivalent will provide the sulfoxide whereas using two equivalents will provide the sulfone. The product or a pharmaceutically acceptable salt thereof can be isolated using conventional methods.
Reaction Scheme I
11+ 11+ O+
N 11 j N~O (~) &N- N.O- (2) N N,C3-- 1 CI NH NH
/
n X Rn / x X OH
(3) N} R2 (5) N N} R (4) N NH2 N NH
R,, / X Rn X Rn X
CI CI Cl XV XIV XIII
(6) NH2 NH5III\-R2 NH2 N N R2 (7) N (8) N N
I \> 30 1 X R5J>-R2 X
CI S S(O)S-z XVI XVII R, XVIII
R~
Compounds of the invention can be prepared according to Reaction Scheme II
where R, R1, R2, X and n are as defined above.
In step (1) of Reaction Scheme II a 3-nitroquinolin-4-amine of Formula XII is reacted with a compound of the Formula Rl-SNa using the method of step (7) of Reaction Scheme Ito provide a 3-nitroquinolin-4-amine of Formula XIX.
In step (2) of Reaction Scheme II a 3-nitroquinolin-4-amine of Formula XIX is reduced using the method of step (3) of Reaction Scheme I to provide a quinoline-3,4-diamine of Formula XX.
11+ 11+ O+
N 11 j N~O (~) &N- N.O- (2) N N,C3-- 1 CI NH NH
/
n X Rn / x X OH
(3) N} R2 (5) N N} R (4) N NH2 N NH
R,, / X Rn X Rn X
CI CI Cl XV XIV XIII
(6) NH2 NH5III\-R2 NH2 N N R2 (7) N (8) N N
I \> 30 1 X R5J>-R2 X
CI S S(O)S-z XVI XVII R, XVIII
R~
Compounds of the invention can be prepared according to Reaction Scheme II
where R, R1, R2, X and n are as defined above.
In step (1) of Reaction Scheme II a 3-nitroquinolin-4-amine of Formula XII is reacted with a compound of the Formula Rl-SNa using the method of step (7) of Reaction Scheme Ito provide a 3-nitroquinolin-4-amine of Formula XIX.
In step (2) of Reaction Scheme II a 3-nitroquinolin-4-amine of Formula XIX is reduced using the method of step (3) of Reaction Scheme I to provide a quinoline-3,4-diamine of Formula XX.
In step (3) of Reaction Scheme II a quinoline-3,4-diamine of Formula XX is cyclized using the method of step (4) of Reaction Scheme Ito provide a 1H-imidazo[4,5-c]quinoline of Formula XXI.
In step (4) of Reaction Scheme II a lH-imidazo[4,5-c]quinoline of Formula XXI
is oxidized to provide a 1H-imidazo[4,5-c]quinolin-5N-oxide of Formula XXII using a conventional oxidizing agent. Preferably a solution of a compound of Formula XXI in a suitable solvent such as chloroform or dichloromethane is treated with at least three equivalents of 3-chloroperoxybenzoic acid at ambient temperature.
In step (5) of Reaction Scheme II a 1H-imidazo[4,5-c]quinolin-5N-oxide of Formula XXII is aminated using the method of step (6) of Reaction Scheme Ito provide a 1H-imidazo[4,5-c]quinolin-4-amine of Formula XVIII which is a subgenus of Formula I.
The product or a pharmaceutically acceptable salt thereof can be isolated using conventional methods.
Reaction Scheme II
0+ 0+
N,- N, - NHN 0(1) N 0(2). N 2 NH NH NH
Rn / X Rn / X Rn / X
XII CI XIX ~ XX S
Ri R1 (3) NHz N NR2 (5) N / N -R2 (4) N N~Rz N N N
Rn - i Rn / X Rn / X
S
Ri Ri Compounds of the invention can be prepared according to Reaction Scheme III
where R, R1, R2, X and n are as defined above.
In step (1) of Reaction Scheme III a 3-nitro-4-amino-quinolin-1-yl alcohol of Formula XI is protected with a tent-butyldimethylsilyl group using conventional methods.
Preferably a compound of Formula XI is combined with tert-butyldimethylsilyl chloride in a suitable solvent such as chloroform in the presence of triethylamine and a catalytic amount of 4-dimethylaminopyridine.
In step (2) of Reaction Scheme III a protected 3-nitro-4-amino-quinolin-l-yl alcohol of Formula XXIII is reduced using the method of step (3) of Reaction Scheme Ito provide a protected 3, 4-diamino-quinolin-l-yl alcohol of Formula XXIV.
In step (3) of Reaction Scheme III a protected 3,4-diamino-quinolin-l-yl alcohol of Formula XXIV is cyclized using the method of step (4) of Reaction Scheme Ito provide a 1H-imidazo[4,5-c]quinoline of Formula XXV.
In step (4) of Reaction Scheme III a 1H-imidazo[4,5-c]quinoline of Formula XXV
is oxidized using the method of step (5) of Reaction Scheme Ito provide a IH-imidazo[4,5-c]quinolin-5N-oxide of Formula XXVI.
In step (5) of Reaction Scheme III a 1H-imidazo[4,5-c]quinolin-5N-oxide of Formula XXVI is aminated using the method of step (6) of Reaction Scheme Ito provide a IH-imidazo[4,5-c]quinolin-4-amine of Formula XXVII.
In step (6) of Reaction Scheme III the protecting group is removed from a 1H-imidazo[4,5-c]quinolin-4-amine of Formula XXVII to provide a IH-imidazo[4,5-c]quinolin-4-amine of Formula XXVIII. Preferably a solution of a compound of Formula XXVII in a suitable solvent such as tetrahydrofuran is treated with tetrabutylammonium fluoride. Some compounds of Formula XXVIII are known, see for example, Gerster, U.S.
Patent No. 4,689,338 and Gerster et al., U.S. Patent 5,605,899.
In step (7) of Reaction Scheme III a 1H-imidazo[4,5-c]quinolin-4-amine of Formula XXVIII is chlorinated using conventional methods to provide a 1H-imidazo[4,5-c]quinolin-4-amine of Formula XVI. A compound of Formula XXVIII can be heated neat with thionyl chloride. Alternatively, phosphorous oxychloride can be added in a controlled fashion to a solution of a compound of Formula XXVIII in a suitable solvent such as N,N-dimethylformamide in the presence of triethylamine.
Steps (8) and (9) of Reaction Scheme III can be carried out in the same manner as steps (7) and (8) respectively of Reaction Scheme I.
Reaction Scheme III
O+ O
N, 11+
N O (1) _ N N, 0-(2) N NH
/ I
R" / NHz / NH Rn I NH R /
X
OH / / X
O
XI Mil -Si- XXIV I
-Si-A-NHz (3) N O\+ N
I 11 N~ Rz N N R2 (5) N j N)- Rz E (4) N
N
Rn X Rn / X Rn / X
O O i O
XXVII -Si- XXVI -Si- XXV -Si-/~-(6) N % N} RZ (7) N (g) N I NX R5J\>-R2 X Rn X
OH CI S
XXVI I I XVI XVI I I
Ri (9) NHz N
N % \}R2 Rn X
XVIII
Compounds of the invention can be prepared according to Reaction Scheme IV
where R, R1, R2, X and n are as defined above and BOC is tert-butoxycarbonyl.
In step (1) of Reaction Scheme IV the hydroxy group of a 6,7,8,9-tetrahydro-lH-imidazo[4,5-c]quinolin-l-yl alcohol of Formula XXIX is protected with a tert-butyldimethylsilyl group using the method of step (1) of Reaction Scheme III.
Compounds of Formula XXIX are known or can be prepared using known synthetic methods, see for example, Nikolaides, et al., U.S. Patent No.5,352,784 and Lindstrom, U.S. Patent No. 5,693,811 and references cited therein.
In step (2) of Reaction Scheme IV the amino group of a 1H-imidazo[4,5-c]quinolin-4-amine of Formula XXX is protected using conventional methods to provide a protected IH-imidazo[4,5-c]quinoline of Formula XXXI. Preferably a compound of Formula XXX is treated with di-test-butyl dicarbonate in a suitable solvent such as tetrahydrofuran in the presence of triethylamine and 4-dimethylaminopyridine.
The reaction can be run at an elevated temperature (60 C).
In step (3) of Reaction Scheme IV the tert-butyldimethylsilyl protecting group of a compound of Formula XXXI is removed using the method of step (6) of Reaction Scheme III to provide a 1H-imidazo[4,5-c]quinolin-lyl alcohol of Formula XXXII.
In step (4) of Reaction Scheme IV a 1H-imidazo[4,5-c]quinolin-lyl alcohol of Formula XXXII is converted to a methanesulfonate of Formula XXXIII. Preferably a solution of a compound of Formula XXXII in a suitable solvent such as dichloromethane is treated with methanesulfonyl chloride in the presence of triethylamine. The reaction can be run at a reduced temperature (-10 C).
In step (5) of Reaction Scheme IV a methanesulfonate of Formula XXXIII is reacted with a thiol of formula R1SH to provide a thioether of Formula XXXIV.
Preferably a solution of a compound of Formula XXXIII in a suitable solvent such as N, N-dimethylformamide is treated with the thiol in the presence of triethylamine. The reaction can be run at an elevated temperature (80 C).
In step (6) of Reaction Scheme IV the tert-butoxycarbonyl protecting groups are removed by hydrolysis under acidic conditions to provide a 1H-imidazo[4,5-c]quinolin-4-amine of Formula XXXV which is a subgenus of Formula II. Preferably a solution of a compound of Formula XXXIV in a suitable solvent such as dichloromethane is treated at ambient temperature with a solution of hydrochloric acid in dioxane. The product or a pharmaceutically acceptable salt thereof can be isolated using conventional methods.
In step (7) of Reaction Scheme IV a thioether of Formula XXXV is oxidized using the method of step (8) of Reaction Scheme Ito provide a sulfone or sulfoxide of Formula XXXVI which is a subgenus of Formula II. The product or a pharmaceutically acceptable salt thereof can be isolated using conventional methods.
Reaction Scheme IV
NH2 N(BOC)2 N N R2 N N - R () N N> R
Rn X Rn X Rn X
OH O
XXIX XXX -Si- XXXI -Si-(3) NBOC)2 N(BOC)2 N(BOC)2 NJ N
6 N>- R2 N R2 (5) N N R2 N /
N N
Rn X Rn X Rn X
S O OH
XXXIV IR XXXIII O-S-O XXXII
(6) N N>-R2 (7) N N\ -R
j 2 , N
Rn S Rn XXXV R XXXVI T(O)1-2 Compounds of the invention can be prepared according to Reaction Scheme V
where R, R1, R2, X and n are as defined above.
In step (1) of Reaction Scheme V a 6,7,8,9-tetrahydro-lH-imidazo[4,5-c]quinolin-1-yl alcohol of Formula XXIX is chlorinated using the method of step (7) of Reaction Scheme III to provide a compound of Formula XXXVII.
In step (2) of Reaction Scheme V a compound of Formula XXXVII is reacted with a compound of formula Rl-SNa using the method of step (7) of Reaction Scheme Ito provide a thioether of Formula XXXV which is a subgenus of Formula II. The product or a pharmaceutically acceptable salt thereof can be isolated using conventional methods.
In step (3) of Reaction Scheme V a thioether of Formula XXXV is oxidized using the method of step (8) of Reaction Scheme Ito provide a sulfone or sulfoxide of Formula XXXVI which is a subgenus of Formula II. The product or a pharmaceutically acceptable salt thereof can be isolated using conventional methods.
Reaction Scheme V
N N (1) (2) -R2 ~ -R2 N R2 N
R X Rn X Rõ X
OH CI S
XXIX XXXVII XXXV
Ri (3) N N
}R2 N
R" X
S(0)a_2 XXXVI
As used herein, the terms "alkyl", "alkenyl" and the prefix "alk-" are inclusive of both straight chain and branched chain groups and of cyclic groups, i.e.
cycloalkyl and cycloalkenyl. Unless otherwise specified, these groups contain from 1 to 20 carbon atoms, with alkenyl groups containing from 2 to 20 carbon atoms. Preferred groups have a total of up to 10 carbon atoms. Cyclic groups can be monocyclic or polycyclic and preferably have from 3 to 10 ring carbon atoms. Exemplary cyclic groups include cyclopropyl, cyclopropylmethyl, cyclopentyl, cyclohexyl and adamantyl.
In addition, the alkyl and alkenyl portions of -X- groups can be unsubstituted or substituted by one or more substituents, which substituents are selected from the groups consisting of alkyl, alkenyl, aryl, heteroaryl, heterocyclyl, arylalkyl, heteroarylalkyl, and heterocyclylalkyl.
The term "haloalkyl" is inclusive of groups that are substituted by one or more halogen atoms, including perfluorinated groups. This is also true of groups that include the prefix "halo". Examples of suitable haloalkyl groups are chloromethyl, trifluoromethyl, and the like.
The term "aryl" as used herein includes carbocyclic aromatic rings or ring systems.
Examples of aryl groups include phenyl, naphthyl, biphenyl, fluorenyl and indenyl. The term "heteroaryl" includes aromatic rings or ring systems that contain at least one ring hetero atom (e.g., 0, S, N). Suitable heteroaryl groups include furyl, thienyl, pyridyl, quinolinyl, isoquinolinyl, indolyl, isoindolyl, triazolyl, pyrrolyl, tetrazolyl, imidazolyl, pyrazolyl, oxazolyl, thiazolyl, benzofuranyl, benzothiophenyl, carbazolyl, benzoxazolyl, pyrimidinyl, benzimidazolyl, quinoxalinyl, benzothiazolyl, naphthyridinyl, isoxazolyl, isothiazolyl, purinyl, quinazolinyl, and so on.
"Heterocyclyl" includes non-aromatic rings or ring systems that contain at least one ring hetero atom (e.g., 0, S, N) and includes all of the fully saturated and partially unsaturated derivatives of the above mentioned heteroaryl groups. Exemplary heterocyclic groups include pyrrolidinyl, tetrahydrofuranyl, morpholinyl, thiomorpholinyl, piperidinyl, piperazinyl, thiazolidinyl, imidazolidinyl, isothiazolidinyl, and the like.
The aryl, heteroaryl, and heterocyclyl groups can be unsubstituted or substituted by one or more substituents independently selected from the group consisting of alkyl, alkoxy, alkylthio, haloalkyl, haloalkoxy, haloalkylthio, halogen, nitro, hydroxy, mercapto, cyano, carboxy, formyl, aryl, aryloxy, arylthio, arylalkoxy, arylalkylthio, heteroaryl, heteroaryloxy, heteroarylthio, heteroarylalkoxy, heteroarylalkylthio, amino, alkylamino, dialkylamino, heterocyclyl, heterocycloalkyl, alkylcarbonyl, alkenylcarbonyl, alkoxycarbonyl, haloalkylcarbonyl, haloalkoxycarbonyl, alkylthiocarbonyl, arylcarbonyl, heteroarylcarbonyl, aryloxycarbonyl, heteroaryloxycarbonyl, arylthiocarbonyl, heteroarylthiocarbonyl, alkanoyloxy, alkanoylthio, alkanoylamino, arylcarbonyloxy, arylcarbonylthio, alkylaminosulfonyl, alkylsulfonyl, arylsulfonyl, heteroarylsulfonyl, aryldiazinyl, alkylsulfonylamino, arylsulfonylamino, arylalkylsulfonylamino, alkylcarbonylamino, alkenylcarbonylamino, arylcarbonylamino, arylalkylcarbonylamino, heteroarylcarbonylamino, heteroarylalkycarbonylamino, alkylsulfonylamino, alkenylsulfonylamino, arylsulfonylamino, arylalkylsulfonylamino, heteroaiylsulfonylamino, heteroarylalkylsulfonylamino, alkylaminocarbonylamino, alkenylaminocarbonylamino, arylaminocarbonylamino, arylalkylaminocarbonylamino, heteroarylaminocarbonylamino, heteroarylalkylcarbonylamino, and, in the case of heterocyclyl, oxo. If any other groups are identified as being "substituted"
or "optionally substituted", then those groups can also be substituted by one or more of the above enumerated substituents.
Certain substituents are generally preferred. For example, preferred X groups include ethylene and n-butylene and preferred Rl groups are alkyl and aryl, with phenyl or substituted phenyl a preferred aryl group. Preferably no R substituents are present (i.e., n is 0). Preferred R2 groups include hydrogen, alkyl groups having 1 to 4 carbon atoms (i.e., methyl, ethyl, propyl, isopropyl, n-butyl, sec-butyl, isobutyl, and cyclopropylmethyl), methoxyethyl, and ethoxymethyl. One or more of these preferred substituents, if present, can be present in the compounds of the invention in any combination.
The invention is inclusive of the compounds described herein in any of their pharmaceutically acceptable forms, including isomers (e.g., diastereomers and enantiomers), salts, solvates, polymorphs, and the like. In particular, if a compound is optically active, the invention specifically includes each of the compound's enantiomers as well as racemic mixtures of the enantiomers.
Pharmaceutical Compositions and Biological Activity Pharmaceutical compositions of the invention contain a therapeutically effective amount of a compound of the invention as described above in combination with a pharmaceutically acceptable carrier.
The term "a therapeutically effective amount" means an amount of the compound sufficient to induce a therapeutic effect, such as cytokine induction, antitumor activity, and/or antiviral activity. Although the exact amount of active compound used in a pharmaceutical composition of the invention will vary according to factors known to those of skill in the art, such as the physical and chemical nature of the compound, the nature of the carrier, and the intended dosing regimen, it is anticipated that the compositions of the invention will contain sufficient active ingredient to provide a dose of about 100 ng/kg to about 50 mg/kg, preferably about 10 g/kg to about 5 mg/kg, of the compound to the subject. Any of the conventional dosage forms may be used, such as tablets, lozenges, parenteral formulations, syrups, creams, ointments, aerosol formulations, transdermal patches, transmucosal patches and the like.
The compounds of the invention can be administered as the single therapeutic agent in the treatment regimen, or the compounds of the invention may be administered in combination with one another or with other active agents, including additional immune response modifiers, antivirals, antibiotics, etc.
The compounds of the invention have been shown to induce the production of certain cytokines in experiments performed according to the tests set forth below. These results indicate that the compounds are useful as immune response modifiers that can modulate the immune response in a number of different ways, rendering them useful in the treatment of a variety of disorders.
Cytokines whose production may be induced by the administration of compounds according to the invention generally include interferon-a (IFN-a) and/or tumor necrosis factor-a (TNF-a) as well as certain interleukins (IL). Cytokines whose biosynthesis may be induced by compounds of the invention include IFN-a, TNF-a, IL-1, IL-6, IL-10 and IL-12, and a variety of other cytokines. Among other effects, these and other cytokines can inhibit virus production and tumor cell growth, making the compounds useful in the treatment of viral diseases and tumors. Accordingly, the invention provides a method of inducing cytokine biosynthesis in an animal comprising administering an effective amount of a compound or composition of the invention to the animal.
Certain compounds of the invention have been found to preferentially induce the expression of IFN-a in a population of hematopoietic cells such as PBMCs (peripheral blood mononuclear cells) containing pDC2 cells (precursor dendritic cell-type 2) without concomitant production of significant levels of inflammatory cytokines.
In addition to the ability to induce the production of cytokines, the compounds of the invention affect other aspects of the innate immune response. For example, natural killer cell activity may be stimulated, an effect that may be due to cytokine induction. The compounds may also activate macrophages, which in turn stimulates secretion of nitric oxide and the production of additional cytokines. Further, the compounds may cause proliferation and differentiation of B-lymphocytes.
Compounds of the invention also have an effect on the acquired immune response.
For example, although there is not believed to be any direct effect on T cells or direct induction of T cell cytokines, the production of the T helper type 1 (Thl) cytokine IFN-y is induced indirectly and the production of the T helper type 2 (Th2) cytokines IL-4, IL-5 and IL-13 are inhibited upon administration of the compounds. This activity means that the compounds are useful in the treatment of diseases where upregulation of the Thl response and/or downregulation of the Th2 response is desired. In view of the ability of compounds of the invention to inhibit the Th2 immune response, the compounds are expected to be useful in the treatment of atopic diseases, e.g., atopic dermatitis, asthma, allergy, allergic rhinitis; systemic lupus erythematosis; as a vaccine adjuvant for cell mediated immunity; and possibly as a treatment for recurrent fungal diseases and chlamydia.
The immune response modifying effects of the compounds make them useful in the treatment of a wide variety of conditions. Because of their ability to induce the production of cytokines such as IFN-a and/or TNF-a, the compounds are particularly useful in the treatment of viral diseases and tumors. This immunomodulating activity suggests that compounds of the invention are useful in treating diseases such as, but not limited to, viral diseases including genital warts; common warts; plantar warts; Hepatitis B; Hepatitis C; Herpes Simplex Virus Type I and Type II; molluscum contagiosum;
variola, particularly variola major; HIV; CMV; VZV; rhinovirus; adenovirus;
influenza;
and para-influenza; intraepithelial neoplasias such as cervical intraepithelial neoplasia;
human papillomavirus (HPV) and associated neoplasias; fungal diseases, e.g.
candida, aspergillus, and cryptococcal meningitis; neoplastic diseases, e.g., basal cell carcinoma, hairy cell leukemia, Kaposi's sarcoma, renal cell carcinoma, squamous cell carcinoma, myelogenous leukemia, multiple myeloma, melanoma, non-Hodgkin's lymphoma, cutaneous T-cell lymphoma, and other cancers; parasitic diseases, e.g.
pneumocystis carnii, cryptosporidiosis, histoplasmosis, toxoplasmosis, trypanosome infection, and leishmaniasis; and bacterial infections, e.g., tuberculosis, and mycobacterium avium.
Additional diseases or conditions that can be treated using the compounds of the invention include actinic keratosis; eczema; eosinophilia; essential thrombocythaemia;
leprosy;
multiple sclerosis; Ommen's syndrome; discoid lupus; Bowen's disease; Bowenoid papulosis; alopecia areata; the inhibition of Keloid formation after surgery and other types of post-surgical scars. In addition, these compounds could enhance or stimulate the healing of wounds, including chronic wounds. The compounds may be useful for treating the opportunistic infections and tumors that occur after suppression of cell mediated immunity in, for example, transplant patients, cancer patients and HIV
patients.
An amount of a compound effective to induce cytokine biosynthesis is an amount sufficient to cause one or more cell types, such as monocytes, macrophages, dendritic cells and B-cells to produce an amount of one or more cytokines such as, for example, IFN-a, TNF-a, IL-1, IL-6, IL-10 and IL-12 that is increased over the background level of such cytokines. The precise amount will vary according to factors known in the art but is expected to be a dose of about 100 ng/kg to about 50 mg/kg, preferably about 10 g/kg to about 5 mg/kg. The invention also provides a method of treating a viral infection in an animal and a method of treating a neoplastic disease in an animal comprising administering an effective amount of a compound or composition of the invention to the animal. An amount effective to treat or inhibit a viral infection is an amount that will cause a reduction in one or more of the manifestations of viral infection, such as viral lesions, viral load, rate of virus production, and mortality as compared to untreated control animals. The precise amount will vary according to factors known in the art but is expected to be a dose of about 100 ng/kg to about 50 mg/kg, preferably about 10 g/kg to about 5 mg/kg. An amount of a compound effective to treat a neoplastic condition is an amount that will cause a reduction in tumor size or in the number of tumor foci. Again, the precise amount will vary according to factors known in the art but is expected to be a dose of about 100 ng/kg to about 50 mg/kg, preferably about 10 gg/kg to about 5 mg/kg.
The invention is further described by the following examples, which are provided for illustration only and are not intended to be limiting in any way.
Example 1 2-butyl- l -[4-(phenylthio)butyl]-1H-imidazo[4,5-c]quinolin-4-amine NHZ
N N
N
S `
Part A
A round bottom flask was charged with a magnetic stir bar, 4-chloro-3-nitroquinoline (109.70 g, 525.87 mmol) and dichloromethane (500 mL). To the solution was added triethylamine (79.82 g, 788.81 mmol) and 4-amino-l-butanol (46.87 g, 525.87 mmol) to give a homogeneous, dark yellow solution. The reaction was judged to be complete after heating at reflux for 30 minutes. The solution was cooled and then partitioned between chloroform and saturated aqueous ammonium chloride. The layers were separated and the aqueous layer was extracted with chloroform (lx). The organic layers were combined and then concentrated under reduced pressure to afford of 4-[(3-nitroquinolin-4-yl)amino]butan- 1 -ol (104.67 g, 400.60 mmol) as a dark yellow solid. This material was used without further purification.
Part B
A round bottom flask was charged with a magnetic stir bar, 4-[(3-nitroquinolin-yl)amino]butan-1-ol (5.0 g, 19.14 mmol), triethylamine (2.91 g, 28.71 mmol), tert-butyldimethylsilyl chloride (3.75 g, 24.9 mmol), 4-dimethylaminopyridine (0.10 g) and chloroform (40 mL) to give a dark yellow solution. The reaction was judged was to complete after stirring at ambient temperature for 2 hours. The solution was partitioned between ethyl acetate and saturated aqueous ammonium chloride. The layers were separated and the organic layer was washed with saturated aqueous sodium bicarbonate, dried over anhydrous sodium sulfate, filtered and then concentrated under reduced pressure to afford N-(4-{[tent-butyl(dimethyl)silyl]oxy}butyl)-3-nitroquinolin-4-amine (6.05 g, 16.11 mmol) as a yellow-green solid. This material was used without further purification. MS (CI) for C19H29N3O3Si m/z 376 (MH), 342, 210.
Part C
A Parr vessel was charged with N-(4-{[tent-butyl(dimethyl)silyl]oxy}butyl)-3-nitroquinolin-4-amine (6.05 g, 16.11 mmol), 5% platinum on carbon (3.0 g), and toluene (32 mL). The vessel was placed on a Parr shaker and pressurized to 50 psi (3.5 Kg/cm2) hydrogen. After shaking for one hour, more catalyst (3.0 g) and toluene (15 mL) were added and the vessel was pressurized to 50 psi (3.5 Kg/cm2) hydrogen and shaking continued. The reaction was judged to be complete after one hour. The catalyst was removed by filtration through fluted paper. The filter cake was washed with toluene (50 mL) and the filtrates were combined. The volatiles were removed under reduced pressure to afford N-(4-f [tert-butyl(dimethyl)silyl]oxy}butyl)quinoline-3,4-diamine (5.57 g, 16.11 ramol) as a dark oil. The material was used without further purification.
Part D
A round bottom flask was charged with a magnetic stir bar, N-(4-{[tert-butyl(dimethyl)silyl]oxy}butyl)quinoline-3,4-diamine (5.57 g, 16.11 mmol), trimethyl orthovalerate (5.23 g, 32.22 mmol) and toluene (47 mL). The reaction was heated to maintain a reflux that brought about a slow distillation to facilitate removal of the methanol byproduct. The reaction was judged to be complete after 15 hours at reflux.
The reaction was cooled and the volatiles were removed under reduced pressure to afford of 2-butyl-l -(4- {[tent-butyl(dimethyl)silyl]oxy}butyl)-1H-imidazo[4,5-c]
quinoline (4.65 g, 11.30 mmol) as a thick, dark brown oil. The material was used without further purification. MS (CI) for C24H37N3OSi m/z 412 (MH), 298.
Part E
A round bottom flask was charged with a magnetic stir bar, 2-butyl- 1 -(4- {
[tert-butyl(dimethyl)silyl]oxy}butyl)-1H-imidazo[4,5-c]quinoline (4.65 g, 11.30 mmol) and chloroform (57 mL). Solid 3-chloroperbenzoic acid (2.78 g, 12.43 mmol) was added portion wise to the solution over 15 minutes and the reaction was stirred at ambient temperature for 1 hour. More 3-chloroperbenzoic acid (0.5g, 2.9 mmol) was added and after 30 minutes the starting material was completely consumed. The solution was partitioned between chloroform and aqueous saturated sodium bicarbonate. The layers were separated. The organic layer was washed with saturated aqueous sodium bicarbonate and brine, dried over anhydrous sodium sulfate, filtered and then concentrated under reduced pressure to afford 2-butyl-l-(4-{[tent-butyl(dimethyl)silyl]oxy}butyl)-imidazo[4,5-c]quinoline-5N-oxide (4.83 g, 11.30 mmol) as a dark oil. The material was used without further purification.
Part F
A round bottom flask was charged with a magnetic stir bar, 2-butyl-1-(4-{[tert-butyl(dimethyl)silyl]oxy}butyl)-1H-imidazo[4,5-c]quinoline-5N-oxide (11.30 mmol) and anhydrous dimethyl formamide (57 mL) under a nitrogen atmosphere. Phosphorus oxychloride (1.91 g, 12.43 mmol) was added to the reaction mixture in a drop wise fashion to give a homogeneous solution after complete addition. The reaction was judged to be complete after stirring for 1.5 hours at ambient temperature and was then partitioned between dichloromethane and saturated aqueous sodium bicarbonate. The layers were separated and the organic portion was washed with aqueous saturated sodium bicarbonate and brine, dried over anhydrous sodium sulfate, filtered and then concentrated under reduced pressure to afford 2-butyl-4-chloro-l-(4-chlorobutyl)-1H-imidazo[4,5-c]quinoline (3.65 g, 10.42 mmol) as a dark brown solid. The material was used without further purification. MS (CI) for C18H21C12N3 m/z 350 (MH+), 314.
Part G
A round bottom flask was charged with a magnetic stir bar, 2-butyl-4-chloro- 1 -(4-chlorobutyl)-1H-imidazo[4,5-c]quinoline (1.18 g, 3.37 mmol), benzenethiol (0.56 g, 5.05 mmol), triethylamine (0.68 g, 6.74 mmol), and dimethyl formamide (15 mL) under a nitrogen atmosphere. The reaction mixture was heated to 80 C to give a homogeneous solution that was maintained at 80 C for 2.5 hours. HPLC analysis indicated no starting material and a 3:1 mixture of 2-butyl-4-chloro-l-[4-(phenylthio)butyl]-1H-imidazo[4,5-c]quinoline and 2-butyl-4-(phenylthio)-I-[4-(phenylthio)butyl]-1H-imidazo[4,5-c]quinoline. The solution was cooled and then partitioned between ethyl acetate and aqueous saturated sodium bicarbonate. The layers were separated and the organic layer was washed with aqueous saturated sodium bicarbonate and brine, dried over anhydrous sodium sulfate, filtered and then concentrated under reduced pressure to afford a 3:1 mixture of the products named above (1.43 g). The material was used without further purification.
Part H
A 3:1 mixture of 2-butyl-4-chloro-l-[4-(phenylthio)butyl]-1H-imidazo[4,5-c]quinoline to 2-butyl-4-(phenylthio)-1-[4-(phenylthio)butyl]-1H-imidazo[4,5-c]quinoline (1.38 g) and a solution of 7% ammonia in methanol (30 mL) were combined in a bomb and heated to 150 C. The reaction was judged to be complete after 5 hours.
The volatiles were removed under reduced pressure and the resulting residue was stirred in water and made basic (pH 10) with solid sodium carbonate. The aqueous mixture was extracted with chloroform (3x). The combined organic layers were washed with saturated aqueous sodium bicarbonate and brine, dried over anhydrous sodium sulfate, filtered and then concentrated under reduced pressure to afford a yellow crystalline solid. The solid (0.8 g) was dissolved in ethyl acetate (50 mL) and brought to reflux. Activated charcoal (0.4 g) was added; the resulting mixture was heated at reflux for 5 minutes and then the charcoal was removed by filtration through fluted paper to provide a colorless solution. The solution was concentrated under reduced pressure to give a solid that was recrystallized from ethyl acetate and hexanes to provide 2-butyl-l-[4-(phenylthio)butyl]-1H-imidazo[4,5-c]quinolin-4-amine (0.51 g, 1.25 mmol) as white needles, m.p. 118-120 C.
Analysis. Calculated for C24H28N4S: %C 71.25; %H, 6.98; %N, 13.85. Found %C
71.12;
%H, 6.81; %N, 13.62 'H-NMR (300 MHz, DMSO) b 8.02 (d, J = 8.3 Hz, IH), 8 7.61 (d, J = 8.3 Hz, 1H), 6 7.41 (t, J = 8.3 Hz, 1H), S 7.16-7.30 (m, 6H), S 6.46 (bs, 2H), S 4.52 (t, J = 7.6 Hz, 2H), S 3.02 (t, J = 7.3 Hz, 2H), 6 2.89 (t, J = 7.8 Hz, 2H), 6 1.95 (m, 2H), 6 1.75 (m, 4H), 6 1.43 (sextet, J = 7.3 Hz, 2H), 6 0.94 (t, J = 7.3 Hz, 3H) MS (Cl) for C24H28N4S m/z 405 (MH+), 282, 241 Example 2 2-butyl-1-[2-(phenylthio)ethyl]-6,7,8,9-tetrahydro-1H-imidazo[4,5-c]quinolin-4-amine hydrochloride NH
N N
S
Part A
A round bottom flask was charged with a magnetic stir bar, 2-(4-amino-2-butyl-6,7,8,9-tetrahydro-lH-imidazo[4,5-c]quinolin-1-yl)ethanol (1.0 g, 3.47 mmol), tert-butyldimethylsilyl chloride (1.62 g, 10.75 mmol), triethylamine (1.58 g, 15.62 mmol), 4-dimethylaminopyridine (0.1 g), and chloroform (30 mL) to give a heterogeneous reaction mixture. The reaction was judged to be complete after stirring at 60 C for 2 hours. The solution was partitioned between ethyl acetate and saturated aqueous ammonium chloride.
The layers were separated and the organic layer was washed with aqueous saturated sodium bicarbonate and brine, dried over anhydrous sodium sulfate, filtered and then concentrated under reduced pressure to afford a 3:1 mixture of 2-butyl- 1 -(2-{[tert-butyl(dimethyl)silyl]oxy}ethyl)-6,7,8,9-tetrahydro-lH-imidazo[4,5-c]quinolin-4-amine and 2-butyl-N-[tent-butyl(dimethyl)silyl]-1-(2-{[tent-butyl(dimethyl)silyl]oxy}ethyl)-6,7,8,9-tetrahydro-1H-imidazo[4,5-c]quinolin-4-amine (1.79 g) as a dark brown oil. The material was used without further purification.
Part B
A round bottom flask was charged with a magnetic stir bar, a 3:1 mixture of 2-butyl-l -(2- { [tent-butyl(dimethyl)silyl]oxy} ethyl)-6,7,8,9-tetrahydro-lH-imidazo[4,5-c]quinolin-4-amine and 2-butyl-N-[tent-butyl(dimethyl)silyl]-1-(2-{[tert-butyl(dimethyl)silyl]oxy} ethyl)-6,7,8,9-tetrahydro-lH-imidazo[4,5-c]quinolin-4-amine (1.6 g) and a 1 M solution of acetic acid in dichloromethane (85 mL) to provide a homogenous solution. The reaction was judged to be complete after stirring at ambient temperature for 30 minutes. The solution was partitioned between chloroform and brine.
The layers were separated and the organic layer was washed with aqueous saturated sodium bicarbonate and brine, dried over anhydrous sodium sulfate, filtered and then concentrated under reduced pressure to afford a dark brown oil. The material was purified by chromatography over silica gel (95/4/1 dichloromethane/methanol/ammonium hydroxide [ 14.8 M in water]) to provide 2-butyl- 1 -(2- { [tert-butyl(dimethyl)silyl]oxy} ethyl)-6,7,8,9-tetrahydro-1H-imidazo[4,5-c]qu nolin-4-amine (1.24 g, 3.10 mmol) as a colorless oil.
Part C
A round bottom flask was charged with a magnetic stir bar, 2-butyl-1-(2-{[tert-butyl(dimethyl)silyl]oxy} ethyl)-6,7,8,9-tetrahydro-lH-imidazo[4,5-c]quinolin-4-amine (0.83 g, 2.06 mmol), di-tert-butyl dicarbonate (1.79 g, 8.24 mmol), triethylamine (0.52 g, 5.15 mmol), 4-dimethylaminopyridine (0.1 g), and anhydrous tetrahydrofuran (21 mL) under a nitrogen atmosphere. The reaction mixture was heated to 60 C to give a homogeneous solution that was maintained at 60 C for 2.5 hours at which time the reaction was judged to be complete. The solution was cooled to ambient temperature and a 1 M solution of tetrabutylammonium fluoride in tetrahydrofuran (2.27 mL, 2.27 mmol) was added. The reaction was judged to be complete after stirring at ambient temperature for 30 minutes. The solution was partitioned between ethyl acetate and saturated aqueous ammonium chloride. The layers were separated. The organic layer was washed with saturated aqueous sodium bicarbonate and brine, dried over anhydrous sodium sulfate, filtered and then concentrated under reduced pressure to afford a light yellow solid. The material was purified by chromatography over silica gel (95/5 dichloromethane/methanol) to provide di(tert-butyl) 2-butyl-l-(2-hydroxyethyl)-6,7,8,9-tetrahydro-lH-imidazo[4,5-c] quinolin-4-ylimidodicarbonate (0.55 g, 1.13 mmol) as a clear gum.
Part D
A round bottom flask was charged with a magnetic stir bar, di(tert-butyl) 2-butyl-1-(2-hydroxyethyl)-6,7,8,9-tetrahydro-lH-imidazo[4,5-c]quinolin-4-ylimidodicarbonate (0.55 g, 1.13 mmol) and anhydrous dichloromethane (11 mL) under a nitrogen atmosphere. The resulting homogeneous solution was cooled to -10 C in a methanol/ice bath. To the cooled solution was added triethylamine (0.23 g, 2.26 mmol) and methanesulfonyl chloride (0.19 g, 1.70 mmol). The reaction was judged to be complete after stirring at -10 C for 15 minutes and was then partitioned between ethyl acetate and saturated aqueous ammonium chloride. The layers were separated. The organic layer was washed with saturated aqueous sodium bicarbonate and brine, dried over anhydrous sodium sulfate, filtered and then concentrated under reduced pressure to afford 2-{4-[bis(tert-butoxycarbonyl)amino]-2-butyl-6,7,8,9-tetrahydro-lH-imidazo[4,5-c]quinolin-l-yl}ethyl methanesulfonate (0.61 g, 1.08 mmol) as a gummy yellow solid. The material was used without further purification. MS (CI) for C27H42N407S m/z 567 (MH+), 467, 367, 271.
Part E
A round bottom flask was charged with a magnetic stir bar, 2-{4-[bis(tert-butoxycarbonyl)amino]-2-butyl-6,7,8,9-tetrahydro-lH-imidazo[4,5-c]quinolin-l -yl} ethyl methanesulfonate (0.61 g, 1.08 mmol), benzenethiol (0.21 g, 1.88 mmol), triethylamine (0.25 g, 2.43 mmol) and anhydrous dimethyl formamide (11 mL) under a nitrogen atmosphere. The reaction mixture was heated to 80 C to give a dark yellow, homogeneous solution that was maintained at 80 C for 2.5 hours at which time the reaction was judged to be complete. The solution was cooled and then partitioned between ethyl acetate and saturated aqueous sodium bicarbonate. The layers were separated. The organic layer was washed with saturated aqueous sodium bicarbonate and brine, dried over anhydrous sodium sulfate, filtered and then concentrated under reduced pressure to afford a yellow oil. The material was purified by chromatography over silica gel (95/5 dichloromethane/methanol) to provide di(tert-butyl) 2-butyl- 1 -[2-(phenylthio)ethyl]-6,7,8,9-tetrahydro-lH-imidazo[4,5-c]quinolin-4-ylimidodicarbonate (0.54 g, 0.93 mmol) as a light yellow oil. MS (CI) for C32H44N4O4S m/z 581 (MH+), 481, 381, 245.
Part F
A round bottom flask was charged with a magnetic stir bar, di(tert-butyl) 2-butyl-1-[2-(phenylthio)ethyl] -6, 7, 8,9-tetrahydro-lH-imidazo[4,5-c]quinolin-4-ylimidodicarbonate (0.50 g, 0.86 mmol), a 4 M solution of hydrochloric acid in dioxane (5 mL), and dichloromethane (5 mL). The reaction was judged to be complete after stirring at ambient temperature for 2 hours. The volatiles were removed under reduced pressure to afford an off white solid. The material was recrystallized from acetonitrile to provide 2-butyl- 1-[2-(phenylthio)ethyl]-6,7,8,9-tetrahydro-1H-imidazo[4,5-c]quinolin-4-amine hydrochloride (0.17 g, 1.30 mmol) as fluffy white needles, m.p. 237-238 C.
Analysis.
Calculated for C22H28N4S =(H2O)114 = (HCl)2: %C 57.70; %H, 6.71; %N, 12.23.
Found %C
57.62; %H, 6.57; %N, 12.41 'H-NMR (300 MHz, DMSO) 6 7.81 (bs, 2H), 6 7.22-7.39 (m, 5H), S 4.64 (t, J =
6.8 Hz, 2H), 6 3.40 (t, J = 6.8 Hz, 2H), 6 2.75 (m, 6H), S 1.71 (m, 6H), S 1.34 (sextet, J = 7.3 Hz, 2H), 8 0.89 (t, J = 7.3 Hz, 3H) MS (CI) for C22H28N4S (H20)114 (HCl)2 m/z 381 (MH+), 245, 137 Example 3 2-butyl-l -[4-(phenylsulfonyl)butyl]-1H-imidazo[4,5-c]quinolin-4-amine N N
N
O=S=O
\
Part A
Using the general method of Example 1 Part E, 2-butyl-1-(4-{[tert-butyl(dimethyl)silyl]oxy}butyl)-1H-imidazo[4,5-c]quinoline (16.0 g, 38.87 mmol) was oxidized to 2-butyl-l-(4-{[tent-butyl(dimethyl)silyl]oxy}butyl)-1H-imidazo[4,5-c]quinoline-5N-oxide (16.61 g, 38.87 mmol) which was isolated without purification as a tan solid.
Part B
A round bottom flask was charged with a magnetic stir bar, 2-butyl-1-(4-{[tert-butyl(dimethyl)silyl]oxy}butyl)-1H-imidazo[4,5-c]quinoline-5N-oxide (16.61 g, 38.87 mmol), a 14.8 M solution of ammonium hydroxide in water (75 mL) and chloroform (200 mL). To the rapidly stirring solution was addedp-toluenesulfonyl chloride (8.15 g, 42.76 mmol) in a portion wise fashion resulting in a mild exotherm. The reaction was judged to be complete after stirring at ambient temperature for 10 minutes. The solution was partitioned between chloroform and aqueous saturated sodium bicarbonate. The layers were separated. The organic layer was washed with saturated aqueous sodium bicarbonate and brine, dried over anhydrous sodium sulfate, filtered and then concentrated under reduced pressure to afford an off-white solid. The material was triturated with ethyl ether and collected by filtration to provide 2-butyl-l-(4-{[tent-butyl(dimethyl)silyl]oxy}butyl)-1H-imidazo[4,5-c]quinolin-4-amine (9.3 g, 21.80 mmol) as a fine white powder.
The material was used without further purification.
Part C
A round bottom flask was charged with a magnetic stir bar, 2-butyl-1-(4-{[tert-butyl(dimethyl)silyl]oxy}butyl)-1H-imidazo[4,5-c]quinolin-4-amine (9.2 g, 21.56 mmol), a 1M solution of tetrabutylammonium fluoride in tetrahydrofuran (23.72 mL, 23.72 mmol), and anhydrous tetrahydrofuran (100 mL) to give a homogeneous, light orange solution. The reaction was judged to be complete after stirring at ambient temperature for 1 hour. While stirring, water (100 mL) was added and resulted in a mild exotherm. The volatiles were removed under reduced pressure until a solid precipitated out of solution.
The solid was collected by filtration and washed with water (20 mL) and acetone (20 mL) to afford a white solid. The material was triturated with ethyl ether (50 mL) and collected by filtration to provide 4-(4-amino-2-butyl-lH-imidazo[4,5-c]quinolin-1-yl)butan-l-ol (6.12 g, 19.59 mmol) as a fine white solid, m.p. 184-186 C.
Analysis. Calculated for C18H24N40: %C 69.20; %H, 7.74; %N, 17.93. Found %C
69.05;
%H, 8.02; %N, 18.03 MS (CI) for C 18H24N40 m/z 313 (MH+) Part D
A round bottom flask was charged with a magnetic stir bar, 4-(4-amino-2-butyl-1 H-imidazo[4,5-c]quinolin-1-yl)butan-l-ol (7.3 g, 23.37 mmol), triethylamine (3.55 g, 35.06 mmol), and anhydrous dimethyl formamide (93 mL) under a nitrogen atmosphere.
To the stirred solution was added phosphorus oxychloride (3.94 g, 25.70 mmol) in a drop wise fashion resulting in an exotherm to give a dark yellow heterogeneous reaction mixture. The reaction mixture was heated to 60 C to give a homogeneous solution that was maintained at 60 C for 5 hours at which time the starting material was completely consumed. The volatiles were removed under reduced pressure to give a dark brown oil.
The material was partitioned between chloroform and saturated aqueous sodium bicarbonate. The layers were separated and the aqueous layer was extracted with chloroform (lx). The organic layers were combined and the volatiles removed under reduced pressure to afford a 2:1 mixture ofN-[2-butyl-l-(4-chlorobutyl)-1H-imidazo[4,5-c]quinolin-4-yl]-N,N-dimethylimidoformamide and 2-butyl-l-(4-chlorobutyl)-1H-imidazo[4,5-c]quinolin-4-amine (7.70 g) as an off-white solid. The material was used without further purification.
Part E
A round bottom flask was charged with a magnetic stir bar, a 2:1 mixture of N-[2-butyl- l -(4-chlorobutyl)-1 H-imidazo [4, 5-c]quinolin-4-yl]-N,N-dimethylimidoformamide and 2-butyl-l-(4-chlorobutyl)-1H-imidazo[4,5-c]quinolin-4-amine (1.3 g), benzenesulfinic acid sodium salt (1.67 g, 10.11 mmol), and anhydrous dimethyl formamide (15 mL) under a nitrogen atmosphere. The resulting solution was heated to 100 C to give a homogeneous solution that was maintained at 100 C for 90 hours at which time the starting materials were completely consumed. The solution was cooled and then partitioned between chloroform and water. The layers were separated. The organic layer was washed with saturated aqueous sodium bicarbonate and brine, dried over anhydrous sodium sulfate, filtered and then concentrated under reduced pressure to afford a dark yellow gum. The material was dissolved in methanol (20 mL) and a 4 M solution of hydrochloric acid in dioxane (3.02 mL, 12.1 mmol). The light orange solution was stirred at ambient temperature for 12 hours at which time the reaction was judged to be complete.
The volatiles were removed under reduced pressure to give a light yellow gum.
The material was partitioned between chloroform and saturated aqueous sodium bicarbonate.
The layers were separated and the aqueous layer was extracted with chloroform (lx). The organic layers were combined, washed with brine, dried over anhydrous sodium sulfate, filtered and then concentrated under reduced pressure to afford a light yellow solid. The material was purified by chromatography over silica gel (95/5 dichloromethane/methanol) to give an off-white solid. The solid (0.63 g) was dissolved in ethyl acetate (50 mL) and brought to reflux. Activated charcoal (0.6 g) was added and the resulting mixture was heated at reflux for 5 minutes. The charcoal was removed by filtration through fluted paper to provide a colorless solution. The solution was concentrated under reduced pressure to give a solid that was recrystallized from ethyl acetate and hexanes to provide 2-butyl-l-[4-(phenylsulfonyl)butyl]-IH-imidazo[4,5-c]quinolin-4-amine (0.37 g, 0.85 mmol) as a white fluffy solid, m.p. 179-180 C. Analysis. Calculated for C24H28N402S:
%C 66.03; %H, 6.46; %N, 12.83. Found %C 65.88; %H, 6.49; %N, 12.76 'H-NMR (300 MHz, DMSO) 6 7.98 (d, J = 8.3 Hz, 1H), 8 7.82 (m, 2H) 8 7.73 (d, J
= 7.3 Hz, 1H), 5 7.62 (m, 3H) 8 7.41 (t, J = 7.6 Hz, 1H), 6 7.22 (t, J = 7.6 Hz, 1H), 8 6.45 (bs, 2H), 6 4.51 (t, J = 7.3 Hz, 2H), 5 3.90 (t, J = 7.8 Hz, 211), 8 2.86 (t, J =
7.6 Hz, 3H), 6 1.69-1.90 (m, 6H), 6 1.43 (sextet, J = 7.3 Hz, 2H), 8 0.95 (t, J = 7.3 Hz, 3H) MS (CI) for C24H28N402S m/z 437 (MH+), 295 Example 4 2-butyl-1 [4-(methylthio)butyl]-lH-imidazo[4,5-c]quinolin-4-amine N N
N
S
Part A
A round bottom flask was charged with a magnetic stir bar, a 2:1 mixture of N-[2-butyl- l -(4-chlorobutyl)-1 H-imidazo [4, 5 -c] quinolin-4-yl]-N,N-dimethylimidoformamide and 2-butyl-l-(4-chlorobutyl)-1H-imidazo[4,5-c]quinolin-4-amine (6.17 g), a 4 M solution of hydrochloric acid in dioxane (21.15 mL, 84.56 mmol), and methanol (200 mL) to provide a light orange solution. The reaction was judged to be complete after stirring at ambient temperature for 43 hours. The volatiles were removed under reduced pressure and the resulting light yellow solid was partitioned between chloroform and saturated aqueous sodium bicarbonate. The layers were separated and the aqueous layer was extracted with chloroform (lx). The organic layers were combined, dried over anhydrous sodium sulfate, filtered and then concentrated under reduced pressure to afford 2-butyl-1-(4-chlorobutyl)-lH-imidazo[4,5-c]quinolin-4-amine (4.65 g, 14.05 mmol) as an off-white solid. The material was used without further purification. MS (CI) for C18H23C1N4 m/z 331 (MH+), 295.
Part B
A round bottom flask was charged with a magnetic stir bar, 2-butyl-1-(4-chlorobutyl)-1H-imidazo[4,5-c]quinolin-4-amine (1.5 g, 4.53 mmol), sodium thiomethoxide (0.48 g, 6.80 mmol), and anhydrous dimethyl formamide (18 mL) under a nitrogen atmosphere, The reaction mixture was heated to 60 C to give a homogeneous solution that was maintained at 60 C for 16 hours at which time the starting material was completely consumed. The solution was cooled and then partitioned between chloroform and water. The layers were separated and the organic layer was washed with saturated aqueous sodium bicarbonate. The combined aqueous layers were extracted with chloroform (lx). The combined organic layers were washed with brine, dried over anhydrous sodium sulfate, filtered and then concentrated under reduced pressure to afford a dark brown oil. The material was purified by chromatography over silica gel (90/10 dichloromethane/methanol) to provide a light yellow solid. The solid was recrystallized from dimethyl forinamide and water to give 2-butyl-l-[4-(methylthio)butyl]-1H-imidazo[4,5-c]quinolin-4-amine (0.83 g, 2.42 mmol) as light yellow needles, m.p. 127-130 C.
Analysis. Calculated for C19H26N4S: %C 66.63; %H, 7.65; %N, 16.36. Found %C
66.68;
%H, 7.53; %N, 16.35 1H-NMR (500 MHz, DMSO) 8 8.04 (d, J = 8.3 Hz, 1H), S 7.61 (d, J = 8.3 Hz, 1H), 8 7.41 (t, J = 8.3 Hz, 1H), 8 7.25 (t, J = 8.3 Hz, 1H), 6 6.43 (bs, 2H), 8 4.52 (t, J
= 7.6 Hz, 2H), 8 2.92 (t, J = 7.8 Hz, 2H), 8 2.53 (t, J = 7.3 Hz, 2H), 8 2.01 (s, 3H), 6 1.90 (m, 2H) 8 1.80 (p, J = 7.8 Hz, 2H) 6 1.71 (p, J = 7.3 Hz, 2H) 8 1.46 (sextet, J = 7.3 Hz, 2H), 6 0.96 (t, J = 7.3 Hz, 3H) MS (CI) for C19H26N4S m/z 343 (MH+), 295, 241 Example 5 2-butyl-l -[4-(methylsulfonyl)butyl]-1H-imidazo[4,5-c]quinolin-4-amine N ~ N
I
6O=S=O
Part A
A round bottom flask was charged with a magnetic stir bar, 2-butyl-l-[4-(methylthio)butyl]-1H-imidazo[4,5-c]quinolin-4-amine (1.2 g, 3.50 mmol), and chloroform (18 mL). Solid 3-chloroperbenzoic acid (1.72 g, 7.71 mmol) was added to the resulting solution portion wise over 15 minutes. The reaction was judged to be complete after stirring at ambient temperature for 5 minutes. The solution was partitioned between chloroform and 1% aqueous sodium carbonate. The layers were separated and the organic layer was washed with brine, dried over anhydrous sodium sulfate, filtered and then concentrated under reduced pressure to afford a light brown solid. The material was purified by chromatography over silica gel (90/10 dichloromethane/methanol) to provide an off-white solid. The solid was recrystallized from acetonitrile and water to give 2-butyl-l-[4-(methylsulfonyl)butyl]-1H-imidazo[4,5-c]quinolin-4-amine (0.61 g, 1.63 mmol) as off-white needles, m.p. 164-165 C.
Analysis. Calculated for C19H26N402S: %C 60.94; %H, 7.00; %N, 14.96. Found %C
60.71; %H, 6.94; %N, 14.94 1H-NMR (300 MHz, DMSO) 6 8.03 (d, J = 8.3 Hz, 1H), 6 7.61 (d, J = 8.3 Hz, 1H), 8 7.42 (t, J = 8.3 Hz, 1H), 8 7.26 (t, J = 8.3 Hz, 1H), 6 6.46 (bs, 2H), S 4.56 (t, J
= 7.6 Hz, 2H), 6 3.21 (t, J = 7.3 Hz, 2H), 6 2.96 (s, 3H), 6 2.93 (t, J = 7.8 Hz, 2H), 6 1.91 (m, 4H), 6 1.81 (p, J = 7.3 Hz, 2H), 8 1.45 (sextet, J = 7.3 Hz, 2H), 8 0.96 (t, J = 7.3 Hz, 3H) MS (CI) for C19H26N402S m/z 375 (MH+), 295 Example 6 1-[2-(phenylthio)ethyl]-1H-imidazo[4,5-c]quinolin-4-amine N N
N
S
Part A
A round bottom flask was charged with a magnetic stir bar, 2-(4-amino-lH-imidazo[4,5-c]quinolin-1-yl)ethanol (8.46 g, 37.06 mmol), and thionyl chloride (68.99 g, 57.99 mmol) under a nitrogen atmosphere. The reaction mixture was heated to 80 C to give a heterogeneous reaction mixture that was maintained at 80 C for 2 hours at which time the starting material was completely consumed. The solution was cooled and quenched by the addition of water (400 mL). To the stirred solution was added solid sodium carbonate until the pH reached 10 at which time a solid precipitated out of solution. The solid was collected by filtration to afford 1-(2-chloroethyl)-1H-imidazo[4,5-c]quinolin-4-amine (7.86 g, 31.86 mmol) as an off-white solid. The material was used without further purification.
Part B
A round bottom flask was charged with a magnetic stir bar, 1-(2-chloroethyl)-imidazo[4,5-c]quinolin-4-amine (2.0 g, 8.11 mmol), sodium benzenethiolate (1.79 g, 12.16 mmol), and anhydrous dimethyl sulfoxide (40 mL) under a nitrogen atmosphere.
The reaction mixture was heated to 100 C to give a homogeneous solution that was maintained at 100 C for 30 minutes at which time the starting material was completely consumed. The hot solution was poured into rapidly stirred water (300 mL) which caused a solid to precipitate out of solution. The solid was collected by filtration to afford an off-white solid. The material was triturated with acetonitrile and collected by filtration to give 1-[2-(phenylthio)ethyl]-1H-imidazo[4,5-c]quinolin-4-amine (2.08 g, 6.49 mmol) as an off-white powder, in. p. 233-235 C.
Analysis. Calculated for C18H16N4S: %C 67.47; %H, 5.03; %N, 17.49. Found: %C
67.20;
%H, 4.95; %N, 17.52 1H-NMR (300 MHz, DMSO) 5 8.14 (s, 1H), 6 7.76 (d, J = 8.3 Hz, 1H), S 7.60 (t, J = 8.3 Hz, 1H), 6 7.28-7.44 (m, 6H), 6 7.12 (t, J = 8.3 Hz, 1H), 6 6.58 (bs, 2H), 6 4.79 (t, J = 6.8 Hz, 2H), 6 3.48 (t, J = 6.8 Hz, 2H) MS (CI) for C18H16N4S m/z 321 (MH), 185, 137 Example 7 1-[4-(phenylsulfonyl)butyl]-1H-imidazo[4,5-c]quinolin-4-amine N N\>
N
O=S=O
Part A
A round bottom flask was charged with a magnetic stir bar, N,N-dibenzyl-1H-imidazo[4,5-c]quinolin-4-amine (20.0 g, 55.04 mmol), sodium hydride (3.3 g, 60%
dispersion, 82.56 mmol), and anhydrous dimethyl formamide (275 mL) under a nitrogen atmosphere. After the reaction mixture had stirred at ambient temperature for 2 hours, 4-chloro-1-iodobutane (19.23 g, 88.06 mmol) was added and the resulting homogeneous solution was stirred at ambient temperature for 48 hours at which time the starting material was consumed. The solution was partitioned between ethyl acetate and water.
The layers were separated and the organic layer was washed with saturated aqueous sodium bicarbonate and brine, dried over anhydrous sodium sulfate, filtered and then concentrated under reduced pressure to afford a light yellow solid. The material was recrystallized from ethyl acetate and hexanes to give N,N-dibenzyl-l-(4-chlorobutyl)-IH-imidazo[4,5-c]quinolin-4-amine (20.7 g, 45.49 mmol) as white needles. MS (CI) for C28H27C1N4 m/z 455 (MH+), 365, 329, 239 Part B
A round bottom flask was charged with a magnetic stir bar, N,N-dibenzyl-1-(4-chlorobutyl)- 1H-imidazo[4,5-c]quinolin-4-amine (7.0 g, 15.38 mmol), sodium benzenethiolate (3.46 g, 26.15 mmol), and anhydrous dimethyl formamide (77 mL) under a nitrogen atmosphere. The reaction mixture was heated to 60 C to give a heterogeneous mixture that was maintained at 60 C for 4 hours at which time the starting material was completely consumed. The cooled solution was partitioned between ethyl acetate and water. The layers were separated. The organic layer was washed with saturated aqueous sodium bicarbonate and brine, dried over anhydrous sodium sulfate, filtered and then concentrated under reduced pressure to afford a colorless oil. The material was purified by chromatography over silica gel (80/20 hexanes/ethyl acetate) to provide N,N-dibenzyl-1-[4-(phenylthio)butyl]-1H-imidazo[4,5-c]quinolin-4-amine (7.5 g, 14.19 mmol) as a colorless oil. MS (CI) for C34H32N4S m/z 529 (MH+), 439, 349 Part C
A round bottom flask was charged with a magnetic stir bar, N,N-dibenzyl-l-[4-(phenylthio)butyl]-1H-imidazo[4,5-c]quinolin-4-amine (3.64 g, 6.88 mmol) and chloroform (34 mL). Solid 3-chloroperbenzoic acid (3.39 g, 15.14 mmol) was added portion wise to the resulting solution over 5 minutes. The reaction was judged to be complete after stirring at ambient temperature for 5 minutes. The solution was partitioned between chloroform and 1 % aqueous sodium carbonate. The layers were separated. The organic layer was washed with brine, dried over anhydrous sodium sulfate, filtered and then concentrated under reduced pressure to afford a red gum. The material was purified by chromatography over silica gel (dichloromethane) to provide N,N-dibenzyl-1-[4-(phenylsulfonyl)butyl]-1H-imidazo[4,5-c]quinolin-4-amine '(2.85 g, 5.08 mmol) as a light pink gum. MS (CI) for C34H32N402S m/z 561 (MH+), 471, 381 Part D
A round bottom flask was charged with a magnetic stir bar, N,N-dibenzyl-1-[4-(phenylsulfonyl)butyl]-1H-imidazo[4,5-c]quinolin-4-amine (1.0 g, 1.78 mmol), triflic acid (2.68 g, 17.83 mmol), and anhydrous dichloromethane (14 mL) under a nitrogen atmosphere. The reaction was judged to be complete after stirring at ambient temperature for 24 hours. The solution was partitioned between chloroform and excess aqueous sodium hydroxide (20%). The layers were separated. The aqueous layer was extracted with chloroform (3x). The organic layers were combined and then concentrated under reduced pressure to afford a light brown solid. The material was purified by chromatography over silica gel (90/10 dichloromethane/methanol) to provide a fine white powder which was recrystallized from acetonitrile to give 1-[4-(phenylsulfonyl)butyl]-1H-imidazo[4,5-c]quinolin-4-amine (0.32 g, 0.84 mmol) as white needles, in. p.
175-177 C.
Analysis. Calculated for C2oH2ON402S: %C 63.14; %H, 5.30; %N, 14.73. Found: %C
63.14; %H, 5.24; %N, 14.77 'H-NMR (300 MHz, DMSO) 8 8.15 (s, 1H), S 8.01 (d, J = 8.3 Hz, 1H), 8 7.80 (m, 2H), 8 7.71 (m, 1H), 6 7.60 (m, 3H), 6 7.44 (t, J = 8.3 Hz, 1H), 6 7.24 (t, J = 8.3 Hz, 1H), 8 6.59 (bs, 2H), 8 4.59 (t, J = 6.8 Hz, 2H), 5 3.38 (t, J = 7.8 Hz, 2H), 6 1.93 (m, 2H), 6 1.58 (m, 2H) MS (CI) for C2oH2oN402S m/z 381 (MH+), 239 Example 8 1-[4-(methylsulfonyl)butyl]-1H-imidazo[4,5-c]quinolin-4-amine NHZ
N N>
N
O=S=O
Part A
Using the general method of Example 7 Part B, N,N-dibenzyl-1-(4-chlorobutyl)-1H-imidazo[4,5-c]quinolin-4-amine (5.0 g, 10.99 mmol) was converted to N,N-dibenzyl-1-[4-(methylthio)butyl]-1H-imidazo[4,5-c]quinolin-4-amine using sodium thiomethoxide (1.16 g, 16.48 mmol). The material was purified by chromatography over silica gel (80/20 hexanes/ethyl acetate) to provide the product (4.91 g, 10.52 mmol) as a colorless oil. MS
(Cl) for C29H30N4S m/z 467 (MH+), 377, 287, 185 Part B
Using the general method of Example 7 Part C, N,N-dibenzyl-1-[4-(methylthio)butyl]-1H-imidazo[4,5-c]quinolin-4-amine (4.91 g, 15.52 mmol) was oxidized to N,N-dibenzyl-l-[4-(methylsulfonyl)butyl]-1H-imidazo[4,5-c]quinolin-4-amine which was purified by chromatography over silica gel (80/20 hexanes/ethyl acetate) to provide the product (4.53 g, 9.08 mmol) as a light orange solid. MS (CI) for C29H30N402S m/z 499 (MH+), 409, 319 Part C
Using the general method of Example 7 Part D, N,N-dibenzyl-l-[4-(methylsulfonyl)butyl]-1H-imidazo[4,5-c]quinolin-4-amine (4.53 g, 9.08 mmol) was converted to 1-[4-(methylsulfonyl)butyl]-1H-imidazo[4,5-c]quinolin-4-amine.
The material was recrystallized from methanol and water to afford the title compound (1.33 g, 4.18 mmol) as white needles, m.p. 203-204 C.
Analysis. Calculated for C15H18N402S: %C 56.58; %H, 5.70; %N, 17.60. Found: %C
56.33; %H, 5.63; %N, 17.41 'H-NMR (300 MHz, DMSO) S 8.22 (s, 1H), S 8.06 (d, J = 8.3 Hz, 1H), 6 7.62 (d, J = 8.3 Hz, I H), S 7.45 (t, J = 8.3 Hz, I H), b 7.27 (t, J = 8.3 Hz, I H), 6 6.59 (bs, 2H), b 4.65 (t, J =
6.8 Hz, 2H), b 3.19 (t, J = 7.8 Hz, 2H), 6 2.93 (s, 3H), S 1.99 (m, 2H), S
1.74 (m, 2H) MS (CI) for C15H18N402S m/z 319 (MH+), 239 Example 9 1-[4-(phenylthio)butyl]-lH-imidazo[4,5-c]quinolin-4-amine N N
N
S
Part A
Using the general method of Example 1 Part D, N-(4-{[tert-butyl(dimethyl)silyl]oxy}butyl)quinoline-3,4-diamine (101.21 g, 292.90 mmol) was cyclized to 1-(4-{[tert-butyl(dimethyl)silyl]oxy}butyl)-1H-imidazo[4,5-c]quinoline using triethyl orthoformate (65.11 g, 439.35 mmol). The product (75.0 g, 210.93 mmol) was isolated as a brown oil and used without further purification.
Part B
Using the general method of Example 1 Part E, 1-(4- { [tert-butyl(dimethyl)silyl]oxy}butyl)-1H-imidazo[4,5-c]quinoline (42.2 g, 118.69 minol) was oxidized to 1-(4-{[tert-butyl(dimethyl)silyl]oxy}butyl)-1H-imidazo[4,5-c]quinoline-5N-oxide (44.10 g, 118.69 mmol) which was isolated without further purification as a tan solid.
Part C
Using the general method of Example 3 Part B, 1-(4-{[tert-butyl(dimethyl)silyl]oxy}butyl)-1H-imidazo[4,5-c]quinoline-5N-oxide (44.10 g, 118.69 mmol) was aminated to provide 1-(4-{[tent-butyl(dimethyl)silyl]oxy}butyl)-lH-imidazo[4,5-c] quinolin-4-amine. The material was triturated with ethyl ether and collected by filtration to afford the product (21.54 g, 58.12 mmol) as a light brown solid which was used without further purification.
Part D
Using the general method of Example 3 Part C, 1-(4-{[tert-butyl(dimethyl)silyljoxy}butyl)-1H-imidazo[4,5-c]quinolin-4-amine (21.5 g, 58.02 mmol) was converted to 4-(4-amino-lH-imidazo[4,5-c]quinolin-1-yl)butan-l-ol. The material was triturated with cold methanol (0 C) and collected by filtration to afford the product (13.92 g, 54.30 mmol) which was used without further purification. MS (CI) for C14Hi6N4O m/z 257 (MH+), 185 Part E
Using the general method of Example 6 Part A, 4-(4-amino-lH-imidazo[4,5-c] quinolin- 1 -yl)butan- 1 -ol (5.0 g, 19.51 mmol) was chlorinated to provide 1-(4-chlorobutyl)- 1H-imidazo[4,5-c]quinolin-4-amine (4.92 g, 17.91 mmol) which was isolated without further purification as an off-white solid.
Part F
Using the general method of Example 6 Part B, except that the reaction temperature was lowered to 80 C, 1-(4-chlorobutyl)-lH-imidazo[4,5-c]quinolin-4-amine (1.5 g, 5.46 mmol) was converted to 1-[4-(phenylthio)butyl]-IH-imidazo[4,5-c]quinolin-4-amine. The resulting solid (1.53 g) was dissolved in acetonitrile (90 mL) and brought to reflux. Activated charcoal (0.9 g) was added and the resulting mixture was heated at reflux for 5 minutes and then the charcoal was removed by filtration through fluted paper to provide a colorless solution. The title compound (0.86 g, 2.47 mmol) was isolated as white needles, m.p 158-160 C.
Analysis. Calculated for C20H2ON4S: %C 68.94; %H, 5.79; %N, 16.08. Found: %C
68.70;
%H, 5.74; %N, 16.08 1H-NMR (300 MHz, DMSO) S 8.18 (s, 1H), 6 8.05 (d, J = 8.3 Hz, 1H), 6 7.63 (d, J = 8.3 Hz, 1H), S 7.45 (t, J = 8.3 Hz, 1H), 6 7.26 (m, 5H), 6 7.14-7.19 (m, 1H), S
6.60 (bs, 2H), 6 4.62 (t, J = 6.8 Hz, 2H), S 3.00 (t, J = 7.3 Hz, 2H), 6 2.00 (m, 2H), S 1.61 (m, 2H) MS (Cl) for C20H2ON4S m/z 349 (MH), 185 Example 10 1-[4-(methylthio)butyl]-1H-imidazo[4,5-c]quinolin-4-amine N N\\
N/
S
Part A
Using the general method of Example 6 Part B, except that the reaction temperature was lowered to 80 C, 1-(4-chlorobutyl)-1H-imidazo[4,5-c]quinolin-4-amine (1.5 g, 5.46 mmol) was converted to 1-[4-(methylthio)butyl]-1H-imidazo[4,5-c]quinolin-4-amine using sodium thiomethoxide (0.88 g, 12.56 mmol) in lieu of sodium benzenethiolate. The resulting solid (1.26 g) was dissolved in acetonitrile (40 mL) and brought to reflux. Activated charcoal (0.7 g) was added, the resulting mixture was heated at reflux for 5 minutes and then the charcoal was removed by filtration through fluted paper to provide a colorless solution. The solution was concentrated under reduced pressure to give a solid that was recrystallized from acetonitrile. The title compound (0.66 g, 2.30 mmol) was isolated as white needles, m.p 163-164 C.
Analysis. Calculated for C15H18N4S: %C 62.91; %H, 6.34; %N, 19.56. Found: %C
62.70;
%H, 6.19; %N, 19.45 'H-NMR (300 MHz, DMSO) 6 8.21 (s, 1H), S 8.06 (d, J = 8.3 Hz, 1H), 6 7.62 (d, J = 8.3 Hz, 1 H), 8 7.44 (t, J = 8.3 Hz, 1 H), S 7.26 (t, J = 8.3 Hz, 1 H), 6 6.59 (bs, 2H), 6 4.62 (t, J =
7.6 Hz, 2H), 6 2.50 (t, J = 6.8 Hz, 2H), 6 1.99 (s, 3H), 6 1.95 (p, J = 7.3 Hz, 2H), 6 1.59 (p, J = 7.3 Hz, 2H) MS (CI) for C15H18N4S m/z 287 (MH+), 185 Example 11 2-butyl-l -[5-(methylsulfonyl)pentyl]-lH-imidazo[4,5-c]quinolin-4-amine NHz N N
I
N
O
,S~
Part A
Using the general method of Example 1 Part A, 4-chloro-3-nitroquinoline (107.7 g, 525.87 mmol) was converted to 5-[(3-nitroquinolin-4-yl)amino]pentan-l-ol using amino- 1 -pentanol (79.82 g, 788.81 mmol) in lieu of 4-amino-butanol. The product (117.22 g, 425.77 mmol) was used without further purification as a dark yellow solid. MS
(CI) for C14H17N303 m/z 276 (MH+), 224 Part B
A round bottom flask was charged with a magnetic stir bar, 5-[(3-nitroquinolin-yl)amino]pentan-l-ol (5.0 g, 18.16 mmol), and thionyl chloride (40.78 g, 0.34 mmol) under a nitrogen atmosphere. The reaction mixture was heated to 80 C to give a homogeneous solution that was maintained at 80 C for 1 hour at which time the starting material was completely consumed. The volatiles were removed under reduced pressure and the resulting oil stirred in water made basic (pH 10) with solid sodium carbonate. The resulting solid was collected by filtration to afford N-(5-chloropentyl)-3-nitroquinolin-4-amine (4.80 g, 16.34 mmol) which was used without further purification.
Part C
Using the general method of Example 6 Part B, except that the reaction temperature was lowered to 80 C, N-(5-chloropentyl)-3-nitroquinolin-4-amine (4.75 g, 16.17 mmol) was converted to N-[5-(methylthio)pentyl]-3-nitroquinolin-4-amine using sodium thiomethoxide (1.43 g, 19.40 mmol) in lieu of sodium benzenethiolate.
The product (3.28 g, 10.74 mmol) was isolated without further purification as a light yellow solid. MS (CI) for C15H19N3O2S m/z 306 (MH+), 272, 117 Part D
Using the general method of Example 1 Part C, N-[5-(methylthio)pentyl]-3-nitroquinolin-4-amine (3.20 g, 10.48 mmol) was reduced to N4-[5-(methylthio)pentyl]quinoline-3,4-diamine (2.89 g, 10.48 mmol) which was isolated without further purification as a brown oil.
Part E
Using the general method of Example 1 Part D, N4-[5-(methylthio)pentyl]quinoline-3,4-diamine (2.89 g, 10.48 mmol) was cyclized to provide 2-butyl-l-[5-(methylthio)pentyl]-1H-imidazo[4,5-c]quinoline. The material was purified by chromatography over silica gel (ethyl acetate) to afford the product (2.10 g, 6.15 mmol) as a light brown oil.
Part F
A round bottom flask was charged with a magnetic stir bar, 2-butyl-l -[5-(methylthio)pentyl]-1H-imidazo[4,5-c]quinoline (2.1 g, 6.15 mmol) and chloroform (31 mL). Solid 3-chloroperbenzoic acid (4.41 g, 19.68 mmol) was added portion wise to the solution over 10 minutes and the reaction was stirred at ambient temperature for 30 minutes at which time the starting material was completely consumed. The solution was partitioned between chloroform and saturated aqueous sodium bicarbonate. The layers were separated. The organic layer was washed with saturated aqueous sodium bicarbonate and brine, dried over anhydrous sodium sulfate, filtered and then concentrated under reduced pressure to afford 2-butyl-l-[5-(methylsulfonyl)pentyl]-1H-imidazo[4,5-c]quinoline-5N-oxide (2.40 g, 6.15 mmol) as a tan solid. The material was used without further purification.
Part G
Using the general method of Example 3 Part B, 2-butyl-1-[5-(methylsulfonyl)pentyl]-1H-imidazo[4,5-c]quinoline-5N-oxide (2.40 g, 6.15 mmol) was aminated to provide 2-butyl-l-[5-(methylsulfonyl)pentyl]-1H-imidazo[4,5-c]quinolin-4-amine. The resulting solid (2.24 g) was dissolved in acetonitrile (40 mL) and brought to reflux. Activated charcoal (1 g) was added and the resulting mixture was heated at reflux for 5 minutes and then the charcoal was removed by filtration through fluted paper to provide a light brown solution. Upon cooling 2-butyl-l-[5-(methylsulfonyl)pentyl]-1H-imidazo[4,5-c]quinolin-4-amine (0.90 g, 2.32 mmol) was isolated as white needles, m.p.
173-175 C.
Analysis. Calculated for C20H28N402S: %C 61.83; %H, 7.26; %N, 14.42. Found: %C
61.58; %H, 7.27; %N, 14.36 'H-NMR (300 MHz, DMSO) 6 8.01 (d, J = 8.3 Hz, 1H), 6 7.61 (d, J = 8.3 Hz, 1H), 6 7.41 (t, J = 8.3 Hz, 1H), 6 7.26 (t, J = 8.3 Hz, 1H), 6 6.45 (bs, 2H), 6 4.51 (t, J
= 7.6 Hz, 2H), 6 3.10 (t, J = 7.8 Hz, 2H), 6 2.92 (s, 3H), 6 2.92 (t, J = 7.3 Hz, 2H), 6 1.76 (m, 6H), 6 1.54 (m, 2H), 6 1.46 (sextet, J = 7.3 Hz, 2H), 6 0.99 (t, J = 7.3 Hz, 3H) MS (CI) for C20H28N402S m/z 389 (MH+) Example 12 2-methyl-l-[5-(methylsulfonyl)pentyl]-1H-imidazo[4,5-c]quinolin-4-amine C
N N>-N
Part A
Using the general method of Example 1 Part D, IV4-[5-(methylthio)pentyl]quinoline-3,4-diamine (4.53 g, 16.37 mmol) was cyclized to provide 2-methyl-l-[5-(methylthio)pentyl]-1H-imidazo[4,5-c]quinoline using 1,1,1-trimethoxyethane (2.95 g, 24.6 mmol) and pyridine hydrochloride (0.1 g). The material was triturated with ethyl ether and collected by filtration to afford the product (3.78 g, 12.62 mmol) as a light brown solid which was used without further purification.
Part B
Using the general method of Example 11 Part F, 2-methyl-l-[5-(methylthio)pentyl]-lH-imidazo[4,5-c]quinoline (3.78 g, 12.62 mmol) was oxidized to 2-methyl-l-[5-(methylsulfonyl)pentyl]-1H-imidazo[4,5-c]quinoline-5N-oxide (4.38 g, 12.62 mmol) which was isolated as a tan solid and used without purification.
Part C
Using the general method of Example 3 Part B, 2-methyl-l-[5-(methylsulfonyl)pentyl]-IH-imidazo[4,5-c]quinoline-5N-oxide (4.38 g, 12.62 mmol) was aminated to provide 2-methyl-l-[5-(methylsulfonyl)pentyl]-1H-imidazo[4,5-c]quinolin-4-amine. The resulting solid was triturated with acetonitrile and collected by filtration to afford the title compound (0.8 g, 2.31 mmol) as an off-white solid, m.p. 235-240 C.
Analysis. Calculated for C17H22N402S: %C 58.94; %H, 6.40; %N, 16.17. Found: %C
58.77; %H, 6.34; %N, 16.39 'H-NMR (300 MHz, DMSO) 8 8.02 (d, J = 8.3 Hz, 1H), 8 7.60 (d, J = 8.3 Hz, IH), 6 7.41 (t, J = 8.3 Hz, 1H), 8 7.25 (t, J = 8.3 Hz, 1H), 6 6.49 (bs, 2H), 8 4.50 (t, J
= 7.3 Hz, 2H), 6 3.12 (t, J = 7.8 Hz, 2H), 6 2.92 (s, 3H), 6 2.61 (s, 3H), 6 1.86 (m, 2H), 6 1.74 (m, 2H), 6 1.53 (m, 2H) MS (Cl) for C17H22N402S m/z 347 (MH+), 267 Example 13 2-ethyl- l -[5-(methylsulfonyl)pentyl]-1H-imidazo [4, 5-c] quinolin-4-amine NHZ
N
N \\ /
N
,0 ,S"~
Part A
Using the general method of Example 1 Part D,1V4-[5-(methylthio)pentyl]quinoline-3,4-diamine (4.53 g, 16.37 mmol) was cyclized to 2-ethyl-l-[5-(methylthio)pentyl]-1H-imidazo[4,5-c]quinoline using triethyl orthopropionate (4.3 g, 24.56 mmol) and pyridine hydrochloride (0.1 g). The material was triturated with ethyl ether and collected by filtration to afford the product (3.25 g, 10.37 mmol) as an off-white powder which was used without further purification.
Part B
Using the general method of Example 11 Part F, 2-ethyl-1 -[5-(methylthio)pentyl]-1H-imidazo[4,5-c]quinoline (3.25 g, 10.37 mmol) was oxidized to 2-ethyl-l-[5-(methylsulfonyl)pentyl]-1H-imidazo[4,5-c]quinoline-5N-oxide (3.75 g, 10.37 mmol) which was isolated as a tan solid and used without purification.
Part C
Using the general method of Example 3 Part B, 2-ethyl-l-[5-(methylsulfonyl)pentyl]-1H-imidazo[4,5-c]quinoline-5N-oxide (3.75 g, 10.37 mmol) was aminated to provide 2-ethyl-l-[5-(methylsulfonyl)pentyl]-1H-imidazo[4,5-c]quinolin-4-amine. The resulting solid was recrystallized sequentially from ethanol and acetonitrile to afford the title compound (1.4 g, 3.88 mmol) as off-white needles, m.p. 189-191 C.
Analysis. Calculated for C18H24N402S: %C 59.98; %H, 6.71; %N, 15.54. Found: %C
59.71; %H, 6.68; %N, 15.64 'H-NMR (300 MHz, DMSO) 6 8.01 (d, J = 8.3 Hz, 1H), S 7.61 (d, J = 8.3 Hz, 1H), 6 7.42 (t, J = 8.3 Hz, 1H), 6 7.26 (t, J = 8.3 Hz, 1H), 6 6.45 (bs, 2H), 6 4.50 (t, J
= 7.6 Hz, 2H), 6 3.10 (t, J = 7.8 Hz, 2H), 8 2.95 (q, J = 7.3 Hz, 2H), 6 2.92 (s, 3H), 6 1.85 (m, 2H), 8 1.74 (m, 2H), 6 1.55 (m, 2H), 6 1.38 (t, J = 7.3 Hz, 3H) MS (CI) for C18H24N402S m/z 361 (MH+), 281 Example 14 1-[5-(methylsulfonyl)pentyl]-1H-imidazo[4,5-c]quinolin-4-amine N N>
N
,O
,S~
Part A
Using the general method of Example 1 Part D, N4-[5-(methylthio)pentyl]quinoline-3,4-diamine (4.53 g, 16.37 mmol) was cyclized to 1-[5-(methylthio)pentyl]-1H-imidazo[4,5-c]quinoline using triethyl orthoformate (3.64 g, 24.56 mmol) and pyridine hydrochloride (0.1 g). The product (4.05 g, 14.19 mmol) was isolated as a brown oil and used without further purification.
Part B
Using the general method of Example 11 Part F, 1-[5-(methylthio)pentyl]-1H-imidazo[4,5-c]quinoline (4.05 g, 14.19 mmol) was oxidized to 1-[5-(methylsulfonyl)pentyl]-1H-imidazo[4,5-c]quinoline-5N-oxide (4.73 g, 14.19 mmol) which was isolated as a tan solid and used without further purification.
Part C
Using the general method of Example 3 Part B, 1-[5-(methylsulfonyl)pentyl]-1H-imidazo[4,5-c]quinoline-5N-oxide (4.73 g, 14.19 mmol) was aminated to provide 1-[5-(methylsulfonyl)pentyl]-1H-imidazo[4,5-c]quinolin-4-amine. The material was purified by chromatography over silica gel (95/5 dichloromethane/methanol) to afford a light yellow solid. The solid was recrystallized from dimethyl formamide to give the title compound (0.43 g, 1.29 mmol) as a light yellow, granular solid, m.p. 199-201 C.
Analysis. Calculated for C16H2oN402S: %C 57.81; %H, 6.06; %N, 16.85. Found: %C
57.01; %H, 6.06; %N, 16.70 'H-NMR (300 MHz, DMSO) 8 8.20 (S, 1H), 6 8.04 (d, J = 8.3 Hz, 1H), S 7.62 (d, J = 8.3 Hz, 1H), 6 7.44 (t, J = 8.3 Hz, 111), 6 7.27 (t, J = 8.3 Hz, I H), 6 6.57 (bs, 2H), 6 4.61 (t, J =
6.8 Hz, 2H), 6 3.09 (t, J = 7.8 Hz, 2H), 6 2.92 (s, 3H), 6 1.91 (p, J = 7.6 Hz, 2H), 8 1.73 (m, 2H), 6 1.45 (m, 2H) MS (CI) for C16H2oN402S m/z 333 (MH+) Example 15 2-hexyl- l -[5-(methylsulfonyl)pentyl]-1H-imidazo[4,5-c]quinolin-4-amine N N
I
N
,o s Part A
A round bottom flask was charged with a magnetic stir bar, 1V4-[5-(methylthio)pentyl] quinoline-3,4-diamine (3.17 g, 11.46 mmol) and anhydrous pyridine (46 mL) under a nitrogen atmosphere. The resulting homogeneous solution was cooled to 0 C in an ice-water bath. To the cooled solution was added neat heptanoyl chloride (1.87 g, 12.61 mmol). The reaction was judged to be complete after stirring at ambient temperature for 1 hour. The volatiles were removed under reduced pressure and the resulting oil was partitioned between chloroform and water. The layers were separated.
The organic layer was washed with saturated aqueous sodium bicarbonate and brine, dried over anhydrous sodium sulfate, filtered and then concentrated under reduced pressure to afford N-(4-{[5-(methylthio)pentyl]amino }quinolin-3-yl)heptanamide (4.44 g, 11.46 mmol) which was isolated as a brown oil and used without further purification.
Part B
A round bottom flask was charged with a magnetic stir bar, N-(4-{[5-(methylthio)pentyl]amino }quinolin-3-yl)heptanamide (4.44 g, 11.46 mmol), pyridine hydrochloride (0.13 g, 1.15 mmol), and anhydrous pyridine (50 mL) under a nitrogen atmosphere. The reaction was judged to be complete after stirring at reflux for 1.5 hours.
The solution was cooled and partitioned between ethyl acetate and water. The layers were separated. The organic layer was washed with saturated aqueous sodium bicarbonate and brine, dried over anhydrous sodium sulfate, filtered and then concentrated under reduced pressure to afford 2-hexyl-l-[5-(methylthio)pentyl]-1H-imidazo[4,5-c]quinoline (4.0 g, 10.82 mmol) as a brown oil which was used without further purification.
Part C
Using the general method of Example 11 Part F, 2-hexyl-l-[5-(methylthio)pentyl]-1H-imidazo[4,5-c]quinoline (4.0 g, 10.82 mmol) was oxidized to 2-hexyl-l-[5-(methylsulfonyl)pentyl]-1H-imidazo[4,5-c]quinoline-5N-oxide (4.52 g, 10.82 mmol) which was isolated as a tan solid and used without further purification.
Part D
Using the general method of Example 3 Part B 2-hexyl-l-[5-(methylsulfonyl)pentyl]-1H-imidazo[4,5-c]quinoline-5N-oxide (4.0 g, 10.82 mmol) was aminated to provide 2-hexyl-l-[5-(methylsulfonyl)pentyl]-1H-imidazo[4,5-c]quinolin-4-amine. The material was recrystallized from acetonitrile to afford the title compound (2.25 g, 5.40 mmol) as off-white needles, m.p. 168-171 C.
Analysis. Calculated for C22H32N402S: %C 63.43; %H, 7.74; %N, 13.45. Found: %C
63.06; %H, 7.66; %N, 13.81 'H-NMR (300 MHz, DMSO) 6 8.01 (d, J = 8.3 Hz, 1H), 8 7.62 (d, J = 8.3 Hz, 1H), 6 7.42 (t, J = 8.3 Hz, 1H), 6 7.26 (t, J = 8.3 Hz, 1H), 8 6.51 (bs, 2H), 6 4.51 (t, J
= 7.3 Hz, 2H), 8 3.10 (t, J = 7.8 Hz, 2H), 6 2.93 (s, 3H), 6 2.93 (t, J = 7.3 Hz, 2H), 6 1.71-1.87 (m, 6H), 8 1.54 (m, 2H), 6 1.44 (m, 2H), 6 1.33 (m, 4H), 6 0.89 (t, J = 7.3 Hz, 3H) MS (CI) for C22H32N402S mlz 417 (MH+), 337 Example 16 2-(2-methoxyethyl)-1-[5-(methylsulfonyl)pentyl]-1 H-imi dazo [4, 5 -c] quinolin-4-amine NHa N
e is Part A
A round bottom flask was charged with a magnetic stir bar,1V4-[5-(methylthio)pentyl]quinoline-3,4-diamine (3.56 g, 12.93 mmol) and anhydrous pyridine (52 mL) under a nitrogen atmosphere. The resulting homogeneous solution was cooled to 0 C in an ice-water bath. To the cooled solution was added neat 3-methoxypropionyl chloride (2.74 g, 22.36 mmol). After addition of the acid chloride, the reaction was heated to reflux for 14 hours at which time the acylated intermediate was completely consumed.
The solution was cooled and then partitioned between chloroform and saturated aqueous ammonium chloride. The layers were separated. The organic layer was washed with saturated aqueous sodium bicarbonate, dried over anhydrous sodium sulfate, filtered and then concentrated under reduced pressure to afford 2-(2-methoxyethyl)-1-[5-(methylthio)pentyl]-1H-imidazo[4,5-c]quinoline (3.0 g, 8.73 mmol) which was isolated as a brown oil and used without further purification.
Part B
Using the general method of Example 11 Part F, 2-(2-methoxyethyl)-1-[5-(methylthio)pentyl]-1H-imidazo[4,5-c]quinoline (3.0 g, 8.73 mmol) was oxidized to 2-(2-methoxyethyl)-1-[5-(methylsulfonyl)pentyl]-1H-imidazo[4,5-c]quinoline-5N-oxide (3.41 g, 8.73 mmol) which was isolated as a tan solid and used without further purification.
Part C
Using the general method of Example 3 Part B, 2-(2-methoxyethyl)- 1 -[5-(methylsulfonyl)pentyl]-1H-imidazo[4,5-c]quinoline-5N-oxide (3.41 g, 8.73 mmol) was aminated to provide 2-(2-methoxyethyl)-1-[5-(methylsulfonyl)pentyl]-1H-imidazo[4,5-c]quinolin-4-amine. The resulting solid was purified by chromatography over silica gel (95/5 dichloromethane/methanol) to provide a gummy solid. The solid was recrystallized from acetonitrile to give the title compound (0.54 g, 1.38 mmol) as an off-white powder, m.p. 158-160 C.
Analysis. Calculated for C19H26N403S: %C 58.44; %H, 6.71; %N, 14.35. Found: %C
58.24; %H, 6.76; %N, 14.70 'H-NMR (300 MHz, DMSO) 6 8.02 (d, J = 8.3 Hz, 1H), 6 7.62 (d, J = 8.3 Hz, 1H), 6 7.42 (t, J = 8.3 Hz, 1H), 8 7.26 (t, J = 8.3 Hz, 1H), 8 6.50 (bs, 2H), 6 4.53 (t, J
= 7.6 Hz, 2H), 6 3.83(t,J=6.8Hz,2H),63.30(s,3H),53.19(t,J=6.8Hz,2H),53.11 (t, J= 7.8 Hz, 2H), 6 2.93 (s, 3H), 6 1.85 (m, 2H), 8 1.76 (m, 2H), 6 1.57 (m, 2H) MS (CI) for C19H26N403S m/z 391 (MH+), 359 Example 17 2-butyl-l -[5-(methylthio)pentyl]-1H-imidazo[4,5-c]quinolin-4-amine N N
N
Part A
Using the general method of Example 1 Part C, N-(5-chloropentyl)-3-nitroquinolin-4-amine (2.0 g, 6.80 mmol) was reduced to provide A4-(5-chloropentyl)quinoline-3,4-diamine (1.79 g, 6.80 mmol) which was isolated as a brown oil and used without further purification.
Part B
Using the general method of Example 1 Part D, A4-(5-chloropentyl)quinoline-3,4-diamine (1.79 g, 6.80 mmol) was cyclized to 2-butyl-l-(5-chloropentyl)-1H-imidazo[4,5-c]quinoline using trimethyl orthovalerate (2.55 g, 15.72 mmol) and pyridine hydrochloride (0.079 g). The product (1.95 g, 5.91 mmol) was isolated as an off-white solid and used without further purification.
Part C
Using the general method of Example 1 Part E, 2-butyl-l-(5-chloropentyl)-1H-imidazo[4,5-c]quinoline (1.95 g, 5.91 mmol) was oxidized to 2-butyl-l-(5-chloropentyl)-1H-imidazo[4,5-c]quinoline-5N-oxide (2.04 g, 5.91 mmol) which was isolated as a tan solid and used without further purification.
Part D
Using the general method of Example 3 Part B, 2-butyl-l-(5-chloropentyl)-lH-imidazo[4,5-c]quinoline-5N-oxide (2.04 g, 5.91 mmol) was aminated to provide 2-butyl-1-(5-chloropentyl)-1H-imidazo[4,5-c]quinolin-4-amine. The resulting solid was recrystallized from ethanol to afford the product (0.85 g, 2.46 mmol) as a fine white powder, m.p. 144-146 C.
Analysis. Calculated for CI9H25C1N4: %C 66.17; %H, 7.31; %N, 16.24. Found: %C
66.44; %H, 7.55; %N, 16.29 MS (CI) for C19H25C1N4 m/z 345 (MH), 309 Part E
Using the general method of Example 6 Part B, except that the reaction temperature was lowered to 80 C, 2-butyl-l-(5-chloropentyl)-1H-imidazo[4,5-c]quinolin-4-amine (2.0 g, 5.80 mmol) was converted to 2-butyl-l-[5-(methylthio)pentyl]-imidazo[4,5-c]quinolin-4-amine using sodium thiomethoxide (0.68 g, 8.70 mmol) in lieu of sodium benzenethiolate. The resulting solid was partitioned between chloroform and saturated aqueous sodium bicarbonate. The layers were separated. The organic layer was washed with brine, dried over anhydrous sodium sulfate, filtered and then concentrated under reduced pressure to afford a white solid. The material was recrystallized from acetonitrile to give the title compound (1.91 g, 5.36 mmol) as a fine white solid, m.p. 112-114 C.
Analysis. Calculated for C20H28N4S: %C 67.38; %H, 7.92; %N, 15.71. Found: %C
67.26;
%H, 8.08; %N, 15.74 'H-NMR (300 MHz, DMSO) S 8.01 (d, J = 8.3 Hz, 1H), 6 7.61 (d, J = 8.3 Hz, 1H), 8 7.41 (t, J = 8.3 Hz, 1H), S 7.25 (t, J = 8.3 Hz, 1H), S 6.45 (bs, 2H), S 4.50 (t, J
= 7.8 Hz, 2H), S
2.92 (t, J = 7.6 Hz, 2H), 6 2.46 (t, J = 7.3 Hz, 2H), S 2.01 (s, 3H), 6 1.80 (in, 4H), 6 1.42-1.61 (m, 6H), S 0.96 (t, J = 7.3 Hz, 3H) MS (CI) for C20H28N4S m/z 357 (MH+), 309 Example 18 2-butyl-l -[5-(methylsulfinyl)pentyl]-1H-imidazo[4,5-c]quinolin-4-amine NHZ
N N
I
~~ N
6S ,O
A round bottom flask was charged with a magnetic stir bar, 2-butyl-l-[5-(methylthio)pentyl]-1H-imidazo[4,5-c]quinolin-4-amine (1.0 g, 2.80 mmol) and chloroform (14 mL). Solid 3-chloroperbenzoic acid (0.69 g, 3.09 mmol) was added portion wise over 5 minutes and the reaction was stirred at ambient temperature for 20 minutes at which time the starting material was completely consumed. The solution was partitioned between chloroform and saturated aqueous sodium bicarbonate. The layers were separated. The organic layer was washed with saturated aqueous sodium bicarbonate and brine, dried over anhydrous sodium sulfate, filtered and then concentrated under reduced pressure to afford an off-white solid which was shown by 1H-NMR to be the 3-chlorobenzoic acid salt of the desired product. The solid was stirred in water and then made basic (pH 10) by addition of solid sodium carbonate. The resulting free base was collected by filtration to provide a white solid which was recrystallized from acetonitrile to give 2-butyl-l-[5-(methylsulfinyl)pentyl]-lH-imidazo[4,5-c]quinolin-4-amine (0.40 g, 1.07 mmol) as a white powder, m.p. 119-121 C.
Analysis. Calculated for C20H28N40S (H20)1: %C 61.51; %H, 7.74; %N, 14.35.
Found:
%C 61.64; %H, 7.82; %N, 14.32 'H-NMR (300 MHz, DMSO) 8 8.01 (d, J = 8.3 Hz, 1H), 8 7.60 (d, J = 8.3 Hz, 1H), 6 7.41 (t, J = 8.3 Hz, 1H), 8 7.26 (t, J = 8.3 Hz, 1H), 6 6.44 (bs, 2H), 6 4.51 (t, J
= 7.6 Hz, 2H), 6 2.92 (t, J = 7.8 Hz, 2H), 6 2.57-2.74 (m, 2H), 6 2.50 (s, 3H), 8 1.80 (m, 4H), 6 1.66 (m, 2H),61.55(m,2H),51.48(m,2H),50.96(t,J=7.3Hz,3H) MS (CI) for C2oH28N40S (H20)1 m/z 373 (MH+), 309, 253 Example 19 2-butyl- l -[3 -(methylsulfonyl)propyl] -1 H-imidazo [4, 5-c] quinolin-4-amine NHZ
N N
N
,0 ,S~
Part A
A round bottom flask was charged with a magnetic stir bar, 3-[(3-nitroquinolin-yl)amino]propan-1-ol (20.75 g, 83.93 mmol), thionyl chloride (15.0 g, 125.89 mmol), and dichloromethane (420 mL). The bright yellow, homogeneous solution was stirred at ambient temperature for 2 hours at which time the starting material was completely consumed. The volatiles were removed under reduced pressure and the resulting solid stirred in water (400 mL) made basic (pH 10) with solid sodium carbonate. A
bright yellow solid was collected by filtration to afford N-(3-chloropropyl)-3-nitroquinolin-4-amine (21.63 g, 81.41 mmol) which was used without further purification.
Part B
Using the general method of Example 1 Part C, N-(3-chloropropyl)-3-nitroquinolin-4-amine (10.0 g, 37.63 mmol) was reduced to provide N4-(3-chloropropyl)quinoline-3,4-diamine (8.87 g, 37.63 mmol) which was isolated as a brown oil and used without further purification.
Part C
Using the general method of Example 1 Part D, N4-(3-chloropropyl)quinoline-3,4-diamine (8.87 g, 37.63 mmol) was cyclized to provide 2-butyl-l-(3-chloropropyl)-1H-imidazo[4,5-c]quinoline using trimethyl orthovalerate (7.33 g, 45.16 mmol) and pyridine hydrochloride (0.43 g). The resulting solid was triturated with ethyl ether and collected by filtration to afford the product (9.00 g, 29.82 mmol) as an off-white solid.
The material was used without further purification.
Part D
Using the general method of Example 1 Part E, 2 butyl-l-(3-chloropropyl)-1H-imidazo[4,5-c]quinoline (9.0 g, 29.82 mmol) was oxidized to 2-butyl-l-(3-chloropropyl)-1H-imidazo[4,5-c]quinoline-5N-oxide (9.48 g, 29.82 mmol) which was isolated as a tan solid and used without purification.
Part E
Using the general method of Example 3 Part B, 2-butyl-l-(3-chloropropyl)-1H-imidazo[4,5-c]quinoline-5N-oxide (9.48 g, 29.82 mmol) was aminated to provide 2-butyl-1-(3-chloropropyl)-1H-imidazo[4,5-c]quinolin-4-amine. The resulting solid was purified by chromatography over silica gel (95/5 dichloromethane/methanol) to provide the product (6.4 g, 20.20 mmol) as a tan solid.
Part F
Using the general method of Example 6 Part B, except that the reaction temperature was lowered to 80 C, 2-butyl-l-(3-chloropropyl)-1H-imidazo[4,5-c]quinolin-4-amine (2.0 g, 6.31 mmol) was converted to 2-butyl-l-[3-(methylthio)propyl]-lH-imidazo[4,5-c]quinolin-4-amine using sodium thiomethoxide (0.74 g, 9.47 mmol) in lieu of sodium benzenethiolate. The resulting solid was partitioned between chloroform and saturated aqueous sodium bicarbonate. The layers were separated. The organic layer was washed with brine, dried over anhydrous sodium sulfate, filtered and then concentrated under reduced pressure to afford the title compound (2.0 g, 6.09 mmol) as a white solid.
The material was used without further purification.
Part G
Using the general method of Example 5 Part A, 2-butyl-1-[3-(methylthio)propyl]-1H-imidazo[4,5-c]quinolin-4-amine (2.0 g, 6.09 mmol) was oxidized to 2-butyl-l-[3-(methylsulfonyl)propyl]-1H-imidazo[4,5-c]quinolin-4-amine. The resulting solid was triturated with methanol and collected by filtration to afford the title compound (0.96 g, 2.66 mmol) as an off-white powder, m.p. 233-236 C.
Analysis. Calculated for C18H24N402S: %C 59.98; %H, 6.71; %N, 15.54. Found: %C
59.71; %H, 6.65; %N, 15.43 1H-NMR (300 MHz, DMSO) 8 8.10 (d, J = 8.3 Hz, 1H), 6 7.61 (d, J = 8.3 Hz, 1H), 6 7.42 (t, J = 8.3 Hz, 1H), 8 7.25 (t, J = 8.3 Hz, 1H), S 6.47 (bs, 2H), 6 4.66 (t, J
= 7.8 Hz, 2H), 6 3.40 (t, J = 7.3 Hz, 2H), 6 3.01 (s, 3H), 6 2.94 (t, J = 7.8 Hz, 2H), S 2.22 (m, 2H), 6 1.80 (m, 2H), 6 1.46 (sextet, J = 7.3 Hz, 2H), 8 0.96 (t, J = 7.3 Hz, 3H) MS (CI) for C18H24N402S m/z 361 (MH+), 281, 235 Example 20 2-butyl-l-[3-(phenylsulfonyl)propyl]-1H-imidazo[4,5-c]quinolin-4-amine N N
N
O
O
Part A
A round bottom flask was charged with a magnetic stir bar, benzenethiol (0.68 g, 6.21 mmol), sodium hydride (0.25 g, 60% dispersion, 6.21 mmol), and anhydrous dimethyl formamide (28 mL) under a nitrogen atmosphere. After the reaction mixture had stirred at ambient temperature for 30 minutes, 2-butyl- 1 -(3 -chloropropyl)-1 H-imidazo [4,5 -c]quinolin-4-amine (1.64 g, 5.18 mmol) was added and the resulting cloudy solution was heated to 80 C and maintained at 80 C for 2.5 hours at which time the starting material was completely consumed. The hot solution was poured into rapidly stirred water (200 mL). The resulting mixture was extracted with chloroform (2x). The combined organic layers were washed with saturated aqueous sodium bicarbonate and brine, dried over anhydrous sodium sulfate, filtered and then concentrated under reduced pressure to afford a light yellow oil. The material was purified by chromatography over silica gel (95/5 dichloromnethane/methanol) to provide 2-butyl-l-[3-(phenylthio)propyl]-lH-imidazo[4,5-c]quinolin-4-amine (1.38 g, 3.53 mmol) as a white solid.
Part B
Using the general method of Example 5 Part A, 2-butyl- 1 - [3 -(phenylthio)propyl] -1H-imidazo[4,5-c]quinolin-4-amine (1.38 g, 3.53 mmol) was oxidized to 2-butyl-l-[3-(phenylsulfonyl)propyl]-1H-imidazo[4,5-c]quinolin-4-amine. The resulting solid was recrystallized from ethanol to provide the title compound (0.85 g, 2.01 mmol) as an off-white powder, m.p. 224-227 C.
Analysis. Calculated for C23H26N402S: %C 65.38; %H, 6.20; %N, 13.26. Found: %C
65.25; %H, 6.23; %N, 13.20 'H-NMR (300 MHz, DMSO) 6 7.96 (d, J = 8.3 Hz, 1H), 6 7.89 (m, 2H), 6 7.73 (m, 1H), 6 7.63 (m, 3H), 6 7.40 (t, J = 8.3 Hz, 1H), 6 7.17 (t, J = 8.3 Hz, 1H), 6 6.46 (bs, 2H), 6 4.60 (t, J = 7.8 Hz, 2H), 6 3.66 (t, J = 7.3 Hz, 2H), 6 2.86 (t, J = 7.8 Hz, 211), 6 2.04 (m, 2H), 6 1.73 (p, J = 7.6 Hz, 2H), 6 1.39 (sextet, J = 7.3 Hz, 2H), 6 0.92 (t, J = 7.3 Hz, 3H) MS (CI) for C23H26N402S m/z 423 (MH+), 322, 281 CYTOKINE INDUCTION IN HUMAN CELLS
An in vitro human blood cell system is used to assess cytokine induction.
Activity is based on the measurement of interferon and tumor necrosis factor (a) (IFN
and TNF, respectively) secreted into culture media as described by Testerman et. al. In "Cytokine Induction by the Immunomodulators Imiquimod and S-27609", Journal of Leukocyte Biology, 58, 365-372 (September, 1995).
Blood Cell Preparation for Culture Whole blood from healthy human donors is collected by venipuncture into EDTA
vacutainer tubes. Peripheral blood mononuclear cells (PBMCs) are separated from whole blood by density gradient centrifugation using Histopaque -1077. The PBMCs are washed twice with Hank's Balanced Salts Solution and then are suspended at 3-4 x 106 cells/mL in RPMI complete. The PBMC suspension is added to 48 well flat bottom sterile tissue culture plates (Costar, Cambridge, MA or Becton Dickinson Labware, Lincoln Park, NJ) containing an equal volume of RPMI complete media containing test compound.
Compound Preparation The compounds are solubilized in dimethyl sulfoxide (DMSO). The DMSO
concentration should not exceed a final concentration of 1 % for addition to the culture wells. The compounds are generally tested initially at concentrations ranging from 0.12 to M. Compounds showing activity at 0.12 M may then be tested at lower concentrations.
Incubation 30 The solution of test compound is added at 60 gM to the first well containing RPMI
complete and serial 3 fold dilutions are made in the wells. The PBMC
suspension is then added to the wells in an equal volume, bringing the test compound concentrations to the desired range (0.12 to 30 M). The final concentration of PBMC suspension is 1.5-2 X
106 cells/mL. The plates are covered with sterile plastic lids, mixed gently and then incubated for 18 to 24 hours at 37 C in a 5% carbon dioxide atmosphere.
Separation Following incubation the plates are centrifuged for 5-10 minutes at 1000 rpm (-200 x g) at 4 C. The cell-free culture supernatant is removed with a sterile polypropylene pipet and transferred to sterile polypropylene tubes. Samples are maintained at -30 to -70 C until analysis. The samples are analyzed for interferon (a) and for tumor necrosis factor (a) by ELISA
Interferon (a) and Tumor Necrosis Factor (a) Analysis by ELISA
Interferon (a) concentration is determined by ELISA using a Human Multi-Species kit from PBL Biomedical Laboratories, New Brunswick, NJ. Results are expressed in pg/mL.
Tumor necrosis factor (a) (TNF)concentration is determined using ELISA kits available from Genzyme, Cambridge, MA; R&D Systems, Minneapolis, MN; or Pharmingen, San Diego, CA. Results are expressed in pg/mL.
The table below lists the lowest concentration found to induce interferon and the lowest concentration found to induce tumor necrosis factor for each compound.
A "*"
indicates that no induction was seen at any of the tested concentrations (0.12, 0.37, 1.11, 3.33, 10 and 30 M).
Cytokine Induction in Human Cells Example Lowest Effective Concentration ( M) Number Interferon Tumor Necrosis Factor 1 0.12 0.12 2 0.12 0.37 3 0.04 0.12 4 0.01 0.01 5 0.01 0.04 6 3.33 10 Cytokine Induction in Human Cells Example Lowest Effective Concentration ( M) Number Interferon Tumor Necrosis Factor 7 3.33 10 9 3.33 3.33 1.11 1.11 11 0.01 0.12 12 0.12 10 13 0.12 3.33 14 3.33 10 0.04 *
16 0.01 0.04 17 0.01 0.04 18 0.01 0.12 19 0.04 0.37 0.04 0.37
In step (4) of Reaction Scheme II a lH-imidazo[4,5-c]quinoline of Formula XXI
is oxidized to provide a 1H-imidazo[4,5-c]quinolin-5N-oxide of Formula XXII using a conventional oxidizing agent. Preferably a solution of a compound of Formula XXI in a suitable solvent such as chloroform or dichloromethane is treated with at least three equivalents of 3-chloroperoxybenzoic acid at ambient temperature.
In step (5) of Reaction Scheme II a 1H-imidazo[4,5-c]quinolin-5N-oxide of Formula XXII is aminated using the method of step (6) of Reaction Scheme Ito provide a 1H-imidazo[4,5-c]quinolin-4-amine of Formula XVIII which is a subgenus of Formula I.
The product or a pharmaceutically acceptable salt thereof can be isolated using conventional methods.
Reaction Scheme II
0+ 0+
N,- N, - NHN 0(1) N 0(2). N 2 NH NH NH
Rn / X Rn / X Rn / X
XII CI XIX ~ XX S
Ri R1 (3) NHz N NR2 (5) N / N -R2 (4) N N~Rz N N N
Rn - i Rn / X Rn / X
S
Ri Ri Compounds of the invention can be prepared according to Reaction Scheme III
where R, R1, R2, X and n are as defined above.
In step (1) of Reaction Scheme III a 3-nitro-4-amino-quinolin-1-yl alcohol of Formula XI is protected with a tent-butyldimethylsilyl group using conventional methods.
Preferably a compound of Formula XI is combined with tert-butyldimethylsilyl chloride in a suitable solvent such as chloroform in the presence of triethylamine and a catalytic amount of 4-dimethylaminopyridine.
In step (2) of Reaction Scheme III a protected 3-nitro-4-amino-quinolin-l-yl alcohol of Formula XXIII is reduced using the method of step (3) of Reaction Scheme Ito provide a protected 3, 4-diamino-quinolin-l-yl alcohol of Formula XXIV.
In step (3) of Reaction Scheme III a protected 3,4-diamino-quinolin-l-yl alcohol of Formula XXIV is cyclized using the method of step (4) of Reaction Scheme Ito provide a 1H-imidazo[4,5-c]quinoline of Formula XXV.
In step (4) of Reaction Scheme III a 1H-imidazo[4,5-c]quinoline of Formula XXV
is oxidized using the method of step (5) of Reaction Scheme Ito provide a IH-imidazo[4,5-c]quinolin-5N-oxide of Formula XXVI.
In step (5) of Reaction Scheme III a 1H-imidazo[4,5-c]quinolin-5N-oxide of Formula XXVI is aminated using the method of step (6) of Reaction Scheme Ito provide a IH-imidazo[4,5-c]quinolin-4-amine of Formula XXVII.
In step (6) of Reaction Scheme III the protecting group is removed from a 1H-imidazo[4,5-c]quinolin-4-amine of Formula XXVII to provide a IH-imidazo[4,5-c]quinolin-4-amine of Formula XXVIII. Preferably a solution of a compound of Formula XXVII in a suitable solvent such as tetrahydrofuran is treated with tetrabutylammonium fluoride. Some compounds of Formula XXVIII are known, see for example, Gerster, U.S.
Patent No. 4,689,338 and Gerster et al., U.S. Patent 5,605,899.
In step (7) of Reaction Scheme III a 1H-imidazo[4,5-c]quinolin-4-amine of Formula XXVIII is chlorinated using conventional methods to provide a 1H-imidazo[4,5-c]quinolin-4-amine of Formula XVI. A compound of Formula XXVIII can be heated neat with thionyl chloride. Alternatively, phosphorous oxychloride can be added in a controlled fashion to a solution of a compound of Formula XXVIII in a suitable solvent such as N,N-dimethylformamide in the presence of triethylamine.
Steps (8) and (9) of Reaction Scheme III can be carried out in the same manner as steps (7) and (8) respectively of Reaction Scheme I.
Reaction Scheme III
O+ O
N, 11+
N O (1) _ N N, 0-(2) N NH
/ I
R" / NHz / NH Rn I NH R /
X
OH / / X
O
XI Mil -Si- XXIV I
-Si-A-NHz (3) N O\+ N
I 11 N~ Rz N N R2 (5) N j N)- Rz E (4) N
N
Rn X Rn / X Rn / X
O O i O
XXVII -Si- XXVI -Si- XXV -Si-/~-(6) N % N} RZ (7) N (g) N I NX R5J\>-R2 X Rn X
OH CI S
XXVI I I XVI XVI I I
Ri (9) NHz N
N % \}R2 Rn X
XVIII
Compounds of the invention can be prepared according to Reaction Scheme IV
where R, R1, R2, X and n are as defined above and BOC is tert-butoxycarbonyl.
In step (1) of Reaction Scheme IV the hydroxy group of a 6,7,8,9-tetrahydro-lH-imidazo[4,5-c]quinolin-l-yl alcohol of Formula XXIX is protected with a tert-butyldimethylsilyl group using the method of step (1) of Reaction Scheme III.
Compounds of Formula XXIX are known or can be prepared using known synthetic methods, see for example, Nikolaides, et al., U.S. Patent No.5,352,784 and Lindstrom, U.S. Patent No. 5,693,811 and references cited therein.
In step (2) of Reaction Scheme IV the amino group of a 1H-imidazo[4,5-c]quinolin-4-amine of Formula XXX is protected using conventional methods to provide a protected IH-imidazo[4,5-c]quinoline of Formula XXXI. Preferably a compound of Formula XXX is treated with di-test-butyl dicarbonate in a suitable solvent such as tetrahydrofuran in the presence of triethylamine and 4-dimethylaminopyridine.
The reaction can be run at an elevated temperature (60 C).
In step (3) of Reaction Scheme IV the tert-butyldimethylsilyl protecting group of a compound of Formula XXXI is removed using the method of step (6) of Reaction Scheme III to provide a 1H-imidazo[4,5-c]quinolin-lyl alcohol of Formula XXXII.
In step (4) of Reaction Scheme IV a 1H-imidazo[4,5-c]quinolin-lyl alcohol of Formula XXXII is converted to a methanesulfonate of Formula XXXIII. Preferably a solution of a compound of Formula XXXII in a suitable solvent such as dichloromethane is treated with methanesulfonyl chloride in the presence of triethylamine. The reaction can be run at a reduced temperature (-10 C).
In step (5) of Reaction Scheme IV a methanesulfonate of Formula XXXIII is reacted with a thiol of formula R1SH to provide a thioether of Formula XXXIV.
Preferably a solution of a compound of Formula XXXIII in a suitable solvent such as N, N-dimethylformamide is treated with the thiol in the presence of triethylamine. The reaction can be run at an elevated temperature (80 C).
In step (6) of Reaction Scheme IV the tert-butoxycarbonyl protecting groups are removed by hydrolysis under acidic conditions to provide a 1H-imidazo[4,5-c]quinolin-4-amine of Formula XXXV which is a subgenus of Formula II. Preferably a solution of a compound of Formula XXXIV in a suitable solvent such as dichloromethane is treated at ambient temperature with a solution of hydrochloric acid in dioxane. The product or a pharmaceutically acceptable salt thereof can be isolated using conventional methods.
In step (7) of Reaction Scheme IV a thioether of Formula XXXV is oxidized using the method of step (8) of Reaction Scheme Ito provide a sulfone or sulfoxide of Formula XXXVI which is a subgenus of Formula II. The product or a pharmaceutically acceptable salt thereof can be isolated using conventional methods.
Reaction Scheme IV
NH2 N(BOC)2 N N R2 N N - R () N N> R
Rn X Rn X Rn X
OH O
XXIX XXX -Si- XXXI -Si-(3) NBOC)2 N(BOC)2 N(BOC)2 NJ N
6 N>- R2 N R2 (5) N N R2 N /
N N
Rn X Rn X Rn X
S O OH
XXXIV IR XXXIII O-S-O XXXII
(6) N N>-R2 (7) N N\ -R
j 2 , N
Rn S Rn XXXV R XXXVI T(O)1-2 Compounds of the invention can be prepared according to Reaction Scheme V
where R, R1, R2, X and n are as defined above.
In step (1) of Reaction Scheme V a 6,7,8,9-tetrahydro-lH-imidazo[4,5-c]quinolin-1-yl alcohol of Formula XXIX is chlorinated using the method of step (7) of Reaction Scheme III to provide a compound of Formula XXXVII.
In step (2) of Reaction Scheme V a compound of Formula XXXVII is reacted with a compound of formula Rl-SNa using the method of step (7) of Reaction Scheme Ito provide a thioether of Formula XXXV which is a subgenus of Formula II. The product or a pharmaceutically acceptable salt thereof can be isolated using conventional methods.
In step (3) of Reaction Scheme V a thioether of Formula XXXV is oxidized using the method of step (8) of Reaction Scheme Ito provide a sulfone or sulfoxide of Formula XXXVI which is a subgenus of Formula II. The product or a pharmaceutically acceptable salt thereof can be isolated using conventional methods.
Reaction Scheme V
N N (1) (2) -R2 ~ -R2 N R2 N
R X Rn X Rõ X
OH CI S
XXIX XXXVII XXXV
Ri (3) N N
}R2 N
R" X
S(0)a_2 XXXVI
As used herein, the terms "alkyl", "alkenyl" and the prefix "alk-" are inclusive of both straight chain and branched chain groups and of cyclic groups, i.e.
cycloalkyl and cycloalkenyl. Unless otherwise specified, these groups contain from 1 to 20 carbon atoms, with alkenyl groups containing from 2 to 20 carbon atoms. Preferred groups have a total of up to 10 carbon atoms. Cyclic groups can be monocyclic or polycyclic and preferably have from 3 to 10 ring carbon atoms. Exemplary cyclic groups include cyclopropyl, cyclopropylmethyl, cyclopentyl, cyclohexyl and adamantyl.
In addition, the alkyl and alkenyl portions of -X- groups can be unsubstituted or substituted by one or more substituents, which substituents are selected from the groups consisting of alkyl, alkenyl, aryl, heteroaryl, heterocyclyl, arylalkyl, heteroarylalkyl, and heterocyclylalkyl.
The term "haloalkyl" is inclusive of groups that are substituted by one or more halogen atoms, including perfluorinated groups. This is also true of groups that include the prefix "halo". Examples of suitable haloalkyl groups are chloromethyl, trifluoromethyl, and the like.
The term "aryl" as used herein includes carbocyclic aromatic rings or ring systems.
Examples of aryl groups include phenyl, naphthyl, biphenyl, fluorenyl and indenyl. The term "heteroaryl" includes aromatic rings or ring systems that contain at least one ring hetero atom (e.g., 0, S, N). Suitable heteroaryl groups include furyl, thienyl, pyridyl, quinolinyl, isoquinolinyl, indolyl, isoindolyl, triazolyl, pyrrolyl, tetrazolyl, imidazolyl, pyrazolyl, oxazolyl, thiazolyl, benzofuranyl, benzothiophenyl, carbazolyl, benzoxazolyl, pyrimidinyl, benzimidazolyl, quinoxalinyl, benzothiazolyl, naphthyridinyl, isoxazolyl, isothiazolyl, purinyl, quinazolinyl, and so on.
"Heterocyclyl" includes non-aromatic rings or ring systems that contain at least one ring hetero atom (e.g., 0, S, N) and includes all of the fully saturated and partially unsaturated derivatives of the above mentioned heteroaryl groups. Exemplary heterocyclic groups include pyrrolidinyl, tetrahydrofuranyl, morpholinyl, thiomorpholinyl, piperidinyl, piperazinyl, thiazolidinyl, imidazolidinyl, isothiazolidinyl, and the like.
The aryl, heteroaryl, and heterocyclyl groups can be unsubstituted or substituted by one or more substituents independently selected from the group consisting of alkyl, alkoxy, alkylthio, haloalkyl, haloalkoxy, haloalkylthio, halogen, nitro, hydroxy, mercapto, cyano, carboxy, formyl, aryl, aryloxy, arylthio, arylalkoxy, arylalkylthio, heteroaryl, heteroaryloxy, heteroarylthio, heteroarylalkoxy, heteroarylalkylthio, amino, alkylamino, dialkylamino, heterocyclyl, heterocycloalkyl, alkylcarbonyl, alkenylcarbonyl, alkoxycarbonyl, haloalkylcarbonyl, haloalkoxycarbonyl, alkylthiocarbonyl, arylcarbonyl, heteroarylcarbonyl, aryloxycarbonyl, heteroaryloxycarbonyl, arylthiocarbonyl, heteroarylthiocarbonyl, alkanoyloxy, alkanoylthio, alkanoylamino, arylcarbonyloxy, arylcarbonylthio, alkylaminosulfonyl, alkylsulfonyl, arylsulfonyl, heteroarylsulfonyl, aryldiazinyl, alkylsulfonylamino, arylsulfonylamino, arylalkylsulfonylamino, alkylcarbonylamino, alkenylcarbonylamino, arylcarbonylamino, arylalkylcarbonylamino, heteroarylcarbonylamino, heteroarylalkycarbonylamino, alkylsulfonylamino, alkenylsulfonylamino, arylsulfonylamino, arylalkylsulfonylamino, heteroaiylsulfonylamino, heteroarylalkylsulfonylamino, alkylaminocarbonylamino, alkenylaminocarbonylamino, arylaminocarbonylamino, arylalkylaminocarbonylamino, heteroarylaminocarbonylamino, heteroarylalkylcarbonylamino, and, in the case of heterocyclyl, oxo. If any other groups are identified as being "substituted"
or "optionally substituted", then those groups can also be substituted by one or more of the above enumerated substituents.
Certain substituents are generally preferred. For example, preferred X groups include ethylene and n-butylene and preferred Rl groups are alkyl and aryl, with phenyl or substituted phenyl a preferred aryl group. Preferably no R substituents are present (i.e., n is 0). Preferred R2 groups include hydrogen, alkyl groups having 1 to 4 carbon atoms (i.e., methyl, ethyl, propyl, isopropyl, n-butyl, sec-butyl, isobutyl, and cyclopropylmethyl), methoxyethyl, and ethoxymethyl. One or more of these preferred substituents, if present, can be present in the compounds of the invention in any combination.
The invention is inclusive of the compounds described herein in any of their pharmaceutically acceptable forms, including isomers (e.g., diastereomers and enantiomers), salts, solvates, polymorphs, and the like. In particular, if a compound is optically active, the invention specifically includes each of the compound's enantiomers as well as racemic mixtures of the enantiomers.
Pharmaceutical Compositions and Biological Activity Pharmaceutical compositions of the invention contain a therapeutically effective amount of a compound of the invention as described above in combination with a pharmaceutically acceptable carrier.
The term "a therapeutically effective amount" means an amount of the compound sufficient to induce a therapeutic effect, such as cytokine induction, antitumor activity, and/or antiviral activity. Although the exact amount of active compound used in a pharmaceutical composition of the invention will vary according to factors known to those of skill in the art, such as the physical and chemical nature of the compound, the nature of the carrier, and the intended dosing regimen, it is anticipated that the compositions of the invention will contain sufficient active ingredient to provide a dose of about 100 ng/kg to about 50 mg/kg, preferably about 10 g/kg to about 5 mg/kg, of the compound to the subject. Any of the conventional dosage forms may be used, such as tablets, lozenges, parenteral formulations, syrups, creams, ointments, aerosol formulations, transdermal patches, transmucosal patches and the like.
The compounds of the invention can be administered as the single therapeutic agent in the treatment regimen, or the compounds of the invention may be administered in combination with one another or with other active agents, including additional immune response modifiers, antivirals, antibiotics, etc.
The compounds of the invention have been shown to induce the production of certain cytokines in experiments performed according to the tests set forth below. These results indicate that the compounds are useful as immune response modifiers that can modulate the immune response in a number of different ways, rendering them useful in the treatment of a variety of disorders.
Cytokines whose production may be induced by the administration of compounds according to the invention generally include interferon-a (IFN-a) and/or tumor necrosis factor-a (TNF-a) as well as certain interleukins (IL). Cytokines whose biosynthesis may be induced by compounds of the invention include IFN-a, TNF-a, IL-1, IL-6, IL-10 and IL-12, and a variety of other cytokines. Among other effects, these and other cytokines can inhibit virus production and tumor cell growth, making the compounds useful in the treatment of viral diseases and tumors. Accordingly, the invention provides a method of inducing cytokine biosynthesis in an animal comprising administering an effective amount of a compound or composition of the invention to the animal.
Certain compounds of the invention have been found to preferentially induce the expression of IFN-a in a population of hematopoietic cells such as PBMCs (peripheral blood mononuclear cells) containing pDC2 cells (precursor dendritic cell-type 2) without concomitant production of significant levels of inflammatory cytokines.
In addition to the ability to induce the production of cytokines, the compounds of the invention affect other aspects of the innate immune response. For example, natural killer cell activity may be stimulated, an effect that may be due to cytokine induction. The compounds may also activate macrophages, which in turn stimulates secretion of nitric oxide and the production of additional cytokines. Further, the compounds may cause proliferation and differentiation of B-lymphocytes.
Compounds of the invention also have an effect on the acquired immune response.
For example, although there is not believed to be any direct effect on T cells or direct induction of T cell cytokines, the production of the T helper type 1 (Thl) cytokine IFN-y is induced indirectly and the production of the T helper type 2 (Th2) cytokines IL-4, IL-5 and IL-13 are inhibited upon administration of the compounds. This activity means that the compounds are useful in the treatment of diseases where upregulation of the Thl response and/or downregulation of the Th2 response is desired. In view of the ability of compounds of the invention to inhibit the Th2 immune response, the compounds are expected to be useful in the treatment of atopic diseases, e.g., atopic dermatitis, asthma, allergy, allergic rhinitis; systemic lupus erythematosis; as a vaccine adjuvant for cell mediated immunity; and possibly as a treatment for recurrent fungal diseases and chlamydia.
The immune response modifying effects of the compounds make them useful in the treatment of a wide variety of conditions. Because of their ability to induce the production of cytokines such as IFN-a and/or TNF-a, the compounds are particularly useful in the treatment of viral diseases and tumors. This immunomodulating activity suggests that compounds of the invention are useful in treating diseases such as, but not limited to, viral diseases including genital warts; common warts; plantar warts; Hepatitis B; Hepatitis C; Herpes Simplex Virus Type I and Type II; molluscum contagiosum;
variola, particularly variola major; HIV; CMV; VZV; rhinovirus; adenovirus;
influenza;
and para-influenza; intraepithelial neoplasias such as cervical intraepithelial neoplasia;
human papillomavirus (HPV) and associated neoplasias; fungal diseases, e.g.
candida, aspergillus, and cryptococcal meningitis; neoplastic diseases, e.g., basal cell carcinoma, hairy cell leukemia, Kaposi's sarcoma, renal cell carcinoma, squamous cell carcinoma, myelogenous leukemia, multiple myeloma, melanoma, non-Hodgkin's lymphoma, cutaneous T-cell lymphoma, and other cancers; parasitic diseases, e.g.
pneumocystis carnii, cryptosporidiosis, histoplasmosis, toxoplasmosis, trypanosome infection, and leishmaniasis; and bacterial infections, e.g., tuberculosis, and mycobacterium avium.
Additional diseases or conditions that can be treated using the compounds of the invention include actinic keratosis; eczema; eosinophilia; essential thrombocythaemia;
leprosy;
multiple sclerosis; Ommen's syndrome; discoid lupus; Bowen's disease; Bowenoid papulosis; alopecia areata; the inhibition of Keloid formation after surgery and other types of post-surgical scars. In addition, these compounds could enhance or stimulate the healing of wounds, including chronic wounds. The compounds may be useful for treating the opportunistic infections and tumors that occur after suppression of cell mediated immunity in, for example, transplant patients, cancer patients and HIV
patients.
An amount of a compound effective to induce cytokine biosynthesis is an amount sufficient to cause one or more cell types, such as monocytes, macrophages, dendritic cells and B-cells to produce an amount of one or more cytokines such as, for example, IFN-a, TNF-a, IL-1, IL-6, IL-10 and IL-12 that is increased over the background level of such cytokines. The precise amount will vary according to factors known in the art but is expected to be a dose of about 100 ng/kg to about 50 mg/kg, preferably about 10 g/kg to about 5 mg/kg. The invention also provides a method of treating a viral infection in an animal and a method of treating a neoplastic disease in an animal comprising administering an effective amount of a compound or composition of the invention to the animal. An amount effective to treat or inhibit a viral infection is an amount that will cause a reduction in one or more of the manifestations of viral infection, such as viral lesions, viral load, rate of virus production, and mortality as compared to untreated control animals. The precise amount will vary according to factors known in the art but is expected to be a dose of about 100 ng/kg to about 50 mg/kg, preferably about 10 g/kg to about 5 mg/kg. An amount of a compound effective to treat a neoplastic condition is an amount that will cause a reduction in tumor size or in the number of tumor foci. Again, the precise amount will vary according to factors known in the art but is expected to be a dose of about 100 ng/kg to about 50 mg/kg, preferably about 10 gg/kg to about 5 mg/kg.
The invention is further described by the following examples, which are provided for illustration only and are not intended to be limiting in any way.
Example 1 2-butyl- l -[4-(phenylthio)butyl]-1H-imidazo[4,5-c]quinolin-4-amine NHZ
N N
N
S `
Part A
A round bottom flask was charged with a magnetic stir bar, 4-chloro-3-nitroquinoline (109.70 g, 525.87 mmol) and dichloromethane (500 mL). To the solution was added triethylamine (79.82 g, 788.81 mmol) and 4-amino-l-butanol (46.87 g, 525.87 mmol) to give a homogeneous, dark yellow solution. The reaction was judged to be complete after heating at reflux for 30 minutes. The solution was cooled and then partitioned between chloroform and saturated aqueous ammonium chloride. The layers were separated and the aqueous layer was extracted with chloroform (lx). The organic layers were combined and then concentrated under reduced pressure to afford of 4-[(3-nitroquinolin-4-yl)amino]butan- 1 -ol (104.67 g, 400.60 mmol) as a dark yellow solid. This material was used without further purification.
Part B
A round bottom flask was charged with a magnetic stir bar, 4-[(3-nitroquinolin-yl)amino]butan-1-ol (5.0 g, 19.14 mmol), triethylamine (2.91 g, 28.71 mmol), tert-butyldimethylsilyl chloride (3.75 g, 24.9 mmol), 4-dimethylaminopyridine (0.10 g) and chloroform (40 mL) to give a dark yellow solution. The reaction was judged was to complete after stirring at ambient temperature for 2 hours. The solution was partitioned between ethyl acetate and saturated aqueous ammonium chloride. The layers were separated and the organic layer was washed with saturated aqueous sodium bicarbonate, dried over anhydrous sodium sulfate, filtered and then concentrated under reduced pressure to afford N-(4-{[tent-butyl(dimethyl)silyl]oxy}butyl)-3-nitroquinolin-4-amine (6.05 g, 16.11 mmol) as a yellow-green solid. This material was used without further purification. MS (CI) for C19H29N3O3Si m/z 376 (MH), 342, 210.
Part C
A Parr vessel was charged with N-(4-{[tent-butyl(dimethyl)silyl]oxy}butyl)-3-nitroquinolin-4-amine (6.05 g, 16.11 mmol), 5% platinum on carbon (3.0 g), and toluene (32 mL). The vessel was placed on a Parr shaker and pressurized to 50 psi (3.5 Kg/cm2) hydrogen. After shaking for one hour, more catalyst (3.0 g) and toluene (15 mL) were added and the vessel was pressurized to 50 psi (3.5 Kg/cm2) hydrogen and shaking continued. The reaction was judged to be complete after one hour. The catalyst was removed by filtration through fluted paper. The filter cake was washed with toluene (50 mL) and the filtrates were combined. The volatiles were removed under reduced pressure to afford N-(4-f [tert-butyl(dimethyl)silyl]oxy}butyl)quinoline-3,4-diamine (5.57 g, 16.11 ramol) as a dark oil. The material was used without further purification.
Part D
A round bottom flask was charged with a magnetic stir bar, N-(4-{[tert-butyl(dimethyl)silyl]oxy}butyl)quinoline-3,4-diamine (5.57 g, 16.11 mmol), trimethyl orthovalerate (5.23 g, 32.22 mmol) and toluene (47 mL). The reaction was heated to maintain a reflux that brought about a slow distillation to facilitate removal of the methanol byproduct. The reaction was judged to be complete after 15 hours at reflux.
The reaction was cooled and the volatiles were removed under reduced pressure to afford of 2-butyl-l -(4- {[tent-butyl(dimethyl)silyl]oxy}butyl)-1H-imidazo[4,5-c]
quinoline (4.65 g, 11.30 mmol) as a thick, dark brown oil. The material was used without further purification. MS (CI) for C24H37N3OSi m/z 412 (MH), 298.
Part E
A round bottom flask was charged with a magnetic stir bar, 2-butyl- 1 -(4- {
[tert-butyl(dimethyl)silyl]oxy}butyl)-1H-imidazo[4,5-c]quinoline (4.65 g, 11.30 mmol) and chloroform (57 mL). Solid 3-chloroperbenzoic acid (2.78 g, 12.43 mmol) was added portion wise to the solution over 15 minutes and the reaction was stirred at ambient temperature for 1 hour. More 3-chloroperbenzoic acid (0.5g, 2.9 mmol) was added and after 30 minutes the starting material was completely consumed. The solution was partitioned between chloroform and aqueous saturated sodium bicarbonate. The layers were separated. The organic layer was washed with saturated aqueous sodium bicarbonate and brine, dried over anhydrous sodium sulfate, filtered and then concentrated under reduced pressure to afford 2-butyl-l-(4-{[tent-butyl(dimethyl)silyl]oxy}butyl)-imidazo[4,5-c]quinoline-5N-oxide (4.83 g, 11.30 mmol) as a dark oil. The material was used without further purification.
Part F
A round bottom flask was charged with a magnetic stir bar, 2-butyl-1-(4-{[tert-butyl(dimethyl)silyl]oxy}butyl)-1H-imidazo[4,5-c]quinoline-5N-oxide (11.30 mmol) and anhydrous dimethyl formamide (57 mL) under a nitrogen atmosphere. Phosphorus oxychloride (1.91 g, 12.43 mmol) was added to the reaction mixture in a drop wise fashion to give a homogeneous solution after complete addition. The reaction was judged to be complete after stirring for 1.5 hours at ambient temperature and was then partitioned between dichloromethane and saturated aqueous sodium bicarbonate. The layers were separated and the organic portion was washed with aqueous saturated sodium bicarbonate and brine, dried over anhydrous sodium sulfate, filtered and then concentrated under reduced pressure to afford 2-butyl-4-chloro-l-(4-chlorobutyl)-1H-imidazo[4,5-c]quinoline (3.65 g, 10.42 mmol) as a dark brown solid. The material was used without further purification. MS (CI) for C18H21C12N3 m/z 350 (MH+), 314.
Part G
A round bottom flask was charged with a magnetic stir bar, 2-butyl-4-chloro- 1 -(4-chlorobutyl)-1H-imidazo[4,5-c]quinoline (1.18 g, 3.37 mmol), benzenethiol (0.56 g, 5.05 mmol), triethylamine (0.68 g, 6.74 mmol), and dimethyl formamide (15 mL) under a nitrogen atmosphere. The reaction mixture was heated to 80 C to give a homogeneous solution that was maintained at 80 C for 2.5 hours. HPLC analysis indicated no starting material and a 3:1 mixture of 2-butyl-4-chloro-l-[4-(phenylthio)butyl]-1H-imidazo[4,5-c]quinoline and 2-butyl-4-(phenylthio)-I-[4-(phenylthio)butyl]-1H-imidazo[4,5-c]quinoline. The solution was cooled and then partitioned between ethyl acetate and aqueous saturated sodium bicarbonate. The layers were separated and the organic layer was washed with aqueous saturated sodium bicarbonate and brine, dried over anhydrous sodium sulfate, filtered and then concentrated under reduced pressure to afford a 3:1 mixture of the products named above (1.43 g). The material was used without further purification.
Part H
A 3:1 mixture of 2-butyl-4-chloro-l-[4-(phenylthio)butyl]-1H-imidazo[4,5-c]quinoline to 2-butyl-4-(phenylthio)-1-[4-(phenylthio)butyl]-1H-imidazo[4,5-c]quinoline (1.38 g) and a solution of 7% ammonia in methanol (30 mL) were combined in a bomb and heated to 150 C. The reaction was judged to be complete after 5 hours.
The volatiles were removed under reduced pressure and the resulting residue was stirred in water and made basic (pH 10) with solid sodium carbonate. The aqueous mixture was extracted with chloroform (3x). The combined organic layers were washed with saturated aqueous sodium bicarbonate and brine, dried over anhydrous sodium sulfate, filtered and then concentrated under reduced pressure to afford a yellow crystalline solid. The solid (0.8 g) was dissolved in ethyl acetate (50 mL) and brought to reflux. Activated charcoal (0.4 g) was added; the resulting mixture was heated at reflux for 5 minutes and then the charcoal was removed by filtration through fluted paper to provide a colorless solution. The solution was concentrated under reduced pressure to give a solid that was recrystallized from ethyl acetate and hexanes to provide 2-butyl-l-[4-(phenylthio)butyl]-1H-imidazo[4,5-c]quinolin-4-amine (0.51 g, 1.25 mmol) as white needles, m.p. 118-120 C.
Analysis. Calculated for C24H28N4S: %C 71.25; %H, 6.98; %N, 13.85. Found %C
71.12;
%H, 6.81; %N, 13.62 'H-NMR (300 MHz, DMSO) b 8.02 (d, J = 8.3 Hz, IH), 8 7.61 (d, J = 8.3 Hz, 1H), 6 7.41 (t, J = 8.3 Hz, 1H), S 7.16-7.30 (m, 6H), S 6.46 (bs, 2H), S 4.52 (t, J = 7.6 Hz, 2H), S 3.02 (t, J = 7.3 Hz, 2H), 6 2.89 (t, J = 7.8 Hz, 2H), 6 1.95 (m, 2H), 6 1.75 (m, 4H), 6 1.43 (sextet, J = 7.3 Hz, 2H), 6 0.94 (t, J = 7.3 Hz, 3H) MS (Cl) for C24H28N4S m/z 405 (MH+), 282, 241 Example 2 2-butyl-1-[2-(phenylthio)ethyl]-6,7,8,9-tetrahydro-1H-imidazo[4,5-c]quinolin-4-amine hydrochloride NH
N N
S
Part A
A round bottom flask was charged with a magnetic stir bar, 2-(4-amino-2-butyl-6,7,8,9-tetrahydro-lH-imidazo[4,5-c]quinolin-1-yl)ethanol (1.0 g, 3.47 mmol), tert-butyldimethylsilyl chloride (1.62 g, 10.75 mmol), triethylamine (1.58 g, 15.62 mmol), 4-dimethylaminopyridine (0.1 g), and chloroform (30 mL) to give a heterogeneous reaction mixture. The reaction was judged to be complete after stirring at 60 C for 2 hours. The solution was partitioned between ethyl acetate and saturated aqueous ammonium chloride.
The layers were separated and the organic layer was washed with aqueous saturated sodium bicarbonate and brine, dried over anhydrous sodium sulfate, filtered and then concentrated under reduced pressure to afford a 3:1 mixture of 2-butyl- 1 -(2-{[tert-butyl(dimethyl)silyl]oxy}ethyl)-6,7,8,9-tetrahydro-lH-imidazo[4,5-c]quinolin-4-amine and 2-butyl-N-[tent-butyl(dimethyl)silyl]-1-(2-{[tent-butyl(dimethyl)silyl]oxy}ethyl)-6,7,8,9-tetrahydro-1H-imidazo[4,5-c]quinolin-4-amine (1.79 g) as a dark brown oil. The material was used without further purification.
Part B
A round bottom flask was charged with a magnetic stir bar, a 3:1 mixture of 2-butyl-l -(2- { [tent-butyl(dimethyl)silyl]oxy} ethyl)-6,7,8,9-tetrahydro-lH-imidazo[4,5-c]quinolin-4-amine and 2-butyl-N-[tent-butyl(dimethyl)silyl]-1-(2-{[tert-butyl(dimethyl)silyl]oxy} ethyl)-6,7,8,9-tetrahydro-lH-imidazo[4,5-c]quinolin-4-amine (1.6 g) and a 1 M solution of acetic acid in dichloromethane (85 mL) to provide a homogenous solution. The reaction was judged to be complete after stirring at ambient temperature for 30 minutes. The solution was partitioned between chloroform and brine.
The layers were separated and the organic layer was washed with aqueous saturated sodium bicarbonate and brine, dried over anhydrous sodium sulfate, filtered and then concentrated under reduced pressure to afford a dark brown oil. The material was purified by chromatography over silica gel (95/4/1 dichloromethane/methanol/ammonium hydroxide [ 14.8 M in water]) to provide 2-butyl- 1 -(2- { [tert-butyl(dimethyl)silyl]oxy} ethyl)-6,7,8,9-tetrahydro-1H-imidazo[4,5-c]qu nolin-4-amine (1.24 g, 3.10 mmol) as a colorless oil.
Part C
A round bottom flask was charged with a magnetic stir bar, 2-butyl-1-(2-{[tert-butyl(dimethyl)silyl]oxy} ethyl)-6,7,8,9-tetrahydro-lH-imidazo[4,5-c]quinolin-4-amine (0.83 g, 2.06 mmol), di-tert-butyl dicarbonate (1.79 g, 8.24 mmol), triethylamine (0.52 g, 5.15 mmol), 4-dimethylaminopyridine (0.1 g), and anhydrous tetrahydrofuran (21 mL) under a nitrogen atmosphere. The reaction mixture was heated to 60 C to give a homogeneous solution that was maintained at 60 C for 2.5 hours at which time the reaction was judged to be complete. The solution was cooled to ambient temperature and a 1 M solution of tetrabutylammonium fluoride in tetrahydrofuran (2.27 mL, 2.27 mmol) was added. The reaction was judged to be complete after stirring at ambient temperature for 30 minutes. The solution was partitioned between ethyl acetate and saturated aqueous ammonium chloride. The layers were separated. The organic layer was washed with saturated aqueous sodium bicarbonate and brine, dried over anhydrous sodium sulfate, filtered and then concentrated under reduced pressure to afford a light yellow solid. The material was purified by chromatography over silica gel (95/5 dichloromethane/methanol) to provide di(tert-butyl) 2-butyl-l-(2-hydroxyethyl)-6,7,8,9-tetrahydro-lH-imidazo[4,5-c] quinolin-4-ylimidodicarbonate (0.55 g, 1.13 mmol) as a clear gum.
Part D
A round bottom flask was charged with a magnetic stir bar, di(tert-butyl) 2-butyl-1-(2-hydroxyethyl)-6,7,8,9-tetrahydro-lH-imidazo[4,5-c]quinolin-4-ylimidodicarbonate (0.55 g, 1.13 mmol) and anhydrous dichloromethane (11 mL) under a nitrogen atmosphere. The resulting homogeneous solution was cooled to -10 C in a methanol/ice bath. To the cooled solution was added triethylamine (0.23 g, 2.26 mmol) and methanesulfonyl chloride (0.19 g, 1.70 mmol). The reaction was judged to be complete after stirring at -10 C for 15 minutes and was then partitioned between ethyl acetate and saturated aqueous ammonium chloride. The layers were separated. The organic layer was washed with saturated aqueous sodium bicarbonate and brine, dried over anhydrous sodium sulfate, filtered and then concentrated under reduced pressure to afford 2-{4-[bis(tert-butoxycarbonyl)amino]-2-butyl-6,7,8,9-tetrahydro-lH-imidazo[4,5-c]quinolin-l-yl}ethyl methanesulfonate (0.61 g, 1.08 mmol) as a gummy yellow solid. The material was used without further purification. MS (CI) for C27H42N407S m/z 567 (MH+), 467, 367, 271.
Part E
A round bottom flask was charged with a magnetic stir bar, 2-{4-[bis(tert-butoxycarbonyl)amino]-2-butyl-6,7,8,9-tetrahydro-lH-imidazo[4,5-c]quinolin-l -yl} ethyl methanesulfonate (0.61 g, 1.08 mmol), benzenethiol (0.21 g, 1.88 mmol), triethylamine (0.25 g, 2.43 mmol) and anhydrous dimethyl formamide (11 mL) under a nitrogen atmosphere. The reaction mixture was heated to 80 C to give a dark yellow, homogeneous solution that was maintained at 80 C for 2.5 hours at which time the reaction was judged to be complete. The solution was cooled and then partitioned between ethyl acetate and saturated aqueous sodium bicarbonate. The layers were separated. The organic layer was washed with saturated aqueous sodium bicarbonate and brine, dried over anhydrous sodium sulfate, filtered and then concentrated under reduced pressure to afford a yellow oil. The material was purified by chromatography over silica gel (95/5 dichloromethane/methanol) to provide di(tert-butyl) 2-butyl- 1 -[2-(phenylthio)ethyl]-6,7,8,9-tetrahydro-lH-imidazo[4,5-c]quinolin-4-ylimidodicarbonate (0.54 g, 0.93 mmol) as a light yellow oil. MS (CI) for C32H44N4O4S m/z 581 (MH+), 481, 381, 245.
Part F
A round bottom flask was charged with a magnetic stir bar, di(tert-butyl) 2-butyl-1-[2-(phenylthio)ethyl] -6, 7, 8,9-tetrahydro-lH-imidazo[4,5-c]quinolin-4-ylimidodicarbonate (0.50 g, 0.86 mmol), a 4 M solution of hydrochloric acid in dioxane (5 mL), and dichloromethane (5 mL). The reaction was judged to be complete after stirring at ambient temperature for 2 hours. The volatiles were removed under reduced pressure to afford an off white solid. The material was recrystallized from acetonitrile to provide 2-butyl- 1-[2-(phenylthio)ethyl]-6,7,8,9-tetrahydro-1H-imidazo[4,5-c]quinolin-4-amine hydrochloride (0.17 g, 1.30 mmol) as fluffy white needles, m.p. 237-238 C.
Analysis.
Calculated for C22H28N4S =(H2O)114 = (HCl)2: %C 57.70; %H, 6.71; %N, 12.23.
Found %C
57.62; %H, 6.57; %N, 12.41 'H-NMR (300 MHz, DMSO) 6 7.81 (bs, 2H), 6 7.22-7.39 (m, 5H), S 4.64 (t, J =
6.8 Hz, 2H), 6 3.40 (t, J = 6.8 Hz, 2H), 6 2.75 (m, 6H), S 1.71 (m, 6H), S 1.34 (sextet, J = 7.3 Hz, 2H), 8 0.89 (t, J = 7.3 Hz, 3H) MS (CI) for C22H28N4S (H20)114 (HCl)2 m/z 381 (MH+), 245, 137 Example 3 2-butyl-l -[4-(phenylsulfonyl)butyl]-1H-imidazo[4,5-c]quinolin-4-amine N N
N
O=S=O
\
Part A
Using the general method of Example 1 Part E, 2-butyl-1-(4-{[tert-butyl(dimethyl)silyl]oxy}butyl)-1H-imidazo[4,5-c]quinoline (16.0 g, 38.87 mmol) was oxidized to 2-butyl-l-(4-{[tent-butyl(dimethyl)silyl]oxy}butyl)-1H-imidazo[4,5-c]quinoline-5N-oxide (16.61 g, 38.87 mmol) which was isolated without purification as a tan solid.
Part B
A round bottom flask was charged with a magnetic stir bar, 2-butyl-1-(4-{[tert-butyl(dimethyl)silyl]oxy}butyl)-1H-imidazo[4,5-c]quinoline-5N-oxide (16.61 g, 38.87 mmol), a 14.8 M solution of ammonium hydroxide in water (75 mL) and chloroform (200 mL). To the rapidly stirring solution was addedp-toluenesulfonyl chloride (8.15 g, 42.76 mmol) in a portion wise fashion resulting in a mild exotherm. The reaction was judged to be complete after stirring at ambient temperature for 10 minutes. The solution was partitioned between chloroform and aqueous saturated sodium bicarbonate. The layers were separated. The organic layer was washed with saturated aqueous sodium bicarbonate and brine, dried over anhydrous sodium sulfate, filtered and then concentrated under reduced pressure to afford an off-white solid. The material was triturated with ethyl ether and collected by filtration to provide 2-butyl-l-(4-{[tent-butyl(dimethyl)silyl]oxy}butyl)-1H-imidazo[4,5-c]quinolin-4-amine (9.3 g, 21.80 mmol) as a fine white powder.
The material was used without further purification.
Part C
A round bottom flask was charged with a magnetic stir bar, 2-butyl-1-(4-{[tert-butyl(dimethyl)silyl]oxy}butyl)-1H-imidazo[4,5-c]quinolin-4-amine (9.2 g, 21.56 mmol), a 1M solution of tetrabutylammonium fluoride in tetrahydrofuran (23.72 mL, 23.72 mmol), and anhydrous tetrahydrofuran (100 mL) to give a homogeneous, light orange solution. The reaction was judged to be complete after stirring at ambient temperature for 1 hour. While stirring, water (100 mL) was added and resulted in a mild exotherm. The volatiles were removed under reduced pressure until a solid precipitated out of solution.
The solid was collected by filtration and washed with water (20 mL) and acetone (20 mL) to afford a white solid. The material was triturated with ethyl ether (50 mL) and collected by filtration to provide 4-(4-amino-2-butyl-lH-imidazo[4,5-c]quinolin-1-yl)butan-l-ol (6.12 g, 19.59 mmol) as a fine white solid, m.p. 184-186 C.
Analysis. Calculated for C18H24N40: %C 69.20; %H, 7.74; %N, 17.93. Found %C
69.05;
%H, 8.02; %N, 18.03 MS (CI) for C 18H24N40 m/z 313 (MH+) Part D
A round bottom flask was charged with a magnetic stir bar, 4-(4-amino-2-butyl-1 H-imidazo[4,5-c]quinolin-1-yl)butan-l-ol (7.3 g, 23.37 mmol), triethylamine (3.55 g, 35.06 mmol), and anhydrous dimethyl formamide (93 mL) under a nitrogen atmosphere.
To the stirred solution was added phosphorus oxychloride (3.94 g, 25.70 mmol) in a drop wise fashion resulting in an exotherm to give a dark yellow heterogeneous reaction mixture. The reaction mixture was heated to 60 C to give a homogeneous solution that was maintained at 60 C for 5 hours at which time the starting material was completely consumed. The volatiles were removed under reduced pressure to give a dark brown oil.
The material was partitioned between chloroform and saturated aqueous sodium bicarbonate. The layers were separated and the aqueous layer was extracted with chloroform (lx). The organic layers were combined and the volatiles removed under reduced pressure to afford a 2:1 mixture ofN-[2-butyl-l-(4-chlorobutyl)-1H-imidazo[4,5-c]quinolin-4-yl]-N,N-dimethylimidoformamide and 2-butyl-l-(4-chlorobutyl)-1H-imidazo[4,5-c]quinolin-4-amine (7.70 g) as an off-white solid. The material was used without further purification.
Part E
A round bottom flask was charged with a magnetic stir bar, a 2:1 mixture of N-[2-butyl- l -(4-chlorobutyl)-1 H-imidazo [4, 5-c]quinolin-4-yl]-N,N-dimethylimidoformamide and 2-butyl-l-(4-chlorobutyl)-1H-imidazo[4,5-c]quinolin-4-amine (1.3 g), benzenesulfinic acid sodium salt (1.67 g, 10.11 mmol), and anhydrous dimethyl formamide (15 mL) under a nitrogen atmosphere. The resulting solution was heated to 100 C to give a homogeneous solution that was maintained at 100 C for 90 hours at which time the starting materials were completely consumed. The solution was cooled and then partitioned between chloroform and water. The layers were separated. The organic layer was washed with saturated aqueous sodium bicarbonate and brine, dried over anhydrous sodium sulfate, filtered and then concentrated under reduced pressure to afford a dark yellow gum. The material was dissolved in methanol (20 mL) and a 4 M solution of hydrochloric acid in dioxane (3.02 mL, 12.1 mmol). The light orange solution was stirred at ambient temperature for 12 hours at which time the reaction was judged to be complete.
The volatiles were removed under reduced pressure to give a light yellow gum.
The material was partitioned between chloroform and saturated aqueous sodium bicarbonate.
The layers were separated and the aqueous layer was extracted with chloroform (lx). The organic layers were combined, washed with brine, dried over anhydrous sodium sulfate, filtered and then concentrated under reduced pressure to afford a light yellow solid. The material was purified by chromatography over silica gel (95/5 dichloromethane/methanol) to give an off-white solid. The solid (0.63 g) was dissolved in ethyl acetate (50 mL) and brought to reflux. Activated charcoal (0.6 g) was added and the resulting mixture was heated at reflux for 5 minutes. The charcoal was removed by filtration through fluted paper to provide a colorless solution. The solution was concentrated under reduced pressure to give a solid that was recrystallized from ethyl acetate and hexanes to provide 2-butyl-l-[4-(phenylsulfonyl)butyl]-IH-imidazo[4,5-c]quinolin-4-amine (0.37 g, 0.85 mmol) as a white fluffy solid, m.p. 179-180 C. Analysis. Calculated for C24H28N402S:
%C 66.03; %H, 6.46; %N, 12.83. Found %C 65.88; %H, 6.49; %N, 12.76 'H-NMR (300 MHz, DMSO) 6 7.98 (d, J = 8.3 Hz, 1H), 8 7.82 (m, 2H) 8 7.73 (d, J
= 7.3 Hz, 1H), 5 7.62 (m, 3H) 8 7.41 (t, J = 7.6 Hz, 1H), 6 7.22 (t, J = 7.6 Hz, 1H), 8 6.45 (bs, 2H), 6 4.51 (t, J = 7.3 Hz, 2H), 5 3.90 (t, J = 7.8 Hz, 211), 8 2.86 (t, J =
7.6 Hz, 3H), 6 1.69-1.90 (m, 6H), 6 1.43 (sextet, J = 7.3 Hz, 2H), 8 0.95 (t, J = 7.3 Hz, 3H) MS (CI) for C24H28N402S m/z 437 (MH+), 295 Example 4 2-butyl-1 [4-(methylthio)butyl]-lH-imidazo[4,5-c]quinolin-4-amine N N
N
S
Part A
A round bottom flask was charged with a magnetic stir bar, a 2:1 mixture of N-[2-butyl- l -(4-chlorobutyl)-1 H-imidazo [4, 5 -c] quinolin-4-yl]-N,N-dimethylimidoformamide and 2-butyl-l-(4-chlorobutyl)-1H-imidazo[4,5-c]quinolin-4-amine (6.17 g), a 4 M solution of hydrochloric acid in dioxane (21.15 mL, 84.56 mmol), and methanol (200 mL) to provide a light orange solution. The reaction was judged to be complete after stirring at ambient temperature for 43 hours. The volatiles were removed under reduced pressure and the resulting light yellow solid was partitioned between chloroform and saturated aqueous sodium bicarbonate. The layers were separated and the aqueous layer was extracted with chloroform (lx). The organic layers were combined, dried over anhydrous sodium sulfate, filtered and then concentrated under reduced pressure to afford 2-butyl-1-(4-chlorobutyl)-lH-imidazo[4,5-c]quinolin-4-amine (4.65 g, 14.05 mmol) as an off-white solid. The material was used without further purification. MS (CI) for C18H23C1N4 m/z 331 (MH+), 295.
Part B
A round bottom flask was charged with a magnetic stir bar, 2-butyl-1-(4-chlorobutyl)-1H-imidazo[4,5-c]quinolin-4-amine (1.5 g, 4.53 mmol), sodium thiomethoxide (0.48 g, 6.80 mmol), and anhydrous dimethyl formamide (18 mL) under a nitrogen atmosphere, The reaction mixture was heated to 60 C to give a homogeneous solution that was maintained at 60 C for 16 hours at which time the starting material was completely consumed. The solution was cooled and then partitioned between chloroform and water. The layers were separated and the organic layer was washed with saturated aqueous sodium bicarbonate. The combined aqueous layers were extracted with chloroform (lx). The combined organic layers were washed with brine, dried over anhydrous sodium sulfate, filtered and then concentrated under reduced pressure to afford a dark brown oil. The material was purified by chromatography over silica gel (90/10 dichloromethane/methanol) to provide a light yellow solid. The solid was recrystallized from dimethyl forinamide and water to give 2-butyl-l-[4-(methylthio)butyl]-1H-imidazo[4,5-c]quinolin-4-amine (0.83 g, 2.42 mmol) as light yellow needles, m.p. 127-130 C.
Analysis. Calculated for C19H26N4S: %C 66.63; %H, 7.65; %N, 16.36. Found %C
66.68;
%H, 7.53; %N, 16.35 1H-NMR (500 MHz, DMSO) 8 8.04 (d, J = 8.3 Hz, 1H), S 7.61 (d, J = 8.3 Hz, 1H), 8 7.41 (t, J = 8.3 Hz, 1H), 8 7.25 (t, J = 8.3 Hz, 1H), 6 6.43 (bs, 2H), 8 4.52 (t, J
= 7.6 Hz, 2H), 8 2.92 (t, J = 7.8 Hz, 2H), 8 2.53 (t, J = 7.3 Hz, 2H), 8 2.01 (s, 3H), 6 1.90 (m, 2H) 8 1.80 (p, J = 7.8 Hz, 2H) 6 1.71 (p, J = 7.3 Hz, 2H) 8 1.46 (sextet, J = 7.3 Hz, 2H), 6 0.96 (t, J = 7.3 Hz, 3H) MS (CI) for C19H26N4S m/z 343 (MH+), 295, 241 Example 5 2-butyl-l -[4-(methylsulfonyl)butyl]-1H-imidazo[4,5-c]quinolin-4-amine N ~ N
I
6O=S=O
Part A
A round bottom flask was charged with a magnetic stir bar, 2-butyl-l-[4-(methylthio)butyl]-1H-imidazo[4,5-c]quinolin-4-amine (1.2 g, 3.50 mmol), and chloroform (18 mL). Solid 3-chloroperbenzoic acid (1.72 g, 7.71 mmol) was added to the resulting solution portion wise over 15 minutes. The reaction was judged to be complete after stirring at ambient temperature for 5 minutes. The solution was partitioned between chloroform and 1% aqueous sodium carbonate. The layers were separated and the organic layer was washed with brine, dried over anhydrous sodium sulfate, filtered and then concentrated under reduced pressure to afford a light brown solid. The material was purified by chromatography over silica gel (90/10 dichloromethane/methanol) to provide an off-white solid. The solid was recrystallized from acetonitrile and water to give 2-butyl-l-[4-(methylsulfonyl)butyl]-1H-imidazo[4,5-c]quinolin-4-amine (0.61 g, 1.63 mmol) as off-white needles, m.p. 164-165 C.
Analysis. Calculated for C19H26N402S: %C 60.94; %H, 7.00; %N, 14.96. Found %C
60.71; %H, 6.94; %N, 14.94 1H-NMR (300 MHz, DMSO) 6 8.03 (d, J = 8.3 Hz, 1H), 6 7.61 (d, J = 8.3 Hz, 1H), 8 7.42 (t, J = 8.3 Hz, 1H), 8 7.26 (t, J = 8.3 Hz, 1H), 6 6.46 (bs, 2H), S 4.56 (t, J
= 7.6 Hz, 2H), 6 3.21 (t, J = 7.3 Hz, 2H), 6 2.96 (s, 3H), 6 2.93 (t, J = 7.8 Hz, 2H), 6 1.91 (m, 4H), 6 1.81 (p, J = 7.3 Hz, 2H), 8 1.45 (sextet, J = 7.3 Hz, 2H), 8 0.96 (t, J = 7.3 Hz, 3H) MS (CI) for C19H26N402S m/z 375 (MH+), 295 Example 6 1-[2-(phenylthio)ethyl]-1H-imidazo[4,5-c]quinolin-4-amine N N
N
S
Part A
A round bottom flask was charged with a magnetic stir bar, 2-(4-amino-lH-imidazo[4,5-c]quinolin-1-yl)ethanol (8.46 g, 37.06 mmol), and thionyl chloride (68.99 g, 57.99 mmol) under a nitrogen atmosphere. The reaction mixture was heated to 80 C to give a heterogeneous reaction mixture that was maintained at 80 C for 2 hours at which time the starting material was completely consumed. The solution was cooled and quenched by the addition of water (400 mL). To the stirred solution was added solid sodium carbonate until the pH reached 10 at which time a solid precipitated out of solution. The solid was collected by filtration to afford 1-(2-chloroethyl)-1H-imidazo[4,5-c]quinolin-4-amine (7.86 g, 31.86 mmol) as an off-white solid. The material was used without further purification.
Part B
A round bottom flask was charged with a magnetic stir bar, 1-(2-chloroethyl)-imidazo[4,5-c]quinolin-4-amine (2.0 g, 8.11 mmol), sodium benzenethiolate (1.79 g, 12.16 mmol), and anhydrous dimethyl sulfoxide (40 mL) under a nitrogen atmosphere.
The reaction mixture was heated to 100 C to give a homogeneous solution that was maintained at 100 C for 30 minutes at which time the starting material was completely consumed. The hot solution was poured into rapidly stirred water (300 mL) which caused a solid to precipitate out of solution. The solid was collected by filtration to afford an off-white solid. The material was triturated with acetonitrile and collected by filtration to give 1-[2-(phenylthio)ethyl]-1H-imidazo[4,5-c]quinolin-4-amine (2.08 g, 6.49 mmol) as an off-white powder, in. p. 233-235 C.
Analysis. Calculated for C18H16N4S: %C 67.47; %H, 5.03; %N, 17.49. Found: %C
67.20;
%H, 4.95; %N, 17.52 1H-NMR (300 MHz, DMSO) 5 8.14 (s, 1H), 6 7.76 (d, J = 8.3 Hz, 1H), S 7.60 (t, J = 8.3 Hz, 1H), 6 7.28-7.44 (m, 6H), 6 7.12 (t, J = 8.3 Hz, 1H), 6 6.58 (bs, 2H), 6 4.79 (t, J = 6.8 Hz, 2H), 6 3.48 (t, J = 6.8 Hz, 2H) MS (CI) for C18H16N4S m/z 321 (MH), 185, 137 Example 7 1-[4-(phenylsulfonyl)butyl]-1H-imidazo[4,5-c]quinolin-4-amine N N\>
N
O=S=O
Part A
A round bottom flask was charged with a magnetic stir bar, N,N-dibenzyl-1H-imidazo[4,5-c]quinolin-4-amine (20.0 g, 55.04 mmol), sodium hydride (3.3 g, 60%
dispersion, 82.56 mmol), and anhydrous dimethyl formamide (275 mL) under a nitrogen atmosphere. After the reaction mixture had stirred at ambient temperature for 2 hours, 4-chloro-1-iodobutane (19.23 g, 88.06 mmol) was added and the resulting homogeneous solution was stirred at ambient temperature for 48 hours at which time the starting material was consumed. The solution was partitioned between ethyl acetate and water.
The layers were separated and the organic layer was washed with saturated aqueous sodium bicarbonate and brine, dried over anhydrous sodium sulfate, filtered and then concentrated under reduced pressure to afford a light yellow solid. The material was recrystallized from ethyl acetate and hexanes to give N,N-dibenzyl-l-(4-chlorobutyl)-IH-imidazo[4,5-c]quinolin-4-amine (20.7 g, 45.49 mmol) as white needles. MS (CI) for C28H27C1N4 m/z 455 (MH+), 365, 329, 239 Part B
A round bottom flask was charged with a magnetic stir bar, N,N-dibenzyl-1-(4-chlorobutyl)- 1H-imidazo[4,5-c]quinolin-4-amine (7.0 g, 15.38 mmol), sodium benzenethiolate (3.46 g, 26.15 mmol), and anhydrous dimethyl formamide (77 mL) under a nitrogen atmosphere. The reaction mixture was heated to 60 C to give a heterogeneous mixture that was maintained at 60 C for 4 hours at which time the starting material was completely consumed. The cooled solution was partitioned between ethyl acetate and water. The layers were separated. The organic layer was washed with saturated aqueous sodium bicarbonate and brine, dried over anhydrous sodium sulfate, filtered and then concentrated under reduced pressure to afford a colorless oil. The material was purified by chromatography over silica gel (80/20 hexanes/ethyl acetate) to provide N,N-dibenzyl-1-[4-(phenylthio)butyl]-1H-imidazo[4,5-c]quinolin-4-amine (7.5 g, 14.19 mmol) as a colorless oil. MS (CI) for C34H32N4S m/z 529 (MH+), 439, 349 Part C
A round bottom flask was charged with a magnetic stir bar, N,N-dibenzyl-l-[4-(phenylthio)butyl]-1H-imidazo[4,5-c]quinolin-4-amine (3.64 g, 6.88 mmol) and chloroform (34 mL). Solid 3-chloroperbenzoic acid (3.39 g, 15.14 mmol) was added portion wise to the resulting solution over 5 minutes. The reaction was judged to be complete after stirring at ambient temperature for 5 minutes. The solution was partitioned between chloroform and 1 % aqueous sodium carbonate. The layers were separated. The organic layer was washed with brine, dried over anhydrous sodium sulfate, filtered and then concentrated under reduced pressure to afford a red gum. The material was purified by chromatography over silica gel (dichloromethane) to provide N,N-dibenzyl-1-[4-(phenylsulfonyl)butyl]-1H-imidazo[4,5-c]quinolin-4-amine '(2.85 g, 5.08 mmol) as a light pink gum. MS (CI) for C34H32N402S m/z 561 (MH+), 471, 381 Part D
A round bottom flask was charged with a magnetic stir bar, N,N-dibenzyl-1-[4-(phenylsulfonyl)butyl]-1H-imidazo[4,5-c]quinolin-4-amine (1.0 g, 1.78 mmol), triflic acid (2.68 g, 17.83 mmol), and anhydrous dichloromethane (14 mL) under a nitrogen atmosphere. The reaction was judged to be complete after stirring at ambient temperature for 24 hours. The solution was partitioned between chloroform and excess aqueous sodium hydroxide (20%). The layers were separated. The aqueous layer was extracted with chloroform (3x). The organic layers were combined and then concentrated under reduced pressure to afford a light brown solid. The material was purified by chromatography over silica gel (90/10 dichloromethane/methanol) to provide a fine white powder which was recrystallized from acetonitrile to give 1-[4-(phenylsulfonyl)butyl]-1H-imidazo[4,5-c]quinolin-4-amine (0.32 g, 0.84 mmol) as white needles, in. p.
175-177 C.
Analysis. Calculated for C2oH2ON402S: %C 63.14; %H, 5.30; %N, 14.73. Found: %C
63.14; %H, 5.24; %N, 14.77 'H-NMR (300 MHz, DMSO) 8 8.15 (s, 1H), S 8.01 (d, J = 8.3 Hz, 1H), 8 7.80 (m, 2H), 8 7.71 (m, 1H), 6 7.60 (m, 3H), 6 7.44 (t, J = 8.3 Hz, 1H), 6 7.24 (t, J = 8.3 Hz, 1H), 8 6.59 (bs, 2H), 8 4.59 (t, J = 6.8 Hz, 2H), 5 3.38 (t, J = 7.8 Hz, 2H), 6 1.93 (m, 2H), 6 1.58 (m, 2H) MS (CI) for C2oH2oN402S m/z 381 (MH+), 239 Example 8 1-[4-(methylsulfonyl)butyl]-1H-imidazo[4,5-c]quinolin-4-amine NHZ
N N>
N
O=S=O
Part A
Using the general method of Example 7 Part B, N,N-dibenzyl-1-(4-chlorobutyl)-1H-imidazo[4,5-c]quinolin-4-amine (5.0 g, 10.99 mmol) was converted to N,N-dibenzyl-1-[4-(methylthio)butyl]-1H-imidazo[4,5-c]quinolin-4-amine using sodium thiomethoxide (1.16 g, 16.48 mmol). The material was purified by chromatography over silica gel (80/20 hexanes/ethyl acetate) to provide the product (4.91 g, 10.52 mmol) as a colorless oil. MS
(Cl) for C29H30N4S m/z 467 (MH+), 377, 287, 185 Part B
Using the general method of Example 7 Part C, N,N-dibenzyl-1-[4-(methylthio)butyl]-1H-imidazo[4,5-c]quinolin-4-amine (4.91 g, 15.52 mmol) was oxidized to N,N-dibenzyl-l-[4-(methylsulfonyl)butyl]-1H-imidazo[4,5-c]quinolin-4-amine which was purified by chromatography over silica gel (80/20 hexanes/ethyl acetate) to provide the product (4.53 g, 9.08 mmol) as a light orange solid. MS (CI) for C29H30N402S m/z 499 (MH+), 409, 319 Part C
Using the general method of Example 7 Part D, N,N-dibenzyl-l-[4-(methylsulfonyl)butyl]-1H-imidazo[4,5-c]quinolin-4-amine (4.53 g, 9.08 mmol) was converted to 1-[4-(methylsulfonyl)butyl]-1H-imidazo[4,5-c]quinolin-4-amine.
The material was recrystallized from methanol and water to afford the title compound (1.33 g, 4.18 mmol) as white needles, m.p. 203-204 C.
Analysis. Calculated for C15H18N402S: %C 56.58; %H, 5.70; %N, 17.60. Found: %C
56.33; %H, 5.63; %N, 17.41 'H-NMR (300 MHz, DMSO) S 8.22 (s, 1H), S 8.06 (d, J = 8.3 Hz, 1H), 6 7.62 (d, J = 8.3 Hz, I H), S 7.45 (t, J = 8.3 Hz, I H), b 7.27 (t, J = 8.3 Hz, I H), 6 6.59 (bs, 2H), b 4.65 (t, J =
6.8 Hz, 2H), b 3.19 (t, J = 7.8 Hz, 2H), 6 2.93 (s, 3H), S 1.99 (m, 2H), S
1.74 (m, 2H) MS (CI) for C15H18N402S m/z 319 (MH+), 239 Example 9 1-[4-(phenylthio)butyl]-lH-imidazo[4,5-c]quinolin-4-amine N N
N
S
Part A
Using the general method of Example 1 Part D, N-(4-{[tert-butyl(dimethyl)silyl]oxy}butyl)quinoline-3,4-diamine (101.21 g, 292.90 mmol) was cyclized to 1-(4-{[tert-butyl(dimethyl)silyl]oxy}butyl)-1H-imidazo[4,5-c]quinoline using triethyl orthoformate (65.11 g, 439.35 mmol). The product (75.0 g, 210.93 mmol) was isolated as a brown oil and used without further purification.
Part B
Using the general method of Example 1 Part E, 1-(4- { [tert-butyl(dimethyl)silyl]oxy}butyl)-1H-imidazo[4,5-c]quinoline (42.2 g, 118.69 minol) was oxidized to 1-(4-{[tert-butyl(dimethyl)silyl]oxy}butyl)-1H-imidazo[4,5-c]quinoline-5N-oxide (44.10 g, 118.69 mmol) which was isolated without further purification as a tan solid.
Part C
Using the general method of Example 3 Part B, 1-(4-{[tert-butyl(dimethyl)silyl]oxy}butyl)-1H-imidazo[4,5-c]quinoline-5N-oxide (44.10 g, 118.69 mmol) was aminated to provide 1-(4-{[tent-butyl(dimethyl)silyl]oxy}butyl)-lH-imidazo[4,5-c] quinolin-4-amine. The material was triturated with ethyl ether and collected by filtration to afford the product (21.54 g, 58.12 mmol) as a light brown solid which was used without further purification.
Part D
Using the general method of Example 3 Part C, 1-(4-{[tert-butyl(dimethyl)silyljoxy}butyl)-1H-imidazo[4,5-c]quinolin-4-amine (21.5 g, 58.02 mmol) was converted to 4-(4-amino-lH-imidazo[4,5-c]quinolin-1-yl)butan-l-ol. The material was triturated with cold methanol (0 C) and collected by filtration to afford the product (13.92 g, 54.30 mmol) which was used without further purification. MS (CI) for C14Hi6N4O m/z 257 (MH+), 185 Part E
Using the general method of Example 6 Part A, 4-(4-amino-lH-imidazo[4,5-c] quinolin- 1 -yl)butan- 1 -ol (5.0 g, 19.51 mmol) was chlorinated to provide 1-(4-chlorobutyl)- 1H-imidazo[4,5-c]quinolin-4-amine (4.92 g, 17.91 mmol) which was isolated without further purification as an off-white solid.
Part F
Using the general method of Example 6 Part B, except that the reaction temperature was lowered to 80 C, 1-(4-chlorobutyl)-lH-imidazo[4,5-c]quinolin-4-amine (1.5 g, 5.46 mmol) was converted to 1-[4-(phenylthio)butyl]-IH-imidazo[4,5-c]quinolin-4-amine. The resulting solid (1.53 g) was dissolved in acetonitrile (90 mL) and brought to reflux. Activated charcoal (0.9 g) was added and the resulting mixture was heated at reflux for 5 minutes and then the charcoal was removed by filtration through fluted paper to provide a colorless solution. The title compound (0.86 g, 2.47 mmol) was isolated as white needles, m.p 158-160 C.
Analysis. Calculated for C20H2ON4S: %C 68.94; %H, 5.79; %N, 16.08. Found: %C
68.70;
%H, 5.74; %N, 16.08 1H-NMR (300 MHz, DMSO) S 8.18 (s, 1H), 6 8.05 (d, J = 8.3 Hz, 1H), 6 7.63 (d, J = 8.3 Hz, 1H), S 7.45 (t, J = 8.3 Hz, 1H), 6 7.26 (m, 5H), 6 7.14-7.19 (m, 1H), S
6.60 (bs, 2H), 6 4.62 (t, J = 6.8 Hz, 2H), S 3.00 (t, J = 7.3 Hz, 2H), 6 2.00 (m, 2H), S 1.61 (m, 2H) MS (Cl) for C20H2ON4S m/z 349 (MH), 185 Example 10 1-[4-(methylthio)butyl]-1H-imidazo[4,5-c]quinolin-4-amine N N\\
N/
S
Part A
Using the general method of Example 6 Part B, except that the reaction temperature was lowered to 80 C, 1-(4-chlorobutyl)-1H-imidazo[4,5-c]quinolin-4-amine (1.5 g, 5.46 mmol) was converted to 1-[4-(methylthio)butyl]-1H-imidazo[4,5-c]quinolin-4-amine using sodium thiomethoxide (0.88 g, 12.56 mmol) in lieu of sodium benzenethiolate. The resulting solid (1.26 g) was dissolved in acetonitrile (40 mL) and brought to reflux. Activated charcoal (0.7 g) was added, the resulting mixture was heated at reflux for 5 minutes and then the charcoal was removed by filtration through fluted paper to provide a colorless solution. The solution was concentrated under reduced pressure to give a solid that was recrystallized from acetonitrile. The title compound (0.66 g, 2.30 mmol) was isolated as white needles, m.p 163-164 C.
Analysis. Calculated for C15H18N4S: %C 62.91; %H, 6.34; %N, 19.56. Found: %C
62.70;
%H, 6.19; %N, 19.45 'H-NMR (300 MHz, DMSO) 6 8.21 (s, 1H), S 8.06 (d, J = 8.3 Hz, 1H), 6 7.62 (d, J = 8.3 Hz, 1 H), 8 7.44 (t, J = 8.3 Hz, 1 H), S 7.26 (t, J = 8.3 Hz, 1 H), 6 6.59 (bs, 2H), 6 4.62 (t, J =
7.6 Hz, 2H), 6 2.50 (t, J = 6.8 Hz, 2H), 6 1.99 (s, 3H), 6 1.95 (p, J = 7.3 Hz, 2H), 6 1.59 (p, J = 7.3 Hz, 2H) MS (CI) for C15H18N4S m/z 287 (MH+), 185 Example 11 2-butyl-l -[5-(methylsulfonyl)pentyl]-lH-imidazo[4,5-c]quinolin-4-amine NHz N N
I
N
O
,S~
Part A
Using the general method of Example 1 Part A, 4-chloro-3-nitroquinoline (107.7 g, 525.87 mmol) was converted to 5-[(3-nitroquinolin-4-yl)amino]pentan-l-ol using amino- 1 -pentanol (79.82 g, 788.81 mmol) in lieu of 4-amino-butanol. The product (117.22 g, 425.77 mmol) was used without further purification as a dark yellow solid. MS
(CI) for C14H17N303 m/z 276 (MH+), 224 Part B
A round bottom flask was charged with a magnetic stir bar, 5-[(3-nitroquinolin-yl)amino]pentan-l-ol (5.0 g, 18.16 mmol), and thionyl chloride (40.78 g, 0.34 mmol) under a nitrogen atmosphere. The reaction mixture was heated to 80 C to give a homogeneous solution that was maintained at 80 C for 1 hour at which time the starting material was completely consumed. The volatiles were removed under reduced pressure and the resulting oil stirred in water made basic (pH 10) with solid sodium carbonate. The resulting solid was collected by filtration to afford N-(5-chloropentyl)-3-nitroquinolin-4-amine (4.80 g, 16.34 mmol) which was used without further purification.
Part C
Using the general method of Example 6 Part B, except that the reaction temperature was lowered to 80 C, N-(5-chloropentyl)-3-nitroquinolin-4-amine (4.75 g, 16.17 mmol) was converted to N-[5-(methylthio)pentyl]-3-nitroquinolin-4-amine using sodium thiomethoxide (1.43 g, 19.40 mmol) in lieu of sodium benzenethiolate.
The product (3.28 g, 10.74 mmol) was isolated without further purification as a light yellow solid. MS (CI) for C15H19N3O2S m/z 306 (MH+), 272, 117 Part D
Using the general method of Example 1 Part C, N-[5-(methylthio)pentyl]-3-nitroquinolin-4-amine (3.20 g, 10.48 mmol) was reduced to N4-[5-(methylthio)pentyl]quinoline-3,4-diamine (2.89 g, 10.48 mmol) which was isolated without further purification as a brown oil.
Part E
Using the general method of Example 1 Part D, N4-[5-(methylthio)pentyl]quinoline-3,4-diamine (2.89 g, 10.48 mmol) was cyclized to provide 2-butyl-l-[5-(methylthio)pentyl]-1H-imidazo[4,5-c]quinoline. The material was purified by chromatography over silica gel (ethyl acetate) to afford the product (2.10 g, 6.15 mmol) as a light brown oil.
Part F
A round bottom flask was charged with a magnetic stir bar, 2-butyl-l -[5-(methylthio)pentyl]-1H-imidazo[4,5-c]quinoline (2.1 g, 6.15 mmol) and chloroform (31 mL). Solid 3-chloroperbenzoic acid (4.41 g, 19.68 mmol) was added portion wise to the solution over 10 minutes and the reaction was stirred at ambient temperature for 30 minutes at which time the starting material was completely consumed. The solution was partitioned between chloroform and saturated aqueous sodium bicarbonate. The layers were separated. The organic layer was washed with saturated aqueous sodium bicarbonate and brine, dried over anhydrous sodium sulfate, filtered and then concentrated under reduced pressure to afford 2-butyl-l-[5-(methylsulfonyl)pentyl]-1H-imidazo[4,5-c]quinoline-5N-oxide (2.40 g, 6.15 mmol) as a tan solid. The material was used without further purification.
Part G
Using the general method of Example 3 Part B, 2-butyl-1-[5-(methylsulfonyl)pentyl]-1H-imidazo[4,5-c]quinoline-5N-oxide (2.40 g, 6.15 mmol) was aminated to provide 2-butyl-l-[5-(methylsulfonyl)pentyl]-1H-imidazo[4,5-c]quinolin-4-amine. The resulting solid (2.24 g) was dissolved in acetonitrile (40 mL) and brought to reflux. Activated charcoal (1 g) was added and the resulting mixture was heated at reflux for 5 minutes and then the charcoal was removed by filtration through fluted paper to provide a light brown solution. Upon cooling 2-butyl-l-[5-(methylsulfonyl)pentyl]-1H-imidazo[4,5-c]quinolin-4-amine (0.90 g, 2.32 mmol) was isolated as white needles, m.p.
173-175 C.
Analysis. Calculated for C20H28N402S: %C 61.83; %H, 7.26; %N, 14.42. Found: %C
61.58; %H, 7.27; %N, 14.36 'H-NMR (300 MHz, DMSO) 6 8.01 (d, J = 8.3 Hz, 1H), 6 7.61 (d, J = 8.3 Hz, 1H), 6 7.41 (t, J = 8.3 Hz, 1H), 6 7.26 (t, J = 8.3 Hz, 1H), 6 6.45 (bs, 2H), 6 4.51 (t, J
= 7.6 Hz, 2H), 6 3.10 (t, J = 7.8 Hz, 2H), 6 2.92 (s, 3H), 6 2.92 (t, J = 7.3 Hz, 2H), 6 1.76 (m, 6H), 6 1.54 (m, 2H), 6 1.46 (sextet, J = 7.3 Hz, 2H), 6 0.99 (t, J = 7.3 Hz, 3H) MS (CI) for C20H28N402S m/z 389 (MH+) Example 12 2-methyl-l-[5-(methylsulfonyl)pentyl]-1H-imidazo[4,5-c]quinolin-4-amine C
N N>-N
Part A
Using the general method of Example 1 Part D, IV4-[5-(methylthio)pentyl]quinoline-3,4-diamine (4.53 g, 16.37 mmol) was cyclized to provide 2-methyl-l-[5-(methylthio)pentyl]-1H-imidazo[4,5-c]quinoline using 1,1,1-trimethoxyethane (2.95 g, 24.6 mmol) and pyridine hydrochloride (0.1 g). The material was triturated with ethyl ether and collected by filtration to afford the product (3.78 g, 12.62 mmol) as a light brown solid which was used without further purification.
Part B
Using the general method of Example 11 Part F, 2-methyl-l-[5-(methylthio)pentyl]-lH-imidazo[4,5-c]quinoline (3.78 g, 12.62 mmol) was oxidized to 2-methyl-l-[5-(methylsulfonyl)pentyl]-1H-imidazo[4,5-c]quinoline-5N-oxide (4.38 g, 12.62 mmol) which was isolated as a tan solid and used without purification.
Part C
Using the general method of Example 3 Part B, 2-methyl-l-[5-(methylsulfonyl)pentyl]-IH-imidazo[4,5-c]quinoline-5N-oxide (4.38 g, 12.62 mmol) was aminated to provide 2-methyl-l-[5-(methylsulfonyl)pentyl]-1H-imidazo[4,5-c]quinolin-4-amine. The resulting solid was triturated with acetonitrile and collected by filtration to afford the title compound (0.8 g, 2.31 mmol) as an off-white solid, m.p. 235-240 C.
Analysis. Calculated for C17H22N402S: %C 58.94; %H, 6.40; %N, 16.17. Found: %C
58.77; %H, 6.34; %N, 16.39 'H-NMR (300 MHz, DMSO) 8 8.02 (d, J = 8.3 Hz, 1H), 8 7.60 (d, J = 8.3 Hz, IH), 6 7.41 (t, J = 8.3 Hz, 1H), 8 7.25 (t, J = 8.3 Hz, 1H), 6 6.49 (bs, 2H), 8 4.50 (t, J
= 7.3 Hz, 2H), 6 3.12 (t, J = 7.8 Hz, 2H), 6 2.92 (s, 3H), 6 2.61 (s, 3H), 6 1.86 (m, 2H), 6 1.74 (m, 2H), 6 1.53 (m, 2H) MS (Cl) for C17H22N402S m/z 347 (MH+), 267 Example 13 2-ethyl- l -[5-(methylsulfonyl)pentyl]-1H-imidazo [4, 5-c] quinolin-4-amine NHZ
N
N \\ /
N
,0 ,S"~
Part A
Using the general method of Example 1 Part D,1V4-[5-(methylthio)pentyl]quinoline-3,4-diamine (4.53 g, 16.37 mmol) was cyclized to 2-ethyl-l-[5-(methylthio)pentyl]-1H-imidazo[4,5-c]quinoline using triethyl orthopropionate (4.3 g, 24.56 mmol) and pyridine hydrochloride (0.1 g). The material was triturated with ethyl ether and collected by filtration to afford the product (3.25 g, 10.37 mmol) as an off-white powder which was used without further purification.
Part B
Using the general method of Example 11 Part F, 2-ethyl-1 -[5-(methylthio)pentyl]-1H-imidazo[4,5-c]quinoline (3.25 g, 10.37 mmol) was oxidized to 2-ethyl-l-[5-(methylsulfonyl)pentyl]-1H-imidazo[4,5-c]quinoline-5N-oxide (3.75 g, 10.37 mmol) which was isolated as a tan solid and used without purification.
Part C
Using the general method of Example 3 Part B, 2-ethyl-l-[5-(methylsulfonyl)pentyl]-1H-imidazo[4,5-c]quinoline-5N-oxide (3.75 g, 10.37 mmol) was aminated to provide 2-ethyl-l-[5-(methylsulfonyl)pentyl]-1H-imidazo[4,5-c]quinolin-4-amine. The resulting solid was recrystallized sequentially from ethanol and acetonitrile to afford the title compound (1.4 g, 3.88 mmol) as off-white needles, m.p. 189-191 C.
Analysis. Calculated for C18H24N402S: %C 59.98; %H, 6.71; %N, 15.54. Found: %C
59.71; %H, 6.68; %N, 15.64 'H-NMR (300 MHz, DMSO) 6 8.01 (d, J = 8.3 Hz, 1H), S 7.61 (d, J = 8.3 Hz, 1H), 6 7.42 (t, J = 8.3 Hz, 1H), 6 7.26 (t, J = 8.3 Hz, 1H), 6 6.45 (bs, 2H), 6 4.50 (t, J
= 7.6 Hz, 2H), 6 3.10 (t, J = 7.8 Hz, 2H), 8 2.95 (q, J = 7.3 Hz, 2H), 6 2.92 (s, 3H), 6 1.85 (m, 2H), 8 1.74 (m, 2H), 6 1.55 (m, 2H), 6 1.38 (t, J = 7.3 Hz, 3H) MS (CI) for C18H24N402S m/z 361 (MH+), 281 Example 14 1-[5-(methylsulfonyl)pentyl]-1H-imidazo[4,5-c]quinolin-4-amine N N>
N
,O
,S~
Part A
Using the general method of Example 1 Part D, N4-[5-(methylthio)pentyl]quinoline-3,4-diamine (4.53 g, 16.37 mmol) was cyclized to 1-[5-(methylthio)pentyl]-1H-imidazo[4,5-c]quinoline using triethyl orthoformate (3.64 g, 24.56 mmol) and pyridine hydrochloride (0.1 g). The product (4.05 g, 14.19 mmol) was isolated as a brown oil and used without further purification.
Part B
Using the general method of Example 11 Part F, 1-[5-(methylthio)pentyl]-1H-imidazo[4,5-c]quinoline (4.05 g, 14.19 mmol) was oxidized to 1-[5-(methylsulfonyl)pentyl]-1H-imidazo[4,5-c]quinoline-5N-oxide (4.73 g, 14.19 mmol) which was isolated as a tan solid and used without further purification.
Part C
Using the general method of Example 3 Part B, 1-[5-(methylsulfonyl)pentyl]-1H-imidazo[4,5-c]quinoline-5N-oxide (4.73 g, 14.19 mmol) was aminated to provide 1-[5-(methylsulfonyl)pentyl]-1H-imidazo[4,5-c]quinolin-4-amine. The material was purified by chromatography over silica gel (95/5 dichloromethane/methanol) to afford a light yellow solid. The solid was recrystallized from dimethyl formamide to give the title compound (0.43 g, 1.29 mmol) as a light yellow, granular solid, m.p. 199-201 C.
Analysis. Calculated for C16H2oN402S: %C 57.81; %H, 6.06; %N, 16.85. Found: %C
57.01; %H, 6.06; %N, 16.70 'H-NMR (300 MHz, DMSO) 8 8.20 (S, 1H), 6 8.04 (d, J = 8.3 Hz, 1H), S 7.62 (d, J = 8.3 Hz, 1H), 6 7.44 (t, J = 8.3 Hz, 111), 6 7.27 (t, J = 8.3 Hz, I H), 6 6.57 (bs, 2H), 6 4.61 (t, J =
6.8 Hz, 2H), 6 3.09 (t, J = 7.8 Hz, 2H), 6 2.92 (s, 3H), 6 1.91 (p, J = 7.6 Hz, 2H), 8 1.73 (m, 2H), 6 1.45 (m, 2H) MS (CI) for C16H2oN402S m/z 333 (MH+) Example 15 2-hexyl- l -[5-(methylsulfonyl)pentyl]-1H-imidazo[4,5-c]quinolin-4-amine N N
I
N
,o s Part A
A round bottom flask was charged with a magnetic stir bar, 1V4-[5-(methylthio)pentyl] quinoline-3,4-diamine (3.17 g, 11.46 mmol) and anhydrous pyridine (46 mL) under a nitrogen atmosphere. The resulting homogeneous solution was cooled to 0 C in an ice-water bath. To the cooled solution was added neat heptanoyl chloride (1.87 g, 12.61 mmol). The reaction was judged to be complete after stirring at ambient temperature for 1 hour. The volatiles were removed under reduced pressure and the resulting oil was partitioned between chloroform and water. The layers were separated.
The organic layer was washed with saturated aqueous sodium bicarbonate and brine, dried over anhydrous sodium sulfate, filtered and then concentrated under reduced pressure to afford N-(4-{[5-(methylthio)pentyl]amino }quinolin-3-yl)heptanamide (4.44 g, 11.46 mmol) which was isolated as a brown oil and used without further purification.
Part B
A round bottom flask was charged with a magnetic stir bar, N-(4-{[5-(methylthio)pentyl]amino }quinolin-3-yl)heptanamide (4.44 g, 11.46 mmol), pyridine hydrochloride (0.13 g, 1.15 mmol), and anhydrous pyridine (50 mL) under a nitrogen atmosphere. The reaction was judged to be complete after stirring at reflux for 1.5 hours.
The solution was cooled and partitioned between ethyl acetate and water. The layers were separated. The organic layer was washed with saturated aqueous sodium bicarbonate and brine, dried over anhydrous sodium sulfate, filtered and then concentrated under reduced pressure to afford 2-hexyl-l-[5-(methylthio)pentyl]-1H-imidazo[4,5-c]quinoline (4.0 g, 10.82 mmol) as a brown oil which was used without further purification.
Part C
Using the general method of Example 11 Part F, 2-hexyl-l-[5-(methylthio)pentyl]-1H-imidazo[4,5-c]quinoline (4.0 g, 10.82 mmol) was oxidized to 2-hexyl-l-[5-(methylsulfonyl)pentyl]-1H-imidazo[4,5-c]quinoline-5N-oxide (4.52 g, 10.82 mmol) which was isolated as a tan solid and used without further purification.
Part D
Using the general method of Example 3 Part B 2-hexyl-l-[5-(methylsulfonyl)pentyl]-1H-imidazo[4,5-c]quinoline-5N-oxide (4.0 g, 10.82 mmol) was aminated to provide 2-hexyl-l-[5-(methylsulfonyl)pentyl]-1H-imidazo[4,5-c]quinolin-4-amine. The material was recrystallized from acetonitrile to afford the title compound (2.25 g, 5.40 mmol) as off-white needles, m.p. 168-171 C.
Analysis. Calculated for C22H32N402S: %C 63.43; %H, 7.74; %N, 13.45. Found: %C
63.06; %H, 7.66; %N, 13.81 'H-NMR (300 MHz, DMSO) 6 8.01 (d, J = 8.3 Hz, 1H), 8 7.62 (d, J = 8.3 Hz, 1H), 6 7.42 (t, J = 8.3 Hz, 1H), 6 7.26 (t, J = 8.3 Hz, 1H), 8 6.51 (bs, 2H), 6 4.51 (t, J
= 7.3 Hz, 2H), 8 3.10 (t, J = 7.8 Hz, 2H), 6 2.93 (s, 3H), 6 2.93 (t, J = 7.3 Hz, 2H), 6 1.71-1.87 (m, 6H), 8 1.54 (m, 2H), 6 1.44 (m, 2H), 6 1.33 (m, 4H), 6 0.89 (t, J = 7.3 Hz, 3H) MS (CI) for C22H32N402S mlz 417 (MH+), 337 Example 16 2-(2-methoxyethyl)-1-[5-(methylsulfonyl)pentyl]-1 H-imi dazo [4, 5 -c] quinolin-4-amine NHa N
e is Part A
A round bottom flask was charged with a magnetic stir bar,1V4-[5-(methylthio)pentyl]quinoline-3,4-diamine (3.56 g, 12.93 mmol) and anhydrous pyridine (52 mL) under a nitrogen atmosphere. The resulting homogeneous solution was cooled to 0 C in an ice-water bath. To the cooled solution was added neat 3-methoxypropionyl chloride (2.74 g, 22.36 mmol). After addition of the acid chloride, the reaction was heated to reflux for 14 hours at which time the acylated intermediate was completely consumed.
The solution was cooled and then partitioned between chloroform and saturated aqueous ammonium chloride. The layers were separated. The organic layer was washed with saturated aqueous sodium bicarbonate, dried over anhydrous sodium sulfate, filtered and then concentrated under reduced pressure to afford 2-(2-methoxyethyl)-1-[5-(methylthio)pentyl]-1H-imidazo[4,5-c]quinoline (3.0 g, 8.73 mmol) which was isolated as a brown oil and used without further purification.
Part B
Using the general method of Example 11 Part F, 2-(2-methoxyethyl)-1-[5-(methylthio)pentyl]-1H-imidazo[4,5-c]quinoline (3.0 g, 8.73 mmol) was oxidized to 2-(2-methoxyethyl)-1-[5-(methylsulfonyl)pentyl]-1H-imidazo[4,5-c]quinoline-5N-oxide (3.41 g, 8.73 mmol) which was isolated as a tan solid and used without further purification.
Part C
Using the general method of Example 3 Part B, 2-(2-methoxyethyl)- 1 -[5-(methylsulfonyl)pentyl]-1H-imidazo[4,5-c]quinoline-5N-oxide (3.41 g, 8.73 mmol) was aminated to provide 2-(2-methoxyethyl)-1-[5-(methylsulfonyl)pentyl]-1H-imidazo[4,5-c]quinolin-4-amine. The resulting solid was purified by chromatography over silica gel (95/5 dichloromethane/methanol) to provide a gummy solid. The solid was recrystallized from acetonitrile to give the title compound (0.54 g, 1.38 mmol) as an off-white powder, m.p. 158-160 C.
Analysis. Calculated for C19H26N403S: %C 58.44; %H, 6.71; %N, 14.35. Found: %C
58.24; %H, 6.76; %N, 14.70 'H-NMR (300 MHz, DMSO) 6 8.02 (d, J = 8.3 Hz, 1H), 6 7.62 (d, J = 8.3 Hz, 1H), 6 7.42 (t, J = 8.3 Hz, 1H), 8 7.26 (t, J = 8.3 Hz, 1H), 8 6.50 (bs, 2H), 6 4.53 (t, J
= 7.6 Hz, 2H), 6 3.83(t,J=6.8Hz,2H),63.30(s,3H),53.19(t,J=6.8Hz,2H),53.11 (t, J= 7.8 Hz, 2H), 6 2.93 (s, 3H), 6 1.85 (m, 2H), 8 1.76 (m, 2H), 6 1.57 (m, 2H) MS (CI) for C19H26N403S m/z 391 (MH+), 359 Example 17 2-butyl-l -[5-(methylthio)pentyl]-1H-imidazo[4,5-c]quinolin-4-amine N N
N
Part A
Using the general method of Example 1 Part C, N-(5-chloropentyl)-3-nitroquinolin-4-amine (2.0 g, 6.80 mmol) was reduced to provide A4-(5-chloropentyl)quinoline-3,4-diamine (1.79 g, 6.80 mmol) which was isolated as a brown oil and used without further purification.
Part B
Using the general method of Example 1 Part D, A4-(5-chloropentyl)quinoline-3,4-diamine (1.79 g, 6.80 mmol) was cyclized to 2-butyl-l-(5-chloropentyl)-1H-imidazo[4,5-c]quinoline using trimethyl orthovalerate (2.55 g, 15.72 mmol) and pyridine hydrochloride (0.079 g). The product (1.95 g, 5.91 mmol) was isolated as an off-white solid and used without further purification.
Part C
Using the general method of Example 1 Part E, 2-butyl-l-(5-chloropentyl)-1H-imidazo[4,5-c]quinoline (1.95 g, 5.91 mmol) was oxidized to 2-butyl-l-(5-chloropentyl)-1H-imidazo[4,5-c]quinoline-5N-oxide (2.04 g, 5.91 mmol) which was isolated as a tan solid and used without further purification.
Part D
Using the general method of Example 3 Part B, 2-butyl-l-(5-chloropentyl)-lH-imidazo[4,5-c]quinoline-5N-oxide (2.04 g, 5.91 mmol) was aminated to provide 2-butyl-1-(5-chloropentyl)-1H-imidazo[4,5-c]quinolin-4-amine. The resulting solid was recrystallized from ethanol to afford the product (0.85 g, 2.46 mmol) as a fine white powder, m.p. 144-146 C.
Analysis. Calculated for CI9H25C1N4: %C 66.17; %H, 7.31; %N, 16.24. Found: %C
66.44; %H, 7.55; %N, 16.29 MS (CI) for C19H25C1N4 m/z 345 (MH), 309 Part E
Using the general method of Example 6 Part B, except that the reaction temperature was lowered to 80 C, 2-butyl-l-(5-chloropentyl)-1H-imidazo[4,5-c]quinolin-4-amine (2.0 g, 5.80 mmol) was converted to 2-butyl-l-[5-(methylthio)pentyl]-imidazo[4,5-c]quinolin-4-amine using sodium thiomethoxide (0.68 g, 8.70 mmol) in lieu of sodium benzenethiolate. The resulting solid was partitioned between chloroform and saturated aqueous sodium bicarbonate. The layers were separated. The organic layer was washed with brine, dried over anhydrous sodium sulfate, filtered and then concentrated under reduced pressure to afford a white solid. The material was recrystallized from acetonitrile to give the title compound (1.91 g, 5.36 mmol) as a fine white solid, m.p. 112-114 C.
Analysis. Calculated for C20H28N4S: %C 67.38; %H, 7.92; %N, 15.71. Found: %C
67.26;
%H, 8.08; %N, 15.74 'H-NMR (300 MHz, DMSO) S 8.01 (d, J = 8.3 Hz, 1H), 6 7.61 (d, J = 8.3 Hz, 1H), 8 7.41 (t, J = 8.3 Hz, 1H), S 7.25 (t, J = 8.3 Hz, 1H), S 6.45 (bs, 2H), S 4.50 (t, J
= 7.8 Hz, 2H), S
2.92 (t, J = 7.6 Hz, 2H), 6 2.46 (t, J = 7.3 Hz, 2H), S 2.01 (s, 3H), 6 1.80 (in, 4H), 6 1.42-1.61 (m, 6H), S 0.96 (t, J = 7.3 Hz, 3H) MS (CI) for C20H28N4S m/z 357 (MH+), 309 Example 18 2-butyl-l -[5-(methylsulfinyl)pentyl]-1H-imidazo[4,5-c]quinolin-4-amine NHZ
N N
I
~~ N
6S ,O
A round bottom flask was charged with a magnetic stir bar, 2-butyl-l-[5-(methylthio)pentyl]-1H-imidazo[4,5-c]quinolin-4-amine (1.0 g, 2.80 mmol) and chloroform (14 mL). Solid 3-chloroperbenzoic acid (0.69 g, 3.09 mmol) was added portion wise over 5 minutes and the reaction was stirred at ambient temperature for 20 minutes at which time the starting material was completely consumed. The solution was partitioned between chloroform and saturated aqueous sodium bicarbonate. The layers were separated. The organic layer was washed with saturated aqueous sodium bicarbonate and brine, dried over anhydrous sodium sulfate, filtered and then concentrated under reduced pressure to afford an off-white solid which was shown by 1H-NMR to be the 3-chlorobenzoic acid salt of the desired product. The solid was stirred in water and then made basic (pH 10) by addition of solid sodium carbonate. The resulting free base was collected by filtration to provide a white solid which was recrystallized from acetonitrile to give 2-butyl-l-[5-(methylsulfinyl)pentyl]-lH-imidazo[4,5-c]quinolin-4-amine (0.40 g, 1.07 mmol) as a white powder, m.p. 119-121 C.
Analysis. Calculated for C20H28N40S (H20)1: %C 61.51; %H, 7.74; %N, 14.35.
Found:
%C 61.64; %H, 7.82; %N, 14.32 'H-NMR (300 MHz, DMSO) 8 8.01 (d, J = 8.3 Hz, 1H), 8 7.60 (d, J = 8.3 Hz, 1H), 6 7.41 (t, J = 8.3 Hz, 1H), 8 7.26 (t, J = 8.3 Hz, 1H), 6 6.44 (bs, 2H), 6 4.51 (t, J
= 7.6 Hz, 2H), 6 2.92 (t, J = 7.8 Hz, 2H), 6 2.57-2.74 (m, 2H), 6 2.50 (s, 3H), 8 1.80 (m, 4H), 6 1.66 (m, 2H),61.55(m,2H),51.48(m,2H),50.96(t,J=7.3Hz,3H) MS (CI) for C2oH28N40S (H20)1 m/z 373 (MH+), 309, 253 Example 19 2-butyl- l -[3 -(methylsulfonyl)propyl] -1 H-imidazo [4, 5-c] quinolin-4-amine NHZ
N N
N
,0 ,S~
Part A
A round bottom flask was charged with a magnetic stir bar, 3-[(3-nitroquinolin-yl)amino]propan-1-ol (20.75 g, 83.93 mmol), thionyl chloride (15.0 g, 125.89 mmol), and dichloromethane (420 mL). The bright yellow, homogeneous solution was stirred at ambient temperature for 2 hours at which time the starting material was completely consumed. The volatiles were removed under reduced pressure and the resulting solid stirred in water (400 mL) made basic (pH 10) with solid sodium carbonate. A
bright yellow solid was collected by filtration to afford N-(3-chloropropyl)-3-nitroquinolin-4-amine (21.63 g, 81.41 mmol) which was used without further purification.
Part B
Using the general method of Example 1 Part C, N-(3-chloropropyl)-3-nitroquinolin-4-amine (10.0 g, 37.63 mmol) was reduced to provide N4-(3-chloropropyl)quinoline-3,4-diamine (8.87 g, 37.63 mmol) which was isolated as a brown oil and used without further purification.
Part C
Using the general method of Example 1 Part D, N4-(3-chloropropyl)quinoline-3,4-diamine (8.87 g, 37.63 mmol) was cyclized to provide 2-butyl-l-(3-chloropropyl)-1H-imidazo[4,5-c]quinoline using trimethyl orthovalerate (7.33 g, 45.16 mmol) and pyridine hydrochloride (0.43 g). The resulting solid was triturated with ethyl ether and collected by filtration to afford the product (9.00 g, 29.82 mmol) as an off-white solid.
The material was used without further purification.
Part D
Using the general method of Example 1 Part E, 2 butyl-l-(3-chloropropyl)-1H-imidazo[4,5-c]quinoline (9.0 g, 29.82 mmol) was oxidized to 2-butyl-l-(3-chloropropyl)-1H-imidazo[4,5-c]quinoline-5N-oxide (9.48 g, 29.82 mmol) which was isolated as a tan solid and used without purification.
Part E
Using the general method of Example 3 Part B, 2-butyl-l-(3-chloropropyl)-1H-imidazo[4,5-c]quinoline-5N-oxide (9.48 g, 29.82 mmol) was aminated to provide 2-butyl-1-(3-chloropropyl)-1H-imidazo[4,5-c]quinolin-4-amine. The resulting solid was purified by chromatography over silica gel (95/5 dichloromethane/methanol) to provide the product (6.4 g, 20.20 mmol) as a tan solid.
Part F
Using the general method of Example 6 Part B, except that the reaction temperature was lowered to 80 C, 2-butyl-l-(3-chloropropyl)-1H-imidazo[4,5-c]quinolin-4-amine (2.0 g, 6.31 mmol) was converted to 2-butyl-l-[3-(methylthio)propyl]-lH-imidazo[4,5-c]quinolin-4-amine using sodium thiomethoxide (0.74 g, 9.47 mmol) in lieu of sodium benzenethiolate. The resulting solid was partitioned between chloroform and saturated aqueous sodium bicarbonate. The layers were separated. The organic layer was washed with brine, dried over anhydrous sodium sulfate, filtered and then concentrated under reduced pressure to afford the title compound (2.0 g, 6.09 mmol) as a white solid.
The material was used without further purification.
Part G
Using the general method of Example 5 Part A, 2-butyl-1-[3-(methylthio)propyl]-1H-imidazo[4,5-c]quinolin-4-amine (2.0 g, 6.09 mmol) was oxidized to 2-butyl-l-[3-(methylsulfonyl)propyl]-1H-imidazo[4,5-c]quinolin-4-amine. The resulting solid was triturated with methanol and collected by filtration to afford the title compound (0.96 g, 2.66 mmol) as an off-white powder, m.p. 233-236 C.
Analysis. Calculated for C18H24N402S: %C 59.98; %H, 6.71; %N, 15.54. Found: %C
59.71; %H, 6.65; %N, 15.43 1H-NMR (300 MHz, DMSO) 8 8.10 (d, J = 8.3 Hz, 1H), 6 7.61 (d, J = 8.3 Hz, 1H), 6 7.42 (t, J = 8.3 Hz, 1H), 8 7.25 (t, J = 8.3 Hz, 1H), S 6.47 (bs, 2H), 6 4.66 (t, J
= 7.8 Hz, 2H), 6 3.40 (t, J = 7.3 Hz, 2H), 6 3.01 (s, 3H), 6 2.94 (t, J = 7.8 Hz, 2H), S 2.22 (m, 2H), 6 1.80 (m, 2H), 6 1.46 (sextet, J = 7.3 Hz, 2H), 8 0.96 (t, J = 7.3 Hz, 3H) MS (CI) for C18H24N402S m/z 361 (MH+), 281, 235 Example 20 2-butyl-l-[3-(phenylsulfonyl)propyl]-1H-imidazo[4,5-c]quinolin-4-amine N N
N
O
O
Part A
A round bottom flask was charged with a magnetic stir bar, benzenethiol (0.68 g, 6.21 mmol), sodium hydride (0.25 g, 60% dispersion, 6.21 mmol), and anhydrous dimethyl formamide (28 mL) under a nitrogen atmosphere. After the reaction mixture had stirred at ambient temperature for 30 minutes, 2-butyl- 1 -(3 -chloropropyl)-1 H-imidazo [4,5 -c]quinolin-4-amine (1.64 g, 5.18 mmol) was added and the resulting cloudy solution was heated to 80 C and maintained at 80 C for 2.5 hours at which time the starting material was completely consumed. The hot solution was poured into rapidly stirred water (200 mL). The resulting mixture was extracted with chloroform (2x). The combined organic layers were washed with saturated aqueous sodium bicarbonate and brine, dried over anhydrous sodium sulfate, filtered and then concentrated under reduced pressure to afford a light yellow oil. The material was purified by chromatography over silica gel (95/5 dichloromnethane/methanol) to provide 2-butyl-l-[3-(phenylthio)propyl]-lH-imidazo[4,5-c]quinolin-4-amine (1.38 g, 3.53 mmol) as a white solid.
Part B
Using the general method of Example 5 Part A, 2-butyl- 1 - [3 -(phenylthio)propyl] -1H-imidazo[4,5-c]quinolin-4-amine (1.38 g, 3.53 mmol) was oxidized to 2-butyl-l-[3-(phenylsulfonyl)propyl]-1H-imidazo[4,5-c]quinolin-4-amine. The resulting solid was recrystallized from ethanol to provide the title compound (0.85 g, 2.01 mmol) as an off-white powder, m.p. 224-227 C.
Analysis. Calculated for C23H26N402S: %C 65.38; %H, 6.20; %N, 13.26. Found: %C
65.25; %H, 6.23; %N, 13.20 'H-NMR (300 MHz, DMSO) 6 7.96 (d, J = 8.3 Hz, 1H), 6 7.89 (m, 2H), 6 7.73 (m, 1H), 6 7.63 (m, 3H), 6 7.40 (t, J = 8.3 Hz, 1H), 6 7.17 (t, J = 8.3 Hz, 1H), 6 6.46 (bs, 2H), 6 4.60 (t, J = 7.8 Hz, 2H), 6 3.66 (t, J = 7.3 Hz, 2H), 6 2.86 (t, J = 7.8 Hz, 211), 6 2.04 (m, 2H), 6 1.73 (p, J = 7.6 Hz, 2H), 6 1.39 (sextet, J = 7.3 Hz, 2H), 6 0.92 (t, J = 7.3 Hz, 3H) MS (CI) for C23H26N402S m/z 423 (MH+), 322, 281 CYTOKINE INDUCTION IN HUMAN CELLS
An in vitro human blood cell system is used to assess cytokine induction.
Activity is based on the measurement of interferon and tumor necrosis factor (a) (IFN
and TNF, respectively) secreted into culture media as described by Testerman et. al. In "Cytokine Induction by the Immunomodulators Imiquimod and S-27609", Journal of Leukocyte Biology, 58, 365-372 (September, 1995).
Blood Cell Preparation for Culture Whole blood from healthy human donors is collected by venipuncture into EDTA
vacutainer tubes. Peripheral blood mononuclear cells (PBMCs) are separated from whole blood by density gradient centrifugation using Histopaque -1077. The PBMCs are washed twice with Hank's Balanced Salts Solution and then are suspended at 3-4 x 106 cells/mL in RPMI complete. The PBMC suspension is added to 48 well flat bottom sterile tissue culture plates (Costar, Cambridge, MA or Becton Dickinson Labware, Lincoln Park, NJ) containing an equal volume of RPMI complete media containing test compound.
Compound Preparation The compounds are solubilized in dimethyl sulfoxide (DMSO). The DMSO
concentration should not exceed a final concentration of 1 % for addition to the culture wells. The compounds are generally tested initially at concentrations ranging from 0.12 to M. Compounds showing activity at 0.12 M may then be tested at lower concentrations.
Incubation 30 The solution of test compound is added at 60 gM to the first well containing RPMI
complete and serial 3 fold dilutions are made in the wells. The PBMC
suspension is then added to the wells in an equal volume, bringing the test compound concentrations to the desired range (0.12 to 30 M). The final concentration of PBMC suspension is 1.5-2 X
106 cells/mL. The plates are covered with sterile plastic lids, mixed gently and then incubated for 18 to 24 hours at 37 C in a 5% carbon dioxide atmosphere.
Separation Following incubation the plates are centrifuged for 5-10 minutes at 1000 rpm (-200 x g) at 4 C. The cell-free culture supernatant is removed with a sterile polypropylene pipet and transferred to sterile polypropylene tubes. Samples are maintained at -30 to -70 C until analysis. The samples are analyzed for interferon (a) and for tumor necrosis factor (a) by ELISA
Interferon (a) and Tumor Necrosis Factor (a) Analysis by ELISA
Interferon (a) concentration is determined by ELISA using a Human Multi-Species kit from PBL Biomedical Laboratories, New Brunswick, NJ. Results are expressed in pg/mL.
Tumor necrosis factor (a) (TNF)concentration is determined using ELISA kits available from Genzyme, Cambridge, MA; R&D Systems, Minneapolis, MN; or Pharmingen, San Diego, CA. Results are expressed in pg/mL.
The table below lists the lowest concentration found to induce interferon and the lowest concentration found to induce tumor necrosis factor for each compound.
A "*"
indicates that no induction was seen at any of the tested concentrations (0.12, 0.37, 1.11, 3.33, 10 and 30 M).
Cytokine Induction in Human Cells Example Lowest Effective Concentration ( M) Number Interferon Tumor Necrosis Factor 1 0.12 0.12 2 0.12 0.37 3 0.04 0.12 4 0.01 0.01 5 0.01 0.04 6 3.33 10 Cytokine Induction in Human Cells Example Lowest Effective Concentration ( M) Number Interferon Tumor Necrosis Factor 7 3.33 10 9 3.33 3.33 1.11 1.11 11 0.01 0.12 12 0.12 10 13 0.12 3.33 14 3.33 10 0.04 *
16 0.01 0.04 17 0.01 0.04 18 0.01 0.12 19 0.04 0.37 0.04 0.37
Claims (25)
1 A compound of the formula (I):
wherein: X is -CHR3-, -CHR3-alkyl-, or -CHR3-alkenyl-;
Z is -S-, -SO-, or -SO2-;
R1 is: -alkyl;
-aryl;
-heteroaryl;
-heterocyclyl;
-alkenyl;
-R4-aryl;
-R4-heteroaryl; or -R4-heterocyclyl;
R2 is: -hydrogen;
-alkyl;
-alkenyl;
-aryl;
-heteroaryl;
-heterocyclyl;
-alkyl-Y-alkyl;
- alkyl-Y- alkenyl;
-alkyl-Y-aryl; or - alkyl or alkenyl substituted by one or more substituents being:
-OH;
-halogen;
-N(R3)2;
-CO-N(R3)2;
-CO-C1-10 alkyl;
-CO-O-C1-10 alkyl;
-N3;
-aryl;
-heteroaryl;
-heterocyclyl;
-CO-aryl; or -CO-heteroaryl;
each R3 is independently H or C1-10 alkyl;
each R4 is independently alkyl or alkenyl;
each Y is independently -O- or -S(O)0-2-;
n is 0 to 4; and each R present is independently C1-10 alkyl, C1-10 alkoxy, hydroxy, halogen or trifluoromethyl;
or a pharmaceutically acceptable salt thereof.
wherein: X is -CHR3-, -CHR3-alkyl-, or -CHR3-alkenyl-;
Z is -S-, -SO-, or -SO2-;
R1 is: -alkyl;
-aryl;
-heteroaryl;
-heterocyclyl;
-alkenyl;
-R4-aryl;
-R4-heteroaryl; or -R4-heterocyclyl;
R2 is: -hydrogen;
-alkyl;
-alkenyl;
-aryl;
-heteroaryl;
-heterocyclyl;
-alkyl-Y-alkyl;
- alkyl-Y- alkenyl;
-alkyl-Y-aryl; or - alkyl or alkenyl substituted by one or more substituents being:
-OH;
-halogen;
-N(R3)2;
-CO-N(R3)2;
-CO-C1-10 alkyl;
-CO-O-C1-10 alkyl;
-N3;
-aryl;
-heteroaryl;
-heterocyclyl;
-CO-aryl; or -CO-heteroaryl;
each R3 is independently H or C1-10 alkyl;
each R4 is independently alkyl or alkenyl;
each Y is independently -O- or -S(O)0-2-;
n is 0 to 4; and each R present is independently C1-10 alkyl, C1-10 alkoxy, hydroxy, halogen or trifluoromethyl;
or a pharmaceutically acceptable salt thereof.
2. A compound of claim 1, wherein Z is -S-.
3. A compound of claim 1, wherein Z is -SO2-.
4. A compound of claim 1, wherein R1 is -alkyl.
5. A compound of claim 1, wherein R1 is -aryl.
6. A compound of claim 1, wherein R1 is phenyl.
7. A compound of claim 1, wherein R1 is heteroaryl.
8. A compound of claim 1, wherein X is -(CH2)2-6-.
9. A compound of claim 1, wherein R2 is H.
10. A compound of claim 1, wherein R2 is -alkyl-O-alkyl.
11. A compound of claim 1, wherein R2 is -alkyl.
12. A compound being:
2-butyl-1-[4-(phenylthio)butyl]-1H-imidazo[4,5-c]quinolin-4-amine;
2-butyl-1-[2-(phenylthio)ethyl]-6,7,8,9-tetrahydro-1H-imidazo[4,5-c]quinolin-4-amine;
2-butyl-1-[4-(phenylsulfonyl)butyl]-1H-imidazo[4,5-c]quinolin-4-amine;
2-butyl-1-[4-(methylthio)butyl]-1H-imidazo[4,5-c]quinolin-4-amine;
2-butyl-1-[4-(methylsulfonyl)butyl]-1H-imidazo[4,5-c]quinolin-4-amine;
1-[2-(phenylthio)ethyl]-1H-imidazo[4,5-c]quinolin-4-amine;
1-[4-(phenyl sulfonyl)butyl]-1H-imidazo[4,5-c]quinolin-4-amine;
1-[4-(methylsulfonyl)butyl]-1H-imidazo[4,5-c]quinolin-4-amine;
1-[4-(phenylthio)butyl]-1H-imidazo[4,5-c]quinolin-4-amine;
1-[4-(methylthio)butyl]-1H-imidazo[4,5-c]quinolin-4-amine;
2-butyl-1-[5-(methylsulfonyl)pentyl]-1H-imidazo[4,5-c]quinolin-4-amine;
2-methyl-1-[5-(methylsulfonyl)pentyl]-1H-imidazo[4,5-c]quinolin-4-amine;
2-ethyl-1-[5-(methylsulfonyl)pentyl]-1H-imidazo[4,5-c]quinolin-4-amine;
1-[5-(methylsulfonyl)pentyl]-1H-imidazo[4,5-c]quinolin-4-amine;
2-hexyl-1-[5-(methylsulfonyl)pentyl]-1H-imidazo[4,5-c]quinolin-4-amine;
2-(2-methoxyethyl)-1-[5-(methylsulfonyl)pentyl]-1H-imidazo[4,5-c]quinolin-4-amine;
2-butyl-1-[5-(methylthio)pentyl]-1H-imidazo[4,5-c]quinolin-4-amine;
2-butyl-1-[5-(methylsulfinyl)pentyl]-1H-imidazo[4,5-c]quinolin-4-amine;
2-butyl-1-[3-(methylsulfonyl)propyl]-1H-imidazo[4,5-c]quinolin-4-amine; or 2-butyl-1-[3-(phenylsulfonyl)propyl]-1H-imidazo [4,5-c] quinolin-4-amine;
or a pharmaceutically acceptable salt thereof.
2-butyl-1-[4-(phenylthio)butyl]-1H-imidazo[4,5-c]quinolin-4-amine;
2-butyl-1-[2-(phenylthio)ethyl]-6,7,8,9-tetrahydro-1H-imidazo[4,5-c]quinolin-4-amine;
2-butyl-1-[4-(phenylsulfonyl)butyl]-1H-imidazo[4,5-c]quinolin-4-amine;
2-butyl-1-[4-(methylthio)butyl]-1H-imidazo[4,5-c]quinolin-4-amine;
2-butyl-1-[4-(methylsulfonyl)butyl]-1H-imidazo[4,5-c]quinolin-4-amine;
1-[2-(phenylthio)ethyl]-1H-imidazo[4,5-c]quinolin-4-amine;
1-[4-(phenyl sulfonyl)butyl]-1H-imidazo[4,5-c]quinolin-4-amine;
1-[4-(methylsulfonyl)butyl]-1H-imidazo[4,5-c]quinolin-4-amine;
1-[4-(phenylthio)butyl]-1H-imidazo[4,5-c]quinolin-4-amine;
1-[4-(methylthio)butyl]-1H-imidazo[4,5-c]quinolin-4-amine;
2-butyl-1-[5-(methylsulfonyl)pentyl]-1H-imidazo[4,5-c]quinolin-4-amine;
2-methyl-1-[5-(methylsulfonyl)pentyl]-1H-imidazo[4,5-c]quinolin-4-amine;
2-ethyl-1-[5-(methylsulfonyl)pentyl]-1H-imidazo[4,5-c]quinolin-4-amine;
1-[5-(methylsulfonyl)pentyl]-1H-imidazo[4,5-c]quinolin-4-amine;
2-hexyl-1-[5-(methylsulfonyl)pentyl]-1H-imidazo[4,5-c]quinolin-4-amine;
2-(2-methoxyethyl)-1-[5-(methylsulfonyl)pentyl]-1H-imidazo[4,5-c]quinolin-4-amine;
2-butyl-1-[5-(methylthio)pentyl]-1H-imidazo[4,5-c]quinolin-4-amine;
2-butyl-1-[5-(methylsulfinyl)pentyl]-1H-imidazo[4,5-c]quinolin-4-amine;
2-butyl-1-[3-(methylsulfonyl)propyl]-1H-imidazo[4,5-c]quinolin-4-amine; or 2-butyl-1-[3-(phenylsulfonyl)propyl]-1H-imidazo [4,5-c] quinolin-4-amine;
or a pharmaceutically acceptable salt thereof.
13. A compound of the formula (II):
wherein: X is -CHR3-, -CHR3-alkyl-, or -CHR3-alkenyl-;
Z is -S-, -SO-, or -SO2-;
R1 is: -alkyl;
-aryl;
-heteroaryl;
-heterocyclyl;
-alkenyl;
-R4-aryl;
-R4- heteroaryl; or -R4-heterocyclyl;
R2 is: -hydrogen;
-alkyl;
-alkenyl;
-aryl;
-heteroaryl;
-heterocyclyl;
-alkyl-Y-alkyl;
-alkyl-Y-alkenyl;
-alkyl-Y-aryl; or - alkyl or alkenyl substituted by one or more substituents being:
-OH;
-halogen;
-N(R3)2;
-CO-N(R3)2;
-CO-C1-10 alkyl;
-CO-O-C1-10 alkyl;
-N3;
-aryl;
-heteroaryl;
-heterocyclyl;
-CO-aryl; or -CO-heteroaryl;
each R3 is independently H or C1-10 alkyl;
each R4 is independently alkyl or alkenyl;
each Y is independently -O- or -S(O)0-2-;
n is 0 to 4; and each R present is independently C1-10 alkyl, C1-10 alkoxy, hydroxy, halogen or trifluoromethyl;
or a pharmaceutically acceptable salt thereof.
wherein: X is -CHR3-, -CHR3-alkyl-, or -CHR3-alkenyl-;
Z is -S-, -SO-, or -SO2-;
R1 is: -alkyl;
-aryl;
-heteroaryl;
-heterocyclyl;
-alkenyl;
-R4-aryl;
-R4- heteroaryl; or -R4-heterocyclyl;
R2 is: -hydrogen;
-alkyl;
-alkenyl;
-aryl;
-heteroaryl;
-heterocyclyl;
-alkyl-Y-alkyl;
-alkyl-Y-alkenyl;
-alkyl-Y-aryl; or - alkyl or alkenyl substituted by one or more substituents being:
-OH;
-halogen;
-N(R3)2;
-CO-N(R3)2;
-CO-C1-10 alkyl;
-CO-O-C1-10 alkyl;
-N3;
-aryl;
-heteroaryl;
-heterocyclyl;
-CO-aryl; or -CO-heteroaryl;
each R3 is independently H or C1-10 alkyl;
each R4 is independently alkyl or alkenyl;
each Y is independently -O- or -S(O)0-2-;
n is 0 to 4; and each R present is independently C1-10 alkyl, C1-10 alkoxy, hydroxy, halogen or trifluoromethyl;
or a pharmaceutically acceptable salt thereof.
14. A compound of claim 13, wherein R1 is phenyl.
15. A compound of claim 13, wherein R2 is H or alkyl.
16. A compound of claim 13, wherein R2 is -alkyl-O-alkyl.
17. A pharmaceutical composition comprising a compound or a pharmaceutically acceptable salt thereof as defined in any one of claims 1 to 16, and a pharmaceutically acceptable carrier.
18. Use of a therapeutically effective amount of a compound as defined in any one of claims 1 to 16, for inducing cytokine biosynthesis in an animal.
19. The use of claim 18, wherein the cytokine is IFN-.alpha..
20. Use of a therapeutically effective amount of a compound as defined in any one of claims 1 to 16, for treating a viral disease in an animal.
21. Use of therapeutically effective amount of a compound as defined in any one of claims 1 to 16, for treating neoplastic disease in an animal.
22. Use of a therapeutically effective amount of a compound as defined in any one of claims 1 to 16, for the manufacture of a medicament for inducing cytokine biosynthesis in an animal.
23. The use of claim 22, wherein the cytokine is IFN-.alpha..
24. Use of a therapeutically effective amount of a compound as defined in any one of claims 1 to 16, for the manufacture of a medicament for treating a viral disease in an animal.
25. Use of a therapeutically effective amount of a compound as defined in any one of claims 1 to 16, for the manufacture of a medicament for treating a neoplastic disease in an animal.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US25421800P | 2000-12-08 | 2000-12-08 | |
US60/254,218 | 2000-12-08 | ||
PCT/US2001/046697 WO2002046192A2 (en) | 2000-12-08 | 2001-12-06 | Thioether substituted imidazoquinolines |
Publications (2)
Publication Number | Publication Date |
---|---|
CA2436846A1 CA2436846A1 (en) | 2002-06-13 |
CA2436846C true CA2436846C (en) | 2010-11-16 |
Family
ID=22963391
Family Applications (6)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA2436980A Expired - Fee Related CA2436980C (en) | 2000-12-08 | 2001-12-06 | Amido ether substituted imidazoquinolines |
CA002430844A Withdrawn CA2430844A1 (en) | 2000-12-08 | 2001-12-06 | Aryl ether substituted imidazoquinolines |
CA2436846A Expired - Fee Related CA2436846C (en) | 2000-12-08 | 2001-12-06 | Thioether substituted imidazoquinolines |
CA002436983A Abandoned CA2436983A1 (en) | 2000-12-08 | 2001-12-06 | Sulfonamido ether substituted imidazoquinolines |
CA002436984A Abandoned CA2436984A1 (en) | 2000-12-08 | 2001-12-06 | Urea substituted imidazoquinoline ethers |
CA002431151A Withdrawn CA2431151A1 (en) | 2000-12-08 | 2001-12-06 | Heterocyclic ether substituted imidazoquinolines |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA2436980A Expired - Fee Related CA2436980C (en) | 2000-12-08 | 2001-12-06 | Amido ether substituted imidazoquinolines |
CA002430844A Withdrawn CA2430844A1 (en) | 2000-12-08 | 2001-12-06 | Aryl ether substituted imidazoquinolines |
Family Applications After (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002436983A Abandoned CA2436983A1 (en) | 2000-12-08 | 2001-12-06 | Sulfonamido ether substituted imidazoquinolines |
CA002436984A Abandoned CA2436984A1 (en) | 2000-12-08 | 2001-12-06 | Urea substituted imidazoquinoline ethers |
CA002431151A Withdrawn CA2431151A1 (en) | 2000-12-08 | 2001-12-06 | Heterocyclic ether substituted imidazoquinolines |
Country Status (32)
Country | Link |
---|---|
US (8) | US6683088B2 (en) |
EP (6) | EP1343784B1 (en) |
JP (7) | JP2004515501A (en) |
KR (6) | KR20040047733A (en) |
CN (6) | CN1252070C (en) |
AR (6) | AR035664A1 (en) |
AT (3) | ATE296301T1 (en) |
AU (12) | AU3951602A (en) |
BR (6) | BR0116464A (en) |
CA (6) | CA2436980C (en) |
CY (2) | CY1105586T1 (en) |
CZ (6) | CZ20031563A3 (en) |
DE (3) | DE60126645T2 (en) |
DK (3) | DK1341790T3 (en) |
EE (6) | EE200300275A (en) |
ES (3) | ES2281456T3 (en) |
HK (3) | HK1064383A1 (en) |
HR (6) | HRP20030461A2 (en) |
HU (6) | HUP0600338A2 (en) |
IL (6) | IL155950A0 (en) |
MX (6) | MXPA03005012A (en) |
NO (6) | NO20032449L (en) |
NZ (6) | NZ526105A (en) |
PL (7) | PL365995A1 (en) |
PT (2) | PT1341791E (en) |
RU (6) | RU2003116063A (en) |
SI (1) | SI1341790T1 (en) |
SK (6) | SK7112003A3 (en) |
TW (3) | TWI222972B (en) |
UA (2) | UA74852C2 (en) |
WO (6) | WO2002046193A2 (en) |
ZA (6) | ZA200305275B (en) |
Families Citing this family (206)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5741908A (en) | 1996-06-21 | 1998-04-21 | Minnesota Mining And Manufacturing Company | Process for reparing imidazoquinolinamines |
UA67760C2 (en) | 1997-12-11 | 2004-07-15 | Міннесота Майнінг Енд Мануфакчурінг Компані | Imidazonaphthyridines and use thereof to induce the biosynthesis of cytokines |
US6756382B2 (en) | 1999-06-10 | 2004-06-29 | 3M Innovative Properties Company | Amide substituted imidazoquinolines |
US6331539B1 (en) | 1999-06-10 | 2001-12-18 | 3M Innovative Properties Company | Sulfonamide and sulfamide substituted imidazoquinolines |
US6573273B1 (en) | 1999-06-10 | 2003-06-03 | 3M Innovative Properties Company | Urea substituted imidazoquinolines |
US6541485B1 (en) | 1999-06-10 | 2003-04-01 | 3M Innovative Properties Company | Urea substituted imidazoquinolines |
US6916925B1 (en) | 1999-11-05 | 2005-07-12 | 3M Innovative Properties Co. | Dye labeled imidazoquinoline compounds |
JP3436512B2 (en) * | 1999-12-28 | 2003-08-11 | 株式会社デンソー | Accelerator device |
US6545017B1 (en) | 2000-12-08 | 2003-04-08 | 3M Innovative Properties Company | Urea substituted imidazopyridines |
US6677348B2 (en) | 2000-12-08 | 2004-01-13 | 3M Innovative Properties Company | Aryl ether substituted imidazoquinolines |
US6525064B1 (en) | 2000-12-08 | 2003-02-25 | 3M Innovative Properties Company | Sulfonamido substituted imidazopyridines |
US6664265B2 (en) | 2000-12-08 | 2003-12-16 | 3M Innovative Properties Company | Amido ether substituted imidazoquinolines |
US6667312B2 (en) | 2000-12-08 | 2003-12-23 | 3M Innovative Properties Company | Thioether substituted imidazoquinolines |
US6545016B1 (en) | 2000-12-08 | 2003-04-08 | 3M Innovative Properties Company | Amide substituted imidazopyridines |
US6660747B2 (en) * | 2000-12-08 | 2003-12-09 | 3M Innovative Properties Company | Amido ether substituted imidazoquinolines |
US6664264B2 (en) * | 2000-12-08 | 2003-12-16 | 3M Innovative Properties Company | Thioether substituted imidazoquinolines |
US6677347B2 (en) * | 2000-12-08 | 2004-01-13 | 3M Innovative Properties Company | Sulfonamido ether substituted imidazoquinolines |
UA74852C2 (en) | 2000-12-08 | 2006-02-15 | 3M Innovative Properties Co | Urea-substituted imidazoquinoline ethers |
US6660735B2 (en) * | 2000-12-08 | 2003-12-09 | 3M Innovative Properties Company | Urea substituted imidazoquinoline ethers |
US7226928B2 (en) * | 2001-06-15 | 2007-06-05 | 3M Innovative Properties Company | Methods for the treatment of periodontal disease |
KR100962751B1 (en) * | 2001-11-29 | 2010-06-09 | 쓰리엠 이노베이티브 프로퍼티즈 컴파니 | Pharmaceutical Formulations Comprising an Immune Response Modifier |
CA2365732A1 (en) | 2001-12-20 | 2003-06-20 | Ibm Canada Limited-Ibm Canada Limitee | Testing measurements |
US6677349B1 (en) | 2001-12-21 | 2004-01-13 | 3M Innovative Properties Company | Sulfonamide and sulfamide substituted imidazoquinolines |
IL147953A (en) * | 2002-02-01 | 2008-04-13 | Meir Bialer | Derivatives and pharmaceutical compositions of n-hydroxymethyl tetramethylcyclopropyl- |
BR0307788A (en) * | 2002-02-22 | 2006-04-04 | 3M Innovative Properties Co | reduction method and treatment of uv-b-induced immunosuppression |
GB0211649D0 (en) * | 2002-05-21 | 2002-07-03 | Novartis Ag | Organic compounds |
MXPA04012199A (en) | 2002-06-07 | 2005-02-25 | 3M Innovative Properties Co | Ether substituted imidazopyridines. |
CA2491680C (en) * | 2002-07-02 | 2012-04-17 | Southern Research Institute | Inhibitors of ftsz and uses thereof |
MXPA05001647A (en) * | 2002-08-15 | 2005-04-19 | 3M Innovative Properties Co | Immunostimulatory compositions and methods of stimulating an immune response. |
EP1542688A4 (en) | 2002-09-26 | 2010-06-02 | 3M Innovative Properties Co | 1h-imidazo dimers |
CA2510375A1 (en) | 2002-12-20 | 2004-07-15 | 3M Innovative Properties Company | Aryl / hetaryl substituted imidazoquinolines |
AU2003300184B8 (en) | 2002-12-30 | 2009-12-03 | 3M Innovative Properties Company | Immunostimulatory combinations |
EP1592302A4 (en) | 2003-02-13 | 2007-04-25 | 3M Innovative Properties Co | Methods and compositions related to irm compounds and toll-like receptor 8 |
WO2004075865A2 (en) * | 2003-02-27 | 2004-09-10 | 3M Innovative Properties Company | Selective modulation of tlr-mediated biological activity |
WO2004078138A2 (en) * | 2003-03-04 | 2004-09-16 | 3M Innovative Properties Company | Prophylactic treatment of uv-induced epidermal neoplasia |
EP1605943A4 (en) * | 2003-03-07 | 2008-01-16 | 3M Innovative Properties Co | 1-amino 1h-imidazoquinolines |
US7163947B2 (en) * | 2003-03-07 | 2007-01-16 | 3M Innovative Properties Company | 1-Amino 1H-imidazoquinolines |
ATE556711T1 (en) | 2003-03-13 | 2012-05-15 | 3M Innovative Properties Co | METHOD FOR IMPROVING SKIN QUALITY |
EP1608282A4 (en) * | 2003-03-13 | 2010-12-08 | 3M Innovative Properties Co | Methods for diagnosing skin lesions |
WO2004080292A2 (en) | 2003-03-13 | 2004-09-23 | 3M Innovative Properties Company | Method of tattoo removal |
US20040192585A1 (en) * | 2003-03-25 | 2004-09-30 | 3M Innovative Properties Company | Treatment for basal cell carcinoma |
US20040265351A1 (en) | 2003-04-10 | 2004-12-30 | Miller Richard L. | Methods and compositions for enhancing immune response |
WO2004091500A2 (en) * | 2003-04-10 | 2004-10-28 | 3M Innovative Properties Company | Delivery of immune response modifier compounds |
EP1617845A4 (en) * | 2003-04-28 | 2006-09-20 | 3M Innovative Properties Co | Compositions and methods for induction of opioid receptors |
WO2004110991A2 (en) | 2003-06-06 | 2004-12-23 | 3M Innovative Properties Company | PROCESS FOR IMIDAZO[4,5-c]PYRIDIN-4-AMINES |
AR044466A1 (en) * | 2003-06-06 | 2005-09-14 | 3M Innovative Properties Co | PROCESS FOR THE PREPARATION OF IMIDAZO [4,5-C] PIRIDIN-4-AMINAS |
AU2004264336B2 (en) * | 2003-08-05 | 2010-12-23 | 3M Innovative Properties Company | Formulations containing an immune response modifier |
AR045260A1 (en) * | 2003-08-12 | 2005-10-19 | 3M Innovative Properties Co | COMPOUNDS CONTAINING IMIDAZO-OXIMA REPLACED |
PL1653959T3 (en) * | 2003-08-14 | 2015-10-30 | 3M Innovative Properties Co | Lipid-modified immune response modifiers |
JP4913593B2 (en) * | 2003-08-14 | 2012-04-11 | スリーエム イノベイティブ プロパティズ カンパニー | Lipid-modified immune response modifier |
JP2007503268A (en) | 2003-08-25 | 2007-02-22 | スリーエム イノベイティブ プロパティズ カンパニー | Delivery of immune response modifying compounds |
EP1660122A4 (en) * | 2003-08-25 | 2007-10-24 | 3M Innovative Properties Co | Immunostimulatory combinations and treatments |
MXPA06002199A (en) * | 2003-08-27 | 2006-05-22 | 3M Innovative Properties Co | Aryloxy and arylalkyleneoxy substituted imidazoquinolines. |
JP2007504172A (en) * | 2003-09-02 | 2007-03-01 | スリーエム イノベイティブ プロパティズ カンパニー | Methods for treatment of mucosa related symptoms |
WO2005023190A2 (en) | 2003-09-05 | 2005-03-17 | 3M Innovative Properties Company | Treatment for cd5+ b cell lymphoma |
US20050059072A1 (en) * | 2003-09-17 | 2005-03-17 | 3M Innovative Properties Company | Selective modulation of TLR gene expression |
WO2005079195A2 (en) | 2003-10-03 | 2005-09-01 | 3M Innovative Properties Company | Pyrazolopyridines and analogs thereof |
US7544697B2 (en) | 2003-10-03 | 2009-06-09 | Coley Pharmaceutical Group, Inc. | Pyrazolopyridines and analogs thereof |
US8871782B2 (en) | 2003-10-03 | 2014-10-28 | 3M Innovative Properties Company | Alkoxy substituted imidazoquinolines |
US20090075980A1 (en) * | 2003-10-03 | 2009-03-19 | Coley Pharmaceutical Group, Inc. | Pyrazolopyridines and Analogs Thereof |
JP2007509987A (en) * | 2003-10-31 | 2007-04-19 | スリーエム イノベイティブ プロパティズ カンパニー | Neutrophil activation by immune response modulator compounds |
US8598192B2 (en) | 2003-11-14 | 2013-12-03 | 3M Innovative Properties Company | Hydroxylamine substituted imidazoquinolines |
CA2545774A1 (en) * | 2003-11-14 | 2005-06-02 | 3M Innovative Properties Company | Oxime substituted imidazo ring compounds |
AR046845A1 (en) * | 2003-11-21 | 2005-12-28 | Novartis Ag | DERIVATIVES OF 1H-IMIDAZO [4,5-C] QUINOLINE FOR THE TREATMENT OF PROTEIN-KINASE DEPENDENT DISEASES |
PL1687305T3 (en) * | 2003-11-21 | 2008-12-31 | Novartis Ag | 1h-imidazoquinoline derivatives as protein kinase inhibitors |
US8778963B2 (en) * | 2003-11-25 | 2014-07-15 | 3M Innovative Properties Company | Hydroxylamine and oxime substituted imidazoquinolines, imidazopyridines, and imidazonaphthyridines |
CA2547020C (en) | 2003-11-25 | 2014-03-25 | 3M Innovative Properties Company | 1h-imidazo[4,5-c]pyridine-4-amine derivatives as immune response modifier |
WO2005055932A2 (en) | 2003-12-02 | 2005-06-23 | 3M Innovative Properties Company | Therapeutic combinations and methods including irm compounds |
US7939526B2 (en) * | 2003-12-04 | 2011-05-10 | 3M Innovative Properties Company | Sulfone substituted imidazo ring ethers |
WO2005066170A1 (en) | 2003-12-29 | 2005-07-21 | 3M Innovative Properties Company | Arylalkenyl and arylalkynyl substituted imidazoquinolines |
CA2552101A1 (en) * | 2003-12-29 | 2005-07-21 | 3M Innovative Properties Company | Piperazine, [1,4]diazepane, [1,4]diazocane, and [1,5]diazocane fused imidazo ring compounds |
WO2005065678A1 (en) * | 2003-12-30 | 2005-07-21 | 3M Innovative Properties Company | Immunomodulatory combinations |
WO2005067500A2 (en) * | 2003-12-30 | 2005-07-28 | 3M Innovative Properties Company | Enhancement of immune responses |
JP2007517044A (en) | 2003-12-30 | 2007-06-28 | スリーエム イノベイティブ プロパティズ カンパニー | Imidazoquinolinyl, imidazopyridinyl, and imidazonaphthyridinylsulfonamide |
AU2005222995B2 (en) | 2004-03-15 | 2010-08-26 | 3M Innovative Properties Company | Immune response modifier formulations and methods |
WO2005094531A2 (en) * | 2004-03-24 | 2005-10-13 | 3M Innovative Properties Company | Amide substituted imidazopyridines, imidazoquinolines, and imidazonaphthyridines |
EP1735010A4 (en) * | 2004-04-09 | 2008-08-27 | 3M Innovative Properties Co | Methods, compositions, and preparations for delivery of immune response modifiers |
US20050267145A1 (en) * | 2004-05-28 | 2005-12-01 | Merrill Bryon A | Treatment for lung cancer |
WO2005123079A2 (en) * | 2004-06-14 | 2005-12-29 | 3M Innovative Properties Company | Urea substituted imidazopyridines, imidazoquinolines, and imidazonaphthyridines |
US8017779B2 (en) | 2004-06-15 | 2011-09-13 | 3M Innovative Properties Company | Nitrogen containing heterocyclyl substituted imidazoquinolines and imidazonaphthyridines |
US20070259881A1 (en) * | 2004-06-18 | 2007-11-08 | Dellaria Joseph F Jr | Substituted Imidazo Ring Systems and Methods |
US8026366B2 (en) | 2004-06-18 | 2011-09-27 | 3M Innovative Properties Company | Aryloxy and arylalkyleneoxy substituted thiazoloquinolines and thiazolonaphthyridines |
WO2006065280A2 (en) | 2004-06-18 | 2006-06-22 | 3M Innovative Properties Company | Isoxazole, dihydroisoxazole, and oxadiazole substituted imidazo ring compounds and methods |
WO2006038923A2 (en) | 2004-06-18 | 2006-04-13 | 3M Innovative Properties Company | Aryl substituted imidazonaphthyridines |
US8541438B2 (en) | 2004-06-18 | 2013-09-24 | 3M Innovative Properties Company | Substituted imidazoquinolines, imidazopyridines, and imidazonaphthyridines |
CA2571360C (en) * | 2004-06-18 | 2014-11-25 | 3M Innovative Properties Company | Substituted imidazoquinolines, imidazopyridines, and imidazonaphthyridines useful in inducing cytokine biosynthesis in animals |
US7579359B2 (en) * | 2004-09-02 | 2009-08-25 | 3M Innovative Properties Company | 1-alkoxy 1H-imidazo ring systems and methods |
US20090270443A1 (en) * | 2004-09-02 | 2009-10-29 | Doris Stoermer | 1-amino imidazo-containing compounds and methods |
EP1784180A4 (en) | 2004-09-02 | 2009-07-22 | 3M Innovative Properties Co | 2-amino 1h imidazo ring systems and methods |
US20080193468A1 (en) * | 2004-09-08 | 2008-08-14 | Children's Medical Center Corporation | Method for Stimulating the Immune Response of Newborns |
US20080213308A1 (en) * | 2004-09-14 | 2008-09-04 | Nicholas Valiante | Imidazoquinoline Compounds |
WO2006042254A2 (en) * | 2004-10-08 | 2006-04-20 | 3M Innovative Properties Company | Adjuvant for dna vaccines |
US20110070575A1 (en) * | 2004-12-08 | 2011-03-24 | Coley Pharmaceutical Group, Inc. | Immunomodulatory Compositions, Combinations and Methods |
US8080560B2 (en) | 2004-12-17 | 2011-12-20 | 3M Innovative Properties Company | Immune response modifier formulations containing oleic acid and methods |
US8436176B2 (en) * | 2004-12-30 | 2013-05-07 | Medicis Pharmaceutical Corporation | Process for preparing 2-methyl-1-(2-methylpropyl)-1H-imidazo[4,5-c][1,5]naphthyridin-4-amine |
WO2006074003A2 (en) | 2004-12-30 | 2006-07-13 | 3M Innovative Properties Company | CHIRAL FUSED [1,2]IMIDAZO[4,5-c] RING COMPOUNDS |
JP5313502B2 (en) | 2004-12-30 | 2013-10-09 | スリーエム イノベイティブ プロパティズ カンパニー | Substituted chiral condensed [1,2] imidazo [4,5-c] cyclic compounds |
EP1833479A2 (en) * | 2004-12-30 | 2007-09-19 | Takeda Pharmaceutical Company Limited | 1-(2-methylpropyl)-1h-imidazo 4,5-c(1,5 )naphthyridin-4-amine ethanesulfonate and 1-(2-methylpropyl)-1h-imidazoý4,5-c 1,5 naphthyridin-4-amine methanesulfonate |
CA2594253C (en) | 2004-12-30 | 2015-08-11 | 3M Innovative Properties Company | Treatment for cutaneous metastases |
US9248127B2 (en) | 2005-02-04 | 2016-02-02 | 3M Innovative Properties Company | Aqueous gel formulations containing immune response modifiers |
US8378102B2 (en) | 2005-02-09 | 2013-02-19 | 3M Innovative Properties Company | Oxime and hydroxylamine substituted thiazolo[4,5-c] ring compounds and methods |
WO2006086449A2 (en) * | 2005-02-09 | 2006-08-17 | Coley Pharmaceutical Group, Inc. | Alkyloxy substituted thiazoloquinolines and thiazolonaphthyridines |
US8658666B2 (en) | 2005-02-11 | 2014-02-25 | 3M Innovative Properties Company | Substituted imidazoquinolines and imidazonaphthyridines |
WO2006086634A2 (en) | 2005-02-11 | 2006-08-17 | Coley Pharmaceutical Group, Inc. | Oxime and hydroxylamine substituted imidazo[4,5-c] ring compounds and methods |
NZ580974A (en) | 2005-02-18 | 2011-05-27 | Novartis Vaccines & Diagnostic | Immunogens from uropathogenic escherichia coli |
NZ561042A (en) | 2005-02-18 | 2011-03-31 | Novartis Vaccines & Diagnostic | Proteins and nucleic acids from meningitis/sepsis-associated escherichia coli - SEQ ID: 7052 |
EP1851224A2 (en) | 2005-02-23 | 2007-11-07 | 3M Innovative Properties Company | Hydroxyalkyl substituted imidazoquinolines |
CA2598639A1 (en) | 2005-02-23 | 2006-08-31 | Coley Pharmaceutical Group, Inc. | Hydroxyalkyl substituted imidazonaphthyridines |
WO2006091567A2 (en) | 2005-02-23 | 2006-08-31 | Coley Pharmaceutical Group, Inc. | Hydroxyalkyl substituted imidazoquinoline compounds and methods |
CA2598437A1 (en) | 2005-02-23 | 2006-08-31 | Coley Pharmaceutical Group, Inc. | Method of preferentially inducing the biosynthesis of interferon |
RU2007137960A (en) | 2005-03-14 | 2009-04-20 | Меда Аб (Se) | METHOD FOR TREATING ACTIN KERATOSIS (OPTIONS) AND 2-METHYL-1- (2-METHYL PROPYL) -1H-IMIDAZO [4,5-c]] 1,5] NAPHTIRIDIN-4-AMINE AS A MEANS OF TREATMENT OF ACTINIC KERO |
US7943610B2 (en) | 2005-04-01 | 2011-05-17 | 3M Innovative Properties Company | Pyrazolopyridine-1,4-diamines and analogs thereof |
AU2006232375A1 (en) | 2005-04-01 | 2006-10-12 | Coley Pharmaceutical Group, Inc. | 1-substituted pyrazolo (3,4-c) ring compounds as modulators of cytokine biosynthesis for the treatment of viral infections and neoplastic diseases |
AU2006241166A1 (en) * | 2005-04-25 | 2006-11-02 | 3M Innovative Properties Company | Immunostimulatory compositions |
EP1909564A4 (en) | 2005-07-18 | 2010-06-30 | Novartis Ag | Small animal model for hcv replication |
ZA200803029B (en) | 2005-09-09 | 2009-02-25 | Coley Pharm Group Inc | Amide and carbamate derivatives of alkyl substituted /V-[4-(4-amino-1H-imidazo[4,5-c] quinolin-1-yl)butyl] methane-sulfonamides and methods |
EP1922317A4 (en) | 2005-09-09 | 2009-04-15 | Coley Pharm Group Inc | Amide and carbamate derivatives of n-{2-ý4-amino-2- (ethoxymethyl)-1h-imidazoý4,5-c¨quinolin-1-yl¨-1,1-dimethylethyl}methanesulfonamide and methods |
US8889154B2 (en) | 2005-09-15 | 2014-11-18 | Medicis Pharmaceutical Corporation | Packaging for 1-(2-methylpropyl)-1H-imidazo[4,5-c] quinolin-4-amine-containing formulation |
US10842867B2 (en) | 2005-11-04 | 2020-11-24 | Seqirus UK Limited | Adjuvanted vaccines with non-virion antigens prepared from influenza viruses grown in cell culture |
NZ567979A (en) | 2005-11-04 | 2012-02-24 | Novartis Vaccines & Diagnostic | Adjuvanted influenza vaccines including a cytokine-inducing agents which is an agonist of Toll-Like Receptor 7 |
WO2007052058A1 (en) | 2005-11-04 | 2007-05-10 | Novartis Vaccines And Diagnostics Srl | Influenza vaccines including combinations of particulate adjuvants and immunopotentiators |
US8088790B2 (en) * | 2005-11-04 | 2012-01-03 | 3M Innovative Properties Company | Hydroxy and alkoxy substituted 1H-imidazoquinolines and methods |
AU2006310163B2 (en) | 2005-11-04 | 2011-09-15 | Seqirus UK Limited | Influenza vaccine with reduced amount of oil-in-water emulsion as adjuvant |
BRPI0707300B8 (en) | 2006-01-27 | 2021-05-25 | Novartis Ag | split influenza virion vaccine or purified surface antigen and method for preparing an immunogenic composition |
EP1988896A4 (en) * | 2006-02-22 | 2011-07-27 | 3M Innovative Properties Co | Immune response modifier conjugates |
US8329721B2 (en) * | 2006-03-15 | 2012-12-11 | 3M Innovative Properties Company | Hydroxy and alkoxy substituted 1H-imidazonaphthyridines and methods |
US8063063B2 (en) * | 2006-03-23 | 2011-11-22 | Novartis Ag | Immunopotentiating compounds |
CA2646539A1 (en) | 2006-03-23 | 2007-09-27 | Novartis Ag | Imidazoquinoxaline compounds as immunomodulators |
EP2010530A2 (en) * | 2006-03-23 | 2009-01-07 | Novartis AG | Methods for the preparation of imidazole-containing compounds |
AU2007231027B2 (en) | 2006-03-24 | 2013-10-03 | Novartis Influenza Vaccines Marburg Gmbh | Storage of influenza vaccines without refrigeration |
CA2647942A1 (en) | 2006-03-31 | 2007-11-08 | Novartis Ag | Combined mucosal and parenteral immunization against hiv |
EP2035035A2 (en) | 2006-06-09 | 2009-03-18 | Novartis AG | Immunogenic compositions for streptococcus agalactiae |
US7906506B2 (en) | 2006-07-12 | 2011-03-15 | 3M Innovative Properties Company | Substituted chiral fused [1,2] imidazo [4,5-c] ring compounds and methods |
GB0614460D0 (en) | 2006-07-20 | 2006-08-30 | Novartis Ag | Vaccines |
EP2586790A3 (en) | 2006-08-16 | 2013-08-14 | Novartis AG | Immunogens from uropathogenic Escherichia coli |
WO2008030511A2 (en) * | 2006-09-06 | 2008-03-13 | Coley Pharmaceuticial Group, Inc. | Substituted 3,4,6,7-tetrahydro-5h, 1,2a,4a,8-tetraazacyclopenta[cd]phenalenes |
MX2009002408A (en) | 2006-09-11 | 2009-03-20 | Novartis Ag | Making influenza virus vaccines without using eggs. |
EP2121011B1 (en) | 2006-12-06 | 2014-05-21 | Novartis AG | Vaccines including antigen from four strains of influenza virus |
US20080149123A1 (en) | 2006-12-22 | 2008-06-26 | Mckay William D | Particulate material dispensing hairbrush with combination bristles |
GB0700562D0 (en) | 2007-01-11 | 2007-02-21 | Novartis Vaccines & Diagnostic | Modified Saccharides |
PT2185191E (en) | 2007-06-27 | 2012-11-27 | Novartis Ag | Low-additive influenza vaccines |
GB0714963D0 (en) | 2007-08-01 | 2007-09-12 | Novartis Ag | Compositions comprising antigens |
GB0810305D0 (en) | 2008-06-05 | 2008-07-09 | Novartis Ag | Influenza vaccination |
GB0818453D0 (en) | 2008-10-08 | 2008-11-12 | Novartis Ag | Fermentation processes for cultivating streptococci and purification processes for obtaining cps therefrom |
NZ586161A (en) * | 2008-01-15 | 2012-05-25 | Meda Ab | Treatment of colon diseases or prevention of colorectal carcinoma with imidazoquinoline derivatives |
PL2268618T3 (en) * | 2008-03-03 | 2015-11-30 | Novartis Ag | Compounds and compositions as tlr activity modulators |
CA2718430A1 (en) | 2008-03-18 | 2009-09-24 | Novartis Ag | Improvements in preparation of influenza virus vaccine antigens |
JP2012519482A (en) | 2009-03-06 | 2012-08-30 | ノバルティス アーゲー | Chlamydia antigen |
PT2411521E (en) | 2009-03-25 | 2015-04-21 | Univ Texas | Compositions for stimulation of mammalian innate immune resistance to pathogens |
DK2510947T3 (en) | 2009-04-14 | 2016-03-21 | Glaxosmithkline Biolog Sa | Compositions for Immunization against Staphylococcus aureus. |
CN102548577A (en) | 2009-04-27 | 2012-07-04 | 诺华有限公司 | Adjuvanted vaccines for protecting against influenza |
GB0907551D0 (en) * | 2009-05-01 | 2009-06-10 | Univ Dundee | Treatment or prophylaxis of proliferative conditions |
AU2013203591B2 (en) * | 2009-05-01 | 2017-01-19 | University Court Of The University Of Dundee | Treatment or prophylaxis of proliferative conditions |
ES2563730T3 (en) | 2009-07-15 | 2016-03-16 | Glaxosmithkline Biologicals S.A. | RSV F protein compositions and manufacturing processes thereof |
DK2464658T3 (en) | 2009-07-16 | 2014-12-15 | Novartis Ag | Detoxified escherichia coli immunogens |
GB0918392D0 (en) | 2009-10-20 | 2009-12-02 | Novartis Ag | Diagnostic and therapeutic methods |
GB0919690D0 (en) | 2009-11-10 | 2009-12-23 | Guy S And St Thomas S Nhs Foun | compositions for immunising against staphylococcus aureus |
GB201009861D0 (en) | 2010-06-11 | 2010-07-21 | Novartis Ag | OMV vaccines |
MX359517B (en) | 2010-08-17 | 2018-10-01 | 3M Innovative Properties Company Star | Lipidated immune response modifier compound compositions, formulations, and methods. |
JP5978225B2 (en) | 2010-12-16 | 2016-08-24 | 大日本住友製薬株式会社 | Imidazo [4,5-c] quinolin-1-yl derivatives useful for therapy |
DK2667892T3 (en) | 2011-01-26 | 2019-05-13 | Glaxosmithkline Biologicals Sa | RSV vaccination program |
HUE034673T2 (en) | 2011-05-13 | 2018-02-28 | Glaxosmithkline Biologicals Sa | Pre-fusion rsv f antigens |
US8728486B2 (en) | 2011-05-18 | 2014-05-20 | University Of Kansas | Toll-like receptor-7 and -8 modulatory 1H imidazoquinoline derived compounds |
AU2012261959B2 (en) | 2011-06-03 | 2015-12-03 | Solventum Intellectual Properties Company | Hydrazino 1H-imidazoquinolin-4-amines and conjugates made therefrom |
US9475804B2 (en) | 2011-06-03 | 2016-10-25 | 3M Innovative Properties Company | Heterobifunctional linkers with polyethylene glycol segments and immune response modifier conjugates made therefrom |
US20130023736A1 (en) | 2011-07-21 | 2013-01-24 | Stanley Dale Harpstead | Systems for drug delivery and monitoring |
CA2854934A1 (en) | 2011-11-07 | 2013-05-16 | Novartis Ag | Carrier molecule comprising a spr0096 and a spr2021 antigen |
WO2013108272A2 (en) | 2012-01-20 | 2013-07-25 | International Centre For Genetic Engineering And Biotechnology | Blood stage malaria vaccine |
CN112587658A (en) | 2012-07-18 | 2021-04-02 | 博笛生物科技有限公司 | Targeted immunotherapy for cancer |
RS61101B1 (en) | 2013-01-07 | 2020-12-31 | Univ Pennsylvania | Compositions and methods for treating cutaneous t cell lymphoma |
WO2015011254A1 (en) | 2013-07-26 | 2015-01-29 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for the treatment of bacterial infections |
PE20160849A1 (en) | 2013-11-05 | 2016-09-14 | 3M Innovative Properties Co | INJECTION FORMULATIONS BASED ON SESAME OIL |
EP2870974A1 (en) | 2013-11-08 | 2015-05-13 | Novartis AG | Salmonella conjugate vaccines |
CN105899537A (en) | 2014-01-10 | 2016-08-24 | 博笛生物科技(北京)有限公司 | Compounds and compositions for treating EGFR expressing tumors |
BR112016022011A2 (en) | 2014-03-26 | 2017-10-24 | Glaxosmithkline Biologicals Sa | ? mutant staphylococcal protein antigen, fusion protein, and immunogenic composition? |
CN105440135A (en) | 2014-09-01 | 2016-03-30 | 博笛生物科技有限公司 | Anti-PD-L1 conjugate for treating tumors |
CN112546231A (en) * | 2014-07-09 | 2021-03-26 | 博笛生物科技有限公司 | Combination therapeutic compositions and combination therapeutic methods for treating cancer |
CA2954446A1 (en) | 2014-07-09 | 2016-01-14 | Shanghai Birdie Biotech, Inc. | Anti-pd-l1 combinations for treating tumors |
CN105461767B (en) * | 2014-08-07 | 2019-03-12 | 富力 | A kind of chemical synthesis process of forsythin |
US10286065B2 (en) | 2014-09-19 | 2019-05-14 | Board Of Regents, The University Of Texas System | Compositions and methods for treating viral infections through stimulated innate immunity in combination with antiviral compounds |
EP3350178B1 (en) * | 2015-09-14 | 2021-10-20 | Pfizer Inc. | Novel imidazo [4,5-c]quinoline and imidazo [4,5-c][1,5]naphthyridine derivatives as lrrk2 inhibitors |
EP3356371A4 (en) * | 2015-09-29 | 2020-06-24 | The University of Chicago | Polymer conjugate vaccines |
WO2017059280A1 (en) | 2015-10-02 | 2017-04-06 | The University Of North Carolina At Chapel Hill | Novel pan-tam inhibitors and mer/axl dual inhibitors |
CN106943597A (en) | 2016-01-07 | 2017-07-14 | 博笛生物科技(北京)有限公司 | Anti-EGFR for treating tumour is combined |
CN106943598A (en) | 2016-01-07 | 2017-07-14 | 博笛生物科技(北京)有限公司 | Anti- HER2 for treating tumour is combined |
CN106943596A (en) | 2016-01-07 | 2017-07-14 | 博笛生物科技(北京)有限公司 | Anti-CD 20 for treating tumour is combined |
AU2017356673B2 (en) | 2016-11-09 | 2023-11-09 | Pulmotect, Inc. | Methods and compositions for adaptive immune modulation |
CN108794467A (en) | 2017-04-27 | 2018-11-13 | 博笛生物科技有限公司 | 2- amino-quinoline derivatives |
JP7080501B2 (en) | 2017-06-23 | 2022-06-06 | バーディー バイオファーマシューティカルズ インコーポレイテッド | Pharmaceutical composition |
CA3086439A1 (en) | 2017-12-20 | 2019-06-27 | 3M Innovative Properties Company | Amide substitued imidazo[4,5-c]quinoline compounds with a branched chain linking group for use as an immune response modifier |
WO2019152955A1 (en) | 2018-02-02 | 2019-08-08 | Steven Albert Everett | Small molecule drug conjugates of gemcitabine monophosphate |
WO2019166946A1 (en) | 2018-02-28 | 2019-09-06 | Pfizer Inc. | Il-15 variants and uses thereof |
CN111788202B (en) * | 2018-02-28 | 2024-03-01 | 3M创新有限公司 | Substituted imidazo [4,5-c ] quinoline compounds with N-1 branched groups |
TWI816396B (en) | 2018-05-23 | 2023-09-21 | 美商輝瑞大藥廠 | Antibodies specific for gucy2c and uses thereof |
MX2020012539A (en) | 2018-05-23 | 2021-02-16 | Pfizer | Antibodies specific for cd3 and uses thereof. |
CN112218864B (en) | 2018-05-24 | 2023-09-08 | 3M创新有限公司 | N-1 branched cycloalkyl substituted imidazo [4,5-c ] quinoline compounds, compositions and methods |
US20210213010A1 (en) * | 2018-07-24 | 2021-07-15 | Torque Therapeutics, Inc. | Tlr7/8 agonists and liposome compositions |
WO2020109898A1 (en) * | 2018-11-26 | 2020-06-04 | 3M Innovative Properties Company | N-1 branched alkyl ether substituted imidazo[4,5-c]quinoline compounds, compositions, and methods |
WO2020128893A1 (en) | 2018-12-21 | 2020-06-25 | Pfizer Inc. | Combination treatments of cancer comprising a tlr agonist |
CN114616234B (en) * | 2019-02-07 | 2024-04-12 | 康威(广州)生物科技有限公司 | Phosphorus imidazoquinoline amine derivative, pharmaceutical composition and application thereof |
JP2022520792A (en) | 2019-02-12 | 2022-04-01 | アンブルックス,インコーポレイテッド | Compositions, Methods, and Uses Containing Antibody-TLR Agonist Conjugates |
CN114599360A (en) * | 2019-10-29 | 2022-06-07 | 骏达贸易有限公司 | 4-amino-imidazoquinoline compounds and uses thereof |
WO2021116420A1 (en) | 2019-12-13 | 2021-06-17 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Use of tlr7 and/or tlr8 agonists for the treatment of leptospirosis |
IL293926A (en) | 2019-12-17 | 2022-08-01 | Pfizer | Antibodies specific for cd47, pd-l1, and uses thereof |
CA3189590A1 (en) | 2020-07-17 | 2022-01-20 | Pfizer Inc. | Therapeutic antibodies and their uses |
WO2022040596A1 (en) | 2020-08-20 | 2022-02-24 | Ambrx, Inc. | Antibody-tlr agonist conjugates, methods and uses thereof |
Family Cites Families (98)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2135210A (en) * | 1937-03-13 | 1938-11-01 | John R Farrar | Golf ball |
US3314941A (en) | 1964-06-23 | 1967-04-18 | American Cyanamid Co | Novel substituted pyridodiazepins |
US3692907A (en) * | 1970-10-27 | 1972-09-19 | Richardson Merrell Inc | Treating viral infections with bis-basic ethers and thioethers of fluorenone and fluorene and pharmaceutical compositons of the same |
US3819190A (en) * | 1972-10-02 | 1974-06-25 | D Nepela | Golf ball |
US4284276A (en) * | 1980-02-13 | 1981-08-18 | Worst Joseph C | Grooved golf ball |
ZA848968B (en) | 1983-11-18 | 1986-06-25 | Riker Laboratories Inc | 1h-imidazo(4,5-c)quinolines and 1h-imidazo(4,5-c)quinolin-4-amines |
IL73534A (en) | 1983-11-18 | 1990-12-23 | Riker Laboratories Inc | 1h-imidazo(4,5-c)quinoline-4-amines,their preparation and pharmaceutical compositions containing certain such compounds |
US4880779A (en) * | 1987-07-31 | 1989-11-14 | Research Corporation Technologies, Inc. | Method of prevention or treatment of AIDS by inhibition of human immunodeficiency virus |
US5238944A (en) | 1988-12-15 | 1993-08-24 | Riker Laboratories, Inc. | Topical formulations and transdermal delivery systems containing 1-isobutyl-1H-imidazo[4,5-c]quinolin-4-amine |
US5756747A (en) | 1989-02-27 | 1998-05-26 | Riker Laboratories, Inc. | 1H-imidazo 4,5-c!quinolin-4-amines |
US4929624A (en) | 1989-03-23 | 1990-05-29 | Minnesota Mining And Manufacturing Company | Olefinic 1H-imidazo(4,5-c)quinolin-4-amines |
US5037986A (en) | 1989-03-23 | 1991-08-06 | Minnesota Mining And Manufacturing Company | Olefinic 1H-imidazo[4,5-c]quinolin-4-amines |
NZ232740A (en) | 1989-04-20 | 1992-06-25 | Riker Laboratories Inc | Solution for parenteral administration comprising a 1h-imidazo(4,5-c) quinolin-4-amine derivative, an acid and a tonicity adjuster |
US4988815A (en) * | 1989-10-26 | 1991-01-29 | Riker Laboratories, Inc. | 3-Amino or 3-nitro quinoline compounds which are intermediates in preparing 1H-imidazo[4,5-c]quinolines |
US5054153A (en) * | 1989-12-01 | 1991-10-08 | Silliman Paul D | Golf club cleaner |
CA2093132C (en) * | 1990-10-05 | 2002-02-26 | John F. Gerster | Process for the preparation of imidazo[4,5-c]quinolin-4-amines |
US5389640A (en) | 1991-03-01 | 1995-02-14 | Minnesota Mining And Manufacturing Company | 1-substituted, 2-substituted 1H-imidazo[4,5-c]quinolin-4-amines |
ATE229943T1 (en) * | 1991-03-01 | 2003-01-15 | Minnesota Mining & Mfg | INTERMEDIATE PRODUCTS FOR THE PRODUCTION OF 1-SUBSTITUTED, 2-SUBSTITUTED-1H-IMIDAZO(4,5-C)QUINOLINE-4-AMINES |
US5175296A (en) * | 1991-03-01 | 1992-12-29 | Minnesota Mining And Manufacturing Company | Imidazo[4,5-c]quinolin-4-amines and processes for their preparation |
US5268376A (en) * | 1991-09-04 | 1993-12-07 | Minnesota Mining And Manufacturing Company | 1-substituted 1H-imidazo[4,5-c]quinolin-4-amines |
US5266575A (en) * | 1991-11-06 | 1993-11-30 | Minnesota Mining And Manufacturing Company | 2-ethyl 1H-imidazo[4,5-ciquinolin-4-amines |
IL105325A (en) | 1992-04-16 | 1996-11-14 | Minnesota Mining & Mfg | Immunogen/vaccine adjuvant composition |
FR2692159B1 (en) * | 1992-06-10 | 1996-10-11 | Vartan Berberian | BALL FOR BALL GAMES AND METHODS OF OBTAINING SUCH A BALL. |
US5395937A (en) * | 1993-01-29 | 1995-03-07 | Minnesota Mining And Manufacturing Company | Process for preparing quinoline amines |
US5352784A (en) * | 1993-07-15 | 1994-10-04 | Minnesota Mining And Manufacturing Company | Fused cycloalkylimidazopyridines |
US5648516A (en) | 1994-07-20 | 1997-07-15 | Minnesota Mining And Manufacturing Company | Fused cycloalkylimidazopyridines |
DE69425661T2 (en) | 1993-07-15 | 2001-04-19 | Minnesota Mining & Mfg | IMIDAZO [4,5-c] PYRIDINE-4-AMINE |
US5644063A (en) | 1994-09-08 | 1997-07-01 | Minnesota Mining And Manufacturing Company | Imidazo[4,5-c]pyridin-4-amine intermediates |
US5482936A (en) | 1995-01-12 | 1996-01-09 | Minnesota Mining And Manufacturing Company | Imidazo[4,5-C]quinoline amines |
JPH09116911A (en) * | 1995-10-20 | 1997-05-02 | Canon Inc | Image pickup system |
JPH09208584A (en) | 1996-01-29 | 1997-08-12 | Terumo Corp | Amide derivative, pharmaceutical preparation containing the same, and intermediate for synthesizing the same |
JPH09255926A (en) | 1996-03-26 | 1997-09-30 | Diatex Co Ltd | Pressure-sensitive tape |
US5693811A (en) * | 1996-06-21 | 1997-12-02 | Minnesota Mining And Manufacturing Company | Process for preparing tetrahdroimidazoquinolinamines |
US5741908A (en) * | 1996-06-21 | 1998-04-21 | Minnesota Mining And Manufacturing Company | Process for reparing imidazoquinolinamines |
US5759109A (en) * | 1996-09-09 | 1998-06-02 | Martini; Byron Rocco | Simulated golf ball instructional device |
KR100518903B1 (en) * | 1996-10-25 | 2005-10-06 | 미네소타 마이닝 앤드 매뉴팩춰링 캄파니 | Immune response modifier compounds for treatment of the th2 mediated and related diseases |
US5939090A (en) | 1996-12-03 | 1999-08-17 | 3M Innovative Properties Company | Gel formulations for topical drug delivery |
JP4101302B2 (en) * | 1997-01-09 | 2008-06-18 | テルモ株式会社 | Novel amide derivatives and synthetic intermediates |
UA67760C2 (en) * | 1997-12-11 | 2004-07-15 | Міннесота Майнінг Енд Мануфакчурінг Компані | Imidazonaphthyridines and use thereof to induce the biosynthesis of cytokines |
JPH11222432A (en) | 1998-02-03 | 1999-08-17 | Terumo Corp | Preparation for external use containing amide derivative inducing interferon |
JPH11255926A (en) | 1998-03-13 | 1999-09-21 | Toray Ind Inc | Silicone molding and its production |
CN1220997C (en) * | 1998-05-22 | 2005-09-28 | 松下电器产业株式会社 | Electrolytic condenser and its manufacturing method |
US6110929A (en) | 1998-07-28 | 2000-08-29 | 3M Innovative Properties Company | Oxazolo, thiazolo and selenazolo [4,5-c]-quinolin-4-amines and analogs thereof |
JP2000119271A (en) | 1998-08-12 | 2000-04-25 | Hokuriku Seiyaku Co Ltd | 1h-imidazopyridine derivative |
SK287112B6 (en) * | 1999-01-08 | 2009-12-07 | 3M Innovative Properties Company | Use of immune response modifiying compound for cervical dysplasias treatment |
US20020058674A1 (en) | 1999-01-08 | 2002-05-16 | Hedenstrom John C. | Systems and methods for treating a mucosal surface |
US6558951B1 (en) * | 1999-02-11 | 2003-05-06 | 3M Innovative Properties Company | Maturation of dendritic cells with immune response modifying compounds |
JP2000247884A (en) | 1999-03-01 | 2000-09-12 | Sumitomo Pharmaceut Co Ltd | Arachidonic acid-induced skin disease-treating agent |
US6331539B1 (en) * | 1999-06-10 | 2001-12-18 | 3M Innovative Properties Company | Sulfonamide and sulfamide substituted imidazoquinolines |
US6756382B2 (en) | 1999-06-10 | 2004-06-29 | 3M Innovative Properties Company | Amide substituted imidazoquinolines |
US6541485B1 (en) * | 1999-06-10 | 2003-04-01 | 3M Innovative Properties Company | Urea substituted imidazoquinolines |
US6573273B1 (en) * | 1999-06-10 | 2003-06-03 | 3M Innovative Properties Company | Urea substituted imidazoquinolines |
US6451810B1 (en) | 1999-06-10 | 2002-09-17 | 3M Innovative Properties Company | Amide substituted imidazoquinolines |
US6376669B1 (en) * | 1999-11-05 | 2002-04-23 | 3M Innovative Properties Company | Dye labeled imidazoquinoline compounds |
US6894060B2 (en) | 2000-03-30 | 2005-05-17 | 3M Innovative Properties Company | Method for the treatment of dermal lesions caused by envenomation |
US20020055517A1 (en) * | 2000-09-15 | 2002-05-09 | 3M Innovative Properties Company | Methods for delaying recurrence of herpes virus symptoms |
JP2002145777A (en) | 2000-11-06 | 2002-05-22 | Sumitomo Pharmaceut Co Ltd | Therapeutic agent for arachidonic acid-induced dermatosis |
US6545017B1 (en) * | 2000-12-08 | 2003-04-08 | 3M Innovative Properties Company | Urea substituted imidazopyridines |
US6677348B2 (en) | 2000-12-08 | 2004-01-13 | 3M Innovative Properties Company | Aryl ether substituted imidazoquinolines |
US6660747B2 (en) * | 2000-12-08 | 2003-12-09 | 3M Innovative Properties Company | Amido ether substituted imidazoquinolines |
US6664264B2 (en) * | 2000-12-08 | 2003-12-16 | 3M Innovative Properties Company | Thioether substituted imidazoquinolines |
US6664260B2 (en) | 2000-12-08 | 2003-12-16 | 3M Innovative Properties Company | Heterocyclic ether substituted imidazoquinolines |
UA74593C2 (en) | 2000-12-08 | 2006-01-16 | 3M Innovative Properties Co | Substituted imidazopyridines |
US6525064B1 (en) | 2000-12-08 | 2003-02-25 | 3M Innovative Properties Company | Sulfonamido substituted imidazopyridines |
US6664265B2 (en) | 2000-12-08 | 2003-12-16 | 3M Innovative Properties Company | Amido ether substituted imidazoquinolines |
US6660735B2 (en) | 2000-12-08 | 2003-12-09 | 3M Innovative Properties Company | Urea substituted imidazoquinoline ethers |
US6667312B2 (en) | 2000-12-08 | 2003-12-23 | 3M Innovative Properties Company | Thioether substituted imidazoquinolines |
US6545016B1 (en) * | 2000-12-08 | 2003-04-08 | 3M Innovative Properties Company | Amide substituted imidazopyridines |
EP1360486A2 (en) | 2000-12-08 | 2003-11-12 | 3M Innovative Properties Company | Screening method for identifying compounds that selectively induce interferon alpha |
US6677347B2 (en) * | 2000-12-08 | 2004-01-13 | 3M Innovative Properties Company | Sulfonamido ether substituted imidazoquinolines |
UA74852C2 (en) | 2000-12-08 | 2006-02-15 | 3M Innovative Properties Co | Urea-substituted imidazoquinoline ethers |
CA2449754A1 (en) | 2001-06-15 | 2002-12-27 | 3M Innovative Properties Company | Immune response modifiers for the treatment of periodontal disease |
US20030133913A1 (en) | 2001-08-30 | 2003-07-17 | 3M Innovative Properties Company | Methods of maturing plasmacytoid dendritic cells using immune response modifier molecules |
AU2002360278A1 (en) | 2001-10-12 | 2003-11-11 | Coley Pharmaceutical Gmbh | Methods and products for enhancing immune responses using imidazoquinoline compounds |
DE60230340D1 (en) | 2001-11-16 | 2009-01-22 | 3M Innovative Properties Co | N-Ä4- (4-amino-2-ethyl-1H-imidazoÄ4,5-quinolin-1-yl) -butyl-methanesulfonamide, pharmaceutical composition containing the same and their use |
KR100962751B1 (en) | 2001-11-29 | 2010-06-09 | 쓰리엠 이노베이티브 프로퍼티즈 컴파니 | Pharmaceutical Formulations Comprising an Immune Response Modifier |
US6677349B1 (en) | 2001-12-21 | 2004-01-13 | 3M Innovative Properties Company | Sulfonamide and sulfamide substituted imidazoquinolines |
BR0307788A (en) | 2002-02-22 | 2006-04-04 | 3M Innovative Properties Co | reduction method and treatment of uv-b-induced immunosuppression |
GB0211649D0 (en) | 2002-05-21 | 2002-07-03 | Novartis Ag | Organic compounds |
US6743920B2 (en) | 2002-05-29 | 2004-06-01 | 3M Innovative Properties Company | Process for imidazo[4,5-c]pyridin-4-amines |
MXPA04012199A (en) | 2002-06-07 | 2005-02-25 | 3M Innovative Properties Co | Ether substituted imidazopyridines. |
MXPA05001647A (en) | 2002-08-15 | 2005-04-19 | 3M Innovative Properties Co | Immunostimulatory compositions and methods of stimulating an immune response. |
EP1542688A4 (en) | 2002-09-26 | 2010-06-02 | 3M Innovative Properties Co | 1h-imidazo dimers |
AU2003287316A1 (en) | 2002-12-11 | 2004-06-30 | 3M Innovative Properties Company | Assays relating to toll-like receptor activity |
AU2003287324A1 (en) | 2002-12-11 | 2004-06-30 | 3M Innovative Properties Company | Gene expression systems and recombinant cell lines |
CA2510375A1 (en) * | 2002-12-20 | 2004-07-15 | 3M Innovative Properties Company | Aryl / hetaryl substituted imidazoquinolines |
AU2003300184B8 (en) | 2002-12-30 | 2009-12-03 | 3M Innovative Properties Company | Immunostimulatory combinations |
EP1592302A4 (en) | 2003-02-13 | 2007-04-25 | 3M Innovative Properties Co | Methods and compositions related to irm compounds and toll-like receptor 8 |
WO2004075865A2 (en) | 2003-02-27 | 2004-09-10 | 3M Innovative Properties Company | Selective modulation of tlr-mediated biological activity |
WO2004078138A2 (en) | 2003-03-04 | 2004-09-16 | 3M Innovative Properties Company | Prophylactic treatment of uv-induced epidermal neoplasia |
EP1605943A4 (en) | 2003-03-07 | 2008-01-16 | 3M Innovative Properties Co | 1-amino 1h-imidazoquinolines |
ATE556711T1 (en) | 2003-03-13 | 2012-05-15 | 3M Innovative Properties Co | METHOD FOR IMPROVING SKIN QUALITY |
WO2004080292A2 (en) | 2003-03-13 | 2004-09-23 | 3M Innovative Properties Company | Method of tattoo removal |
EP1608282A4 (en) | 2003-03-13 | 2010-12-08 | 3M Innovative Properties Co | Methods for diagnosing skin lesions |
US20040192585A1 (en) | 2003-03-25 | 2004-09-30 | 3M Innovative Properties Company | Treatment for basal cell carcinoma |
EP1613956A2 (en) | 2003-03-25 | 2006-01-11 | 3M Innovative Properties Company | Selective activation of cellular activities mediated through a common toll-like receptor |
WO2004091500A2 (en) | 2003-04-10 | 2004-10-28 | 3M Innovative Properties Company | Delivery of immune response modifier compounds |
NZ545536A (en) | 2003-09-05 | 2010-04-30 | Anadys Pharmaceuticals Inc | TLR7 ligands for the treatment of hepatitis C |
-
2001
- 2001-06-12 UA UA2003065275A patent/UA74852C2/en unknown
- 2001-06-12 UA UA2003065277A patent/UA75622C2/en unknown
- 2001-12-06 IL IL15595001A patent/IL155950A0/en unknown
- 2001-12-06 CN CNB018199070A patent/CN1252070C/en not_active Expired - Fee Related
- 2001-12-06 MX MXPA03005012A patent/MXPA03005012A/en active IP Right Grant
- 2001-12-06 EP EP01992018A patent/EP1343784B1/en not_active Expired - Lifetime
- 2001-12-06 NZ NZ526105A patent/NZ526105A/en unknown
- 2001-12-06 CZ CZ20031563A patent/CZ20031563A3/en unknown
- 2001-12-06 BR BRPI0116464-3A patent/BR0116464A/en not_active IP Right Cessation
- 2001-12-06 SI SI200130720T patent/SI1341790T1/en unknown
- 2001-12-06 CZ CZ20031561A patent/CZ20031561A3/en unknown
- 2001-12-06 SK SK711-2003A patent/SK7112003A3/en unknown
- 2001-12-06 US US10/012,599 patent/US6683088B2/en not_active Expired - Fee Related
- 2001-12-06 EE EEP200300275A patent/EE200300275A/en unknown
- 2001-12-06 WO PCT/US2001/046704 patent/WO2002046193A2/en active IP Right Grant
- 2001-12-06 KR KR10-2003-7007539A patent/KR20040047733A/en not_active Application Discontinuation
- 2001-12-06 AU AU3951602A patent/AU3951602A/en active Pending
- 2001-12-06 HU HU0600338A patent/HUP0600338A2/en active IP Right Revival
- 2001-12-06 EE EEP200300268A patent/EE200300268A/en unknown
- 2001-12-06 CN CNA018201687A patent/CN1479739A/en active Pending
- 2001-12-06 KR KR10-2003-7007537A patent/KR20030070050A/en not_active Application Discontinuation
- 2001-12-06 SK SK710-2003A patent/SK287264B6/en not_active IP Right Cessation
- 2001-12-06 HU HU0600605A patent/HUP0600605A2/en unknown
- 2001-12-06 IL IL15604401A patent/IL156044A0/en unknown
- 2001-12-06 JP JP2002547930A patent/JP2004515501A/en active Pending
- 2001-12-06 IL IL15604301A patent/IL156043A0/en unknown
- 2001-12-06 WO PCT/US2001/046582 patent/WO2002046190A2/en active IP Right Grant
- 2001-12-06 EP EP01990852A patent/EP1339715A2/en not_active Withdrawn
- 2001-12-06 CA CA2436980A patent/CA2436980C/en not_active Expired - Fee Related
- 2001-12-06 CZ CZ20031591A patent/CZ20031591A3/en unknown
- 2001-12-06 PL PL01365995A patent/PL365995A1/en unknown
- 2001-12-06 ES ES01987283T patent/ES2281456T3/en not_active Expired - Lifetime
- 2001-12-06 BR BRPI0116052-4A patent/BR0116052A/en not_active Application Discontinuation
- 2001-12-06 CA CA002430844A patent/CA2430844A1/en not_active Withdrawn
- 2001-12-06 HU HU0400710A patent/HUP0400710A2/en unknown
- 2001-12-06 EE EEP200300274A patent/EE200300274A/en unknown
- 2001-12-06 SK SK712-2003A patent/SK7122003A3/en unknown
- 2001-12-06 CN CNA018201725A patent/CN1894244A/en active Pending
- 2001-12-06 SK SK715-2003A patent/SK7152003A3/en unknown
- 2001-12-06 MX MXPA03004974A patent/MXPA03004974A/en active IP Right Grant
- 2001-12-06 RU RU2003116063/04A patent/RU2003116063A/en not_active Application Discontinuation
- 2001-12-06 EP EP01987297A patent/EP1341791B1/en not_active Expired - Lifetime
- 2001-12-06 AU AU3061802A patent/AU3061802A/en active Pending
- 2001-12-06 PL PL01361948A patent/PL361948A1/en not_active Application Discontinuation
- 2001-12-06 EP EP01992005A patent/EP1341792A2/en not_active Withdrawn
- 2001-12-06 CA CA2436846A patent/CA2436846C/en not_active Expired - Fee Related
- 2001-12-06 PL PL01366115A patent/PL366115A1/en not_active Application Discontinuation
- 2001-12-06 AU AU2002232482A patent/AU2002232482B2/en not_active Ceased
- 2001-12-06 WO PCT/US2001/046697 patent/WO2002046192A2/en active IP Right Grant
- 2001-12-06 MX MXPA03005011A patent/MXPA03005011A/en active IP Right Grant
- 2001-12-06 KR KR10-2003-7007538A patent/KR20040028691A/en not_active Application Discontinuation
- 2001-12-06 ES ES01992018T patent/ES2260323T3/en not_active Expired - Lifetime
- 2001-12-06 CZ CZ20031592A patent/CZ303462B6/en not_active IP Right Cessation
- 2001-12-06 PL PL01365907A patent/PL365907A1/en not_active Application Discontinuation
- 2001-12-06 AU AU3248202A patent/AU3248202A/en active Pending
- 2001-12-06 PT PT01987297T patent/PT1341791E/en unknown
- 2001-12-06 RU RU2003116060/04A patent/RU2302418C2/en active
- 2001-12-06 KR KR10-2003-7007534A patent/KR20030070049A/en active IP Right Grant
- 2001-12-06 DK DK01987283T patent/DK1341790T3/en active
- 2001-12-06 PL PL01365883A patent/PL365883A1/en not_active Application Discontinuation
- 2001-12-06 EE EEP200300272A patent/EE200300272A/en unknown
- 2001-12-06 MX MXPA03004975A patent/MXPA03004975A/en active IP Right Grant
- 2001-12-06 PT PT01987283T patent/PT1341790E/en unknown
- 2001-12-06 DK DK01987297T patent/DK1341791T3/en active
- 2001-12-06 BR BR0116026-5A patent/BR0116026A/en not_active IP Right Cessation
- 2001-12-06 NZ NZ526088A patent/NZ526088A/en unknown
- 2001-12-06 AU AU2002239517A patent/AU2002239517B2/en not_active Ceased
- 2001-12-06 PL PL392462A patent/PL392462A1/en unknown
- 2001-12-06 JP JP2002547925A patent/JP4437189B2/en not_active Expired - Fee Related
- 2001-12-06 US US10/013,060 patent/US6656938B2/en not_active Expired - Fee Related
- 2001-12-06 JP JP2002547928A patent/JP2004521092A/en not_active Ceased
- 2001-12-06 PL PL366330A patent/PL207340B1/en not_active IP Right Cessation
- 2001-12-06 RU RU2003116061/04A patent/RU2315049C2/en not_active IP Right Cessation
- 2001-12-06 BR BR0116047-8A patent/BR0116047A/en not_active IP Right Cessation
- 2001-12-06 AT AT01987297T patent/ATE296301T1/en active
- 2001-12-06 NZ NZ526086A patent/NZ526086A/en unknown
- 2001-12-06 DK DK01992018T patent/DK1343784T3/en active
- 2001-12-06 ES ES01987297T patent/ES2242782T3/en not_active Expired - Lifetime
- 2001-12-06 CZ CZ20031560A patent/CZ295848B6/en not_active IP Right Cessation
- 2001-12-06 CN CNB018201679A patent/CN1297554C/en not_active Expired - Fee Related
- 2001-12-06 JP JP2002547926A patent/JP2004523498A/en active Pending
- 2001-12-06 IL IL15590301A patent/IL155903A0/en unknown
- 2001-12-06 EP EP01987282A patent/EP1341789A2/en not_active Ceased
- 2001-12-06 AU AU3951702A patent/AU3951702A/en active Pending
- 2001-12-06 AU AU3953002A patent/AU3953002A/en active Pending
- 2001-12-06 KR KR10-2003-7007532A patent/KR20040023576A/en not_active Application Discontinuation
- 2001-12-06 RU RU2003116649/04A patent/RU2351598C2/en not_active IP Right Cessation
- 2001-12-06 WO PCT/US2001/046696 patent/WO2002046191A2/en active IP Right Grant
- 2001-12-06 WO PCT/US2001/046359 patent/WO2002046188A2/en active IP Right Grant
- 2001-12-06 HU HU0600600A patent/HUP0600600A2/en unknown
- 2001-12-06 AT AT01987283T patent/ATE353895T1/en not_active IP Right Cessation
- 2001-12-06 DE DE60126645T patent/DE60126645T2/en not_active Expired - Fee Related
- 2001-12-06 AT AT01992018T patent/ATE319711T1/en not_active IP Right Cessation
- 2001-12-06 JP JP2002547927A patent/JP2004529078A/en active Pending
- 2001-12-06 IL IL15588401A patent/IL155884A0/en unknown
- 2001-12-06 CZ CZ20031562A patent/CZ20031562A3/en unknown
- 2001-12-06 NZ NZ526087A patent/NZ526087A/en unknown
- 2001-12-06 AU AU2002239530A patent/AU2002239530B2/en not_active Ceased
- 2001-12-06 HU HU0700062A patent/HUP0700062A2/en active IP Right Revival
- 2001-12-06 AU AU2002230618A patent/AU2002230618B2/en not_active Ceased
- 2001-12-06 EP EP01987283A patent/EP1341790B1/en not_active Expired - Lifetime
- 2001-12-06 IL IL15590401A patent/IL155904A0/en unknown
- 2001-12-06 DE DE60111076T patent/DE60111076T2/en not_active Expired - Lifetime
- 2001-12-06 NZ NZ526089A patent/NZ526089A/en unknown
- 2001-12-06 CA CA002436983A patent/CA2436983A1/en not_active Abandoned
- 2001-12-06 JP JP2002547929A patent/JP2004515500A/en not_active Withdrawn
- 2001-12-06 DE DE60117859T patent/DE60117859T2/en not_active Expired - Fee Related
- 2001-12-06 KR KR10-2003-7007535A patent/KR20040028690A/en not_active Application Discontinuation
- 2001-12-06 HU HU0400704A patent/HUP0400704A2/en unknown
- 2001-12-06 CA CA002436984A patent/CA2436984A1/en not_active Abandoned
- 2001-12-06 RU RU2003116123/04A patent/RU2003116123A/en not_active Application Discontinuation
- 2001-12-06 MX MXPA03004972A patent/MXPA03004972A/en active IP Right Grant
- 2001-12-06 CN CNB018201598A patent/CN1247575C/en not_active Expired - Fee Related
- 2001-12-06 CN CNB01820161XA patent/CN1253452C/en not_active Expired - Fee Related
- 2001-12-06 EE EEP200300271A patent/EE200300271A/en unknown
- 2001-12-06 AU AU3249702A patent/AU3249702A/en active Pending
- 2001-12-06 EE EEP200300270A patent/EE200300270A/en unknown
- 2001-12-06 CA CA002431151A patent/CA2431151A1/en not_active Withdrawn
- 2001-12-06 WO PCT/US2001/046581 patent/WO2002046189A2/en active IP Right Grant
- 2001-12-06 BR BRPI0116032-0A patent/BR0116032A/en not_active IP Right Cessation
- 2001-12-06 NZ NZ526106A patent/NZ526106A/en not_active IP Right Cessation
- 2001-12-06 RU RU2003116059/04A patent/RU2308456C2/en not_active IP Right Cessation
- 2001-12-06 BR BR0116470-8A patent/BR0116470A/en not_active IP Right Cessation
- 2001-12-06 SK SK684-2003A patent/SK6842003A3/en not_active Application Discontinuation
- 2001-12-06 US US10/013,202 patent/US6670372B2/en not_active Expired - Fee Related
- 2001-12-06 AU AU2002239516A patent/AU2002239516B2/en not_active Ceased
- 2001-12-06 SK SK713-2003A patent/SK287732B6/en not_active IP Right Cessation
- 2001-12-06 MX MXPA03004973A patent/MXPA03004973A/en not_active Application Discontinuation
- 2001-12-06 AU AU2002232497A patent/AU2002232497B2/en not_active Ceased
- 2001-12-07 TW TW090130402A patent/TWI222972B/en active
- 2001-12-07 TW TW090130404A patent/TWI293300B/en active
- 2001-12-07 TW TW090130401A patent/TW584633B/en not_active IP Right Cessation
- 2001-12-10 AR ARP010105726A patent/AR035664A1/en active IP Right Grant
- 2001-12-10 AR ARP010105731A patent/AR035669A1/en unknown
- 2001-12-10 AR ARP010105730A patent/AR035668A1/en unknown
- 2001-12-10 AR ARP010105728A patent/AR035666A1/en unknown
- 2001-12-10 AR ARP010105727A patent/AR035665A1/en unknown
- 2001-12-10 AR ARP010105729A patent/AR035667A1/en unknown
-
2003
- 2003-05-28 NO NO20032449A patent/NO20032449L/en not_active Application Discontinuation
- 2003-05-28 NO NO20032452A patent/NO20032452L/en not_active Application Discontinuation
- 2003-05-28 NO NO20032451A patent/NO20032451L/en not_active Application Discontinuation
- 2003-05-30 NO NO20032473A patent/NO326159B1/en not_active IP Right Cessation
- 2003-06-06 HR HR20030461A patent/HRP20030461A2/en not_active Application Discontinuation
- 2003-06-06 HR HR20030462A patent/HRP20030462A2/en not_active Application Discontinuation
- 2003-06-06 HR HR20030467A patent/HRP20030467B1/en not_active IP Right Cessation
- 2003-06-06 NO NO20032595A patent/NO20032595L/en not_active Application Discontinuation
- 2003-06-06 HR HR20030466A patent/HRP20030466A2/en not_active Application Discontinuation
- 2003-06-06 NO NO20032596A patent/NO20032596D0/en not_active Application Discontinuation
- 2003-06-06 HR HR20030464A patent/HRP20030464A2/en not_active Application Discontinuation
- 2003-06-06 HR HR20030463A patent/HRP20030463A2/en not_active Application Discontinuation
- 2003-07-08 ZA ZA200305275A patent/ZA200305275B/en unknown
- 2003-07-08 ZA ZA200305270A patent/ZA200305270B/en unknown
- 2003-07-08 ZA ZA200305273A patent/ZA200305273B/en unknown
- 2003-07-08 ZA ZA2003/05272A patent/ZA200305272B/en unknown
- 2003-07-08 ZA ZA200305274A patent/ZA200305274B/en unknown
- 2003-07-08 ZA ZA200305271A patent/ZA200305271B/en unknown
- 2003-10-07 US US10/680,989 patent/US7049439B2/en not_active Expired - Fee Related
- 2003-10-29 US US10/696,753 patent/US6953804B2/en not_active Expired - Fee Related
- 2003-10-29 US US10/696,476 patent/US20040092545A1/en not_active Abandoned
-
2004
- 2004-09-20 HK HK04107230A patent/HK1064383A1/en not_active IP Right Cessation
- 2004-11-11 HK HK04108904A patent/HK1066005A1/en not_active IP Right Cessation
-
2005
- 2005-01-25 HK HK05100647A patent/HK1069166A1/en not_active IP Right Cessation
- 2005-02-28 US US11/069,033 patent/US7132429B2/en not_active Expired - Fee Related
- 2005-05-19 US US11/132,900 patent/US7612083B2/en not_active Expired - Fee Related
- 2005-08-24 CY CY20051101024T patent/CY1105586T1/en unknown
-
2007
- 2007-05-09 CY CY20071100621T patent/CY1106569T1/en unknown
-
2009
- 2009-11-06 JP JP2009255040A patent/JP2010031040A/en not_active Ceased
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2436846C (en) | Thioether substituted imidazoquinolines | |
US6664264B2 (en) | Thioether substituted imidazoquinolines | |
US6667312B2 (en) | Thioether substituted imidazoquinolines | |
AU2002239530A1 (en) | Thioether substituted imidazoquinolines | |
US6660747B2 (en) | Amido ether substituted imidazoquinolines | |
US20020107262A1 (en) | Substituted imidazopyridines | |
AU2002232497A1 (en) | Urea substituted imidazoquinoline ethers | |
EP1541572A1 (en) | Thioether substituted imidazoquinolines | |
AU2002315009B2 (en) | Thioether substituted imidazoquinolines |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
MKLA | Lapsed |
Effective date: 20141208 |